US20030104526A1 - Position dependent recognition of GNN nucleotide triplets by zinc fingers - Google Patents

Position dependent recognition of GNN nucleotide triplets by zinc fingers Download PDF

Info

Publication number
US20030104526A1
US20030104526A1 US09/989,994 US98999401A US2003104526A1 US 20030104526 A1 US20030104526 A1 US 20030104526A1 US 98999401 A US98999401 A US 98999401A US 2003104526 A1 US2003104526 A1 US 2003104526A1
Authority
US
United States
Prior art keywords
amino acid
acid sequence
zinc finger
finger protein
rsdnlar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/989,994
Inventor
Qiang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/535,008 external-priority patent/US6465629B1/en
Priority claimed from US09/716,637 external-priority patent/US6794136B1/en
Application filed by Individual filed Critical Individual
Priority to US09/989,994 priority Critical patent/US20030104526A1/en
Assigned to SANGAMO BIOSCIENCES, INC. reassignment SANGAMO BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, QIANG
Publication of US20030104526A1 publication Critical patent/US20030104526A1/en
Assigned to SANGAMO BIOSCIENCES, INC. reassignment SANGAMO BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JAMIESON, ANDREW C., REBAR, EDWARD
Priority to US11/202,009 priority patent/US7585849B2/en
Priority to US11/225,686 priority patent/US20060019349A1/en
Priority to US11/893,341 priority patent/US8383766B2/en
Priority to US13/743,204 priority patent/US8524874B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • Zinc finger proteins are proteins that can bind to DNA in a sequence-specific manner. Zinc fingers were first identified in the transcription factor TFIIIA from the oocytes of the African clawed toad, Xenopus laevis .
  • An exemplary motif characterizing one class of these protein is -Cys-(X) 2-4 -Cys-(X) 12 -His-(X) 3-5 -His (where X is any amino acid) (SEQ. ID. No:1).
  • a single finger domain is about 30 amino acids in length, and several structural studies have demonstrated that it contains an alpha helix containing the two invariant histidine residues and two invariant cysteine residues in a beta turn co-ordinated through zinc. To date, over 10,000 zinc finger sequences have been identified in several thousand known or putative transcription factors. Zinc finger domains are involved not only in DNA-recognition, but also in RNA binding and in protein-protein binding. Current estimates are that this class of molecules will constitute about 2% of all human genes.
  • the target strand If the strand with which a zinc finger protein makes most contacts is designated the target strand, some zinc finger proteins bind to a three base triplet in the target strand and a fourth base on the nontarget strand.
  • the fourth base is complementary to the base immediately 3′ of the three base subsite.
  • Combinatorial libraries were constructed with randomized side-chains in either the first or middle finger of Zif268 and then used to select for an altered Zif268 binding site in which the appropriate DNA sub-site was replaced by an altered DNA triplet. Further, correlation between the nature of introduced mutations and the resulting alteration in binding specificity gave rise to a partial set of substitution rules for design of ZFPs with altered binding specificity.
  • Liu et al., PNAS 94, 5525-5530 (1997) report forming a composite zinc finger protein by using a peptide spacer to link two component zinc finger proteins each having three fingers. The composite protein was then further linked to transcriptional activation domain. It was reported that the resulting chimeric protein bound to a target site formed from the target segments bound by the two component zinc finger proteins. It was further reported that the chimeric zinc finger protein could activate transcription of a reporter gene when its target site was inserted into a reporter plasmid in proximity to a promoter operably linked to the reporter.
  • Choo et al., WO 98/53058, WO98/53059, and WO 98/53060 discuss selection of zinc finger proteins to bind to a target site within the HIV Tat gene. Choo et al. also discuss selection of a zinc finger protein to bind to a target site encompassing a site of a common mutation in the oncogene ras. The target site within ras was thus constrained by the position of the mutation.
  • Previously-disclosed methods for the design of sequence-specific zinc finger proteins have often been based on modularity of individual zinc fingers; i.e., the ability of a zinc finger to recognize the same target subsite regardless of the location of the finger in a multi-finger protein.
  • a zinc finger retains the same sequence specificity regardless of its location within a multi-finger protein; in certain cases, the sequence specificity of a zinc finger depends on its position. For example, it is possible for a finger to recognize a particular triplet sequence when it is present as finger 1 of a three-finger protein, but to recognize a different triplet sequence when present as finger 2 of a three-finger protein.
  • compositions comprising and methods involving position dependent recognition of GNN nucleotide triplets by zinc fingers.
  • a zinc finger protein that binds to a target site, said zinc finger protein comprising a first (F1), a second (F2), and a third (F3) zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, said target site comprising, in 3′ to 5′ direction, a first (S1), a second (S2), and a third (S3) target subsite, each target subsite having the nucleotide sequence GNN, wherein if S1 comprises GAA, F1 comprises the amino acid sequence QRSNLVR; if S2 comprises GAA, ⁇ 2 comprises the amino acid sequence QSGNLA R; if S3 comprises GAA, F3 comprises the amino acid sequence QSGNLAR; if S1 comprises GAG , F1 comprises the amino acid sequence RSDNLAR; if S2 comprises GAG, F2 comprises the amino acid sequence RSDNLAR; if S3 comprises GAG, F3 comprises the amino acid sequence RSDNLTR; if S1 comprises GAA, F1 comprises the
  • a zinc finger protein comprising a first (F1), a second (F2), and a third (F3) zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus that binds to a target site comprising, in 3′ to 5′ direction, a first (S1), a second (S2), and a third (S3) target subsite, each target subsite having the nucleotide sequence GNN, the method comprising the steps of (a) selecting the F1 zinc finger such that it binds to the S1 target subsite, wherein if S1 comprises GAA, F1 comprises the amino acid sequence QRSNLVR; if S1 comprises GAG, F1 comprises the amino acid sequence RSDNLAR; if S1 comprises GAC, F1 comprises the amino acid sequence DRSNLTR; if S1 comprises GAT, F1 comprises the amino acid sequence QSSNLAR; if S1 comprises GGA, F1 comprises the amino acid sequence QSGHLAR; if S1 comprises
  • S1 comprises GAA and F1 comprises the amino acid sequence QRSNLVR.
  • S2 comprises GAA and F2 comprises the amino acid sequence QSGNLAR.
  • S3 comprises GAA and F3 comprises the amino acid sequence QSGNLAR.
  • S1 comprises GAG and F1 comprises the amino acid sequence RSDNLAR.
  • S2 comprises GAG and F2 comprises the amino acid sequence RSDNLAR.
  • S3 comprises GAG and F3 comprises the amino acid sequence RSDNLTR.
  • S1 comprises GAC and F1 comprises the amino acid sequence DRSNLTR.
  • S2 comprises GAC and F2 comprises the amino acid sequence DRSNLTR.
  • S3 comprises GAC and F3 comprises the amino acid sequence DRSNLTR .
  • S1 comprises GAT and F1 comprises the amino acid sequence QSSNLAR.
  • S2 comprises GAT and F2 comprises the amino acid sequence TSGNLVR .
  • S3 comprises GAT and F3 comprises the amino acid sequence TSANLSR.
  • S1 comprises GGA and F1 comprises the amino acid sequence QSGHLAR.
  • S2 comprises GGA and F2 comprises the amino acid sequence QSGHLQR.
  • S3 comprises GGA and F3 comprises the amino acid sequence QSGHLQR.
  • S1 comprises GGG and F1 comprises the amino acid sequence RSDHLAR.
  • S2 comprises GGG and F2 comprises the amino acid sequence RSDHLSR.
  • S3 comprises GGG and F3 comprises the amino acid sequence RSDHLSR.
  • S1 comprises GGC and F1 comprises the amino acid sequence DRSHLTR.
  • S2 comprises GGC and F2 comprises the amino acid sequence DRSHLAR.
  • S1 comprises GGT and F1 comprises the amino acid sequence QSSHLTR.
  • S2 comprises GGT and F2 comprises the amino acid sequence TSGHLSR.
  • S3 comprises GGT and F3 comprises the amino acid sequence TSGHLVR.
  • S1 comprises GCA and F1 comprises the amino acid sequence QSGSLTR.
  • S2 comprises GCA and F2 comprises the amino acid sequence QSGDLTR.
  • S3 comprises GCA and F3 comprises the amino acid sequence QSGDLTR.
  • S1 comprises GCG and F1 comprises the amino acid sequence RSDDLTR.
  • S2 comprises GCG and F2 comprises the amino acid sequence RSDDLQR.
  • S3 comprises GCG and F3 comprises the amino acid sequence RSDDLTR.
  • S1 comprises GCC and F1 comprises the amino acid sequence ERGTLAR.
  • S2 comprises GCC and F2 comprises the amino acid sequence DRSDLTR.
  • S3 comprises GCC and F3 comprises the amino acid sequence DRSDLTR.
  • S1 comprises GCT and F1 comprises the amino acid sequence QSSDLTR.
  • S2 comprises GCT and F2 comprises the amino acid sequence QSSDLTR.
  • S3 comprises GCT and F3 comprises the amino acid sequence QSSDLQR.
  • S1 comprises GTA and F1 comprises the amino acid sequence QSGALTR .
  • S2 comprises GTA and F2 comprises the amino acid sequence QSGALAR .
  • S1 comprises GTG and F1 comprises the amino acid sequence RSDALTR.
  • S2 comprises GTG and F2 comprises the amino acid sequence RSDALSR.
  • S3 comprises GTG and F3 comprises the amino acid sequence RSDALTR.
  • S1 comprises GTC and F1 comprises the amino acid sequence DRSALAR.
  • S2 comprises GTC and F2 comprises the amino acid sequence DRSALAR .
  • S3 comprises GTC and p3 comprises the amino acid sequence DRSALAR.
  • polypeptides comprising any of zinc finger proteins described herein.
  • the polypeptide further comprises at least one functional domain.
  • polynucleotides encoding any of the polypeptides described herein are also provided.
  • nucleic acid encoding zinc fingers including all of the zinc fingers described above.
  • segments of a zinc finger comprising a sequence of seven contiguous amino acids as shown herein. Also provided are nucleic acids encoding any of these segments and zinc fingers comprising the same.
  • zinc finger proteins comprising first, second and third zinc fingers.
  • the first, second and third zinc fingers comprise respectively first, second and third segments of seven contiguous amino acids as shown herein.
  • nucleic acids encoding such zinc finger proteins.
  • FIG. 1 shows results of site selection analysis of two representative zinc finger proteins (leftmost 4 columns) and measurements of binding affinity for each of these proteins to their intended target sequences and to variant target sequences. (rightmost 3 columns). Analysis of ZFP1 is shown in the upper portion of the figure and analysis of ZFP2 is shown in the lower portion of the figure.
  • the amino acid sequences of residues ⁇ 1 through +6 of the recognition helix of each of the three component zinc fingers (F3, F2 and F1) are shown across the top row; the intended target sequence (divided into finger-specific target subsites) is shown across the second row, and a summary of the sequences bound is shown in the third row. Data for F3 is shown in the second column, data for F2 is shown in the third column, and data for F1 is shown in the third column.
  • FIG. 2 shows amino acid sequences of zinc finger recognition regions (amino acids ⁇ 1 through +6 of the recognition helix) that bind to each of the 16 GNN triplet subsites.
  • Three amino acid sequences are shown for each trinucleotide subsite; these correspond to optimal amino acid sequences for recognition of the subsite from each of the three positions (finger 1, F1; finger 2, F2; or finger 3, F3) in a three-finger zinc finger protein.
  • Amino acid sequences are from N-terminal to C-terminal; nucleotide sequences are from 5′ to 3′.
  • site selection results for each of the 48 position-dependent GNN-recognizing zinc fingers show the number of times a particular nucleotide was present, at a given position, in a collection of oligonucleotide sequences bound by the finger.
  • 15 contained a G in the 5′-most position of the subsite
  • 15 contained a G in the middle position of the subsite
  • 10 contained an A
  • 3 contained a G
  • 2 contained a T. Accordingly, this particular amino acid sequence is optimal for binding a GGA triplet from the F1 position.
  • FIGS. 3A, 3B and 3 C show site selection data indicating positional dependence of GCA-, GAT- and GGT-binding zinc fingers.
  • the first and fourth (where applicable) rows of each figure show portions of the amino acid sequence of a designed zinc finger protein. Amino acid residues ⁇ 1 through +6 of each ⁇ -helix are listed from left to right.
  • the second and fifth (where applicable) rows show the target sequence, divided into three triplet subsites, one for each finger of the protein shown in the first and fourth (where applicable) rows, respectively.
  • the third and sixth (where applicable) rows show the distribution of nucleotides in the oligonucleotides obtained by site selection with the proteins shown in the first and fourth (where applicable) rows, respectively.
  • FIG. 3A shows data for fingers designed to bind GCA
  • FIG. 3B shows data for fingers designed to bind GAT
  • FIG. 3C shows data for fingers designed to bind GGT.
  • FIGS. 4A and 4B show properties of the engineered ZFP EP2C.
  • FIG. 4A shows site selection data. The first row provides the amino acid sequences of residues ⁇ 1 through +6 of the recognition helices for each of the three zinc fingers of the EP2C protein. The second row shows the target sequence (5′ to 3′); with the distribution of nucleotides in the oligonucleotides obtained by site selection indicated below the target sequence.
  • FIG. 4B shows in vitro and in vivo assays for the binding specificity of EP2C.
  • the first three columns show in vitro measurements of binding affinity of EP2C to its intended target sequence and several related sequences.
  • the first column gives the name of each sequence (2C0 is the intended target sequence, compare to FIG. 4A).
  • the second column shows the nucleotide sequence of various target sequences, with differences from the intended target sequence (2C0) highlighted.
  • the third column shows the K d (in nM) for binding of EP2C to each of the target sequences. K d s were determined by gel shift assays, using 2-fold dilution series of EP2C.
  • the right side of the figure shows relative luciferase activities (normalized to ⁇ -galactosidase levels) in stable cell lines in which expression of EP2C is inducible.
  • Cells were co-transfected with a vector containing a luciferase coding region under the transcriptional control of the target sequence shown in the same row of the figure, and a control vector encoding ⁇ -galactosidase. Luciferase and ⁇ -galactosidase levels were measured after induction of EP2C expression. Triplicate samples were assayed and the standard deviations are shown in the bar graph.
  • pGL3 is a luciferase-encoding vector lacking EP2C target sequences.
  • 3B is another negative control, in which luciferase expression is under transcriptional control of sequences (3B) unrelated to the EP2C target sequence.
  • a zinc finger DNA binding protein is a protein or segment within a larger protein that binds DNA in a sequence-specific manner as a result of stabilization of protein structure through coordination of a zinc ion.
  • the term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
  • Zinc finger proteins can be engineered to recognize a selected target sequence in a nucleic acid. Any method known in the art or disclosed herein can be used to construct an engineered zinc finger protein or a nucleic acid encoding an engineered zinc finger protein. These include, but are not limited to, rational design, selection methods (e.g., phage display) random mutagenesis, combinatorial libraries, computer design, affinity selection, use of databases matching zinc finger amino acid sequences with target subsite nucleotide sequences, cloning from cDNA and/or genomic libraries, and synthetic constructions.
  • An engineered zinc finger protein can comprise a new combination of naturally-occurring zinc finger sequences.
  • Methods for engineering zinc finger proteins are disclosed in co-owned WO 00/41566 and WO 00/42219; as well as in WO 98/53057; WO 98/53058; WO 98/53059 and WO 98/53060; the disclosures of which are hereby incorporated by reference in their entireties. Methods for identifying preferred target sequences, and for engineering zinc finger proteins to bind to such preferred target sequences, are disclosed in co-owned WO 00/42219.
  • a designed zinc finger protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data.
  • a selected zinc finger protein is a protein not found in nature whose production results primarily from an empirical process such as phage display.
  • Naturally-occurring is used to describe an object that can be found in nature as distinct from being artificially produced by man.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.
  • the term naturally-occurring refers to an object as present in a non-pathological (undiseased) individual, such as would be typical for the species.
  • a nucleic acid is operably linked when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it increases the transcription of the coding sequence.
  • Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
  • enhancers generally function when separated from the promoter by up to several kilobases or more and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous.
  • a specific binding affinity between, for example, a ZFP and a specific target site means a binding affinity of at least 1 ⁇ 10 6 M ⁇ 1 .
  • modulating expression “inhibiting expression” and “activating expression” of a gene refer to the ability of a zinc finger protein to activate or inhibit transcription of a gene. Activation includes prevention of subsequent transcriptional inhibition (i.e., prevention of repression of gene expression) and inhibition includes prevention of subsequent transcriptional activation (i.e., prevention of gene activation). Modulation can be assayed by determining any parameter that is indirectly or directly affected by the expression of the target gene.
  • Such parameters include, e.g., changes in RNA or protein levels, changes in protein activity, changes in product levels, changes in downstream gene expression, changes in reporter gene transcription (luciferase, CAT, beta-galactosidase, GFP (see, e.g., Mistili & Spector, Nature Biotechnology 15:961-964 (1997)); changes in signal transduction, phosphorylation and dephosphorylation, receptor-ligand interactions, second messenger concentrations (e.g., cGMP, cAMP, IP3, and Ca2+), cell growth, neovascularization, in vitro, in vivo, and ex vivo.
  • reporter gene transcription luciferase, CAT, beta-galactosidase, GFP (see, e.g., Mistili & Spector, Nature Biotechnology 15:961-964 (1997)
  • changes in signal transduction, phosphorylation and dephosphorylation, receptor-ligand interactions e.g., cGMP, c
  • Such functional effects can be measured by any means known to those skilled in the art, e.g., measurement of RNA or protein levels, measurement of RNA stability, identification of downstream or reporter gene expression, e.g., via chemiluminescence, fluorescence, calorimetric reactions, antibody binding, inducible markers, ligand binding assays; changes in intracellular second messengers such as cGMP and inositol triphosphate (IP3); changes in intracellular calcium levels; cytokine release, and the like.
  • chemiluminescence, fluorescence, calorimetric reactions, antibody binding, inducible markers, ligand binding assays e.g., via chemiluminescence, fluorescence, calorimetric reactions, antibody binding, inducible markers, ligand binding assays
  • changes in intracellular second messengers such as cGMP and inositol triphosphate (IP3)
  • changes in intracellular calcium levels cytokine release, and the like.
  • a “regulatory domain” refers to a protein or a protein subsequence that has transcriptional modulation activity.
  • a regulatory domain is covalently or non-covalently linked to a ZFP to modulate transcription.
  • a ZFP can act alone, without a regulatory domain, or with multiple regulatory domains to modulate transcription.
  • a D-able subsite within a target site has the motif 5′NNGK3′.
  • a target site containing one or more such motifs is sometimes described as a D-able target site.
  • a zinc finger appropriately designed to bind to a D-able subsite is sometimes referred to as a D-able finger.
  • a zinc finger protein containing at least one finger designed or selected to bind to a target site including at least one D-able subsite is sometimes referred to as a D-able zinc finger protein.
  • Tables 1-5 list a collection of nonnaturally occurring zinc finger protein sequences and their corresponding target sites.
  • the first column of each table is an internal reference number.
  • the second column lists a 9 or 10 base target site bound by a three-finger zinc finger protein, with the target sites listed in 5′ to 3′ orientation.
  • the third column provides SEQ ID NOs for the target site sequences listed in column 2.
  • the fourth, sixth and eighth columns list amino acid residues from the first, second and third fingers, respectively, of a zinc finger protein which recognizes the target sequence listed in the second column. For each finger, seven amino acids, occupying positions ⁇ 1 to +6 of the finger, are listed. The numbering convention for zinc fingers is defined below.
  • Each finger binds to a triplet of bases within a corresponding target sequence.
  • the first finger binds to the first triplet starting from the 3′ end of a target site
  • the second finger binds to the second triplet
  • the third finger binds the third (i.e., the 5′-most) triplet of the target sequence.
  • the RSDSLTS finger SEQ ID NO:646 of SBS# 201 (Table 2) binds to 5′TTG3′
  • the ERSTLTR finger SEQ ID NO:851
  • the QRADLRR finger SEQ ID NO:1056
  • Table 6 lists a collection of consensus sequences for zinc fingers and the target sites bound by such sequences.
  • Conventional one letter amino acid codes are used to designate amino acids occupying consensus positions.
  • the symbol “X” designates a nonconsensus position that can in principle be occupied by any amino acid.
  • binding specificity is principally conferred by residues ⁇ 1, +2, +3 and +6. Accordingly, consensus sequence determining binding specificity typically include at least these residues.
  • Consensus sequences are useful for designing zinc fingers to bind to a given target sequence. Residues occupying other positions can be selected based on sequences in Tables 1-5, or other known zinc finger sequences.
  • these positions can be randomized with a plurality of candidate amino acids and screened against one or more target sequences to refine binding specificity or improve binding specificity.
  • the same consensus sequence can be used for design of a zinc finger regardless of the relative position of that finger in a multi-finger zinc finger protein.
  • the sequence RXDNXXR can be used to design a N-terminal, central or C-terminal finger of three finger protein.
  • some consensus sequences are most suitable for designing a zinc finger to occupy a particular position in a multi-finger protein.
  • the consensus sequence RXDHXXQ is most suitable for designing a C-terminal finger of a three-finger protein.
  • Zinc finger proteins are formed from zinc finger components.
  • zinc finger proteins can have one to thirty-seven fingers, commonly having 2, 3, 4, 5 or 6 fingers.
  • a zinc finger protein recognizes and binds to a target site (sometimes referred to as a target segment) that represents a relatively small subsequence within a target gene.
  • Each component finger of a zinc finger protein can bind to a subsite within the target site.
  • the subsite includes a triplet of three contiguous bases all on the same strand (sometimes referred to as the target strand).
  • the subsite may or may not also include a fourth base on the opposite strand that is the complement of the base immediately 3′ of the three contiguous bases on the target strand.
  • a zinc finger binds to its triplet subsite substantially independently of other fingers in the same zinc finger protein. Accordingly, the binding specificity of zinc finger protein containing multiple fingers is usually approximately the aggregate of the specificities of its component fingers. For example, if a zinc finger protein is formed from first, second and third fingers that individually bind to triplets XXX, YYY, and ZZZ, the binding specificity of the zinc finger protein is 3′XXX YYY ZZZ5′.
  • the relative order of fingers in a zinc finger protein from N-terminal to C-terminal determines the relative order of triplets in the 3′ to 5′ direction in the target. For example, if a zinc finger protein comprises from N-terminal to C-terminal first, second and third fingers that individualy bind, respectively, to triplets 5′ GAC3′, 5′GTA3′ and 5′′GGC3′ then the zinc finger protein binds to the target segment 3′CAGATGCGG5′.
  • the zinc finger protein comprises the fingers in another order, for example, second finger, first finger, third finger
  • the zinc finger protein binds to a target segment comprising a different permutation of triplets, in this example, 3′ATGCAGCGG5′ (see Berg & Shi, Science 271, 1081-1086 (1996)).
  • the assessment of binding properties of a zinc finger protein as the aggregate of its component fingers may, in some cases, be influenced by context-dependent interactions of multiple fingers binding in the same protein.
  • Two or more zinc finger proteins can be linked to have a target specificity that is the aggregate of that of the component zinc finger proteins (see e.g., Kim & Pabo, PNAS 95, 2812-2817 (1998)).
  • a first zinc finger protein having first, second and third component fingers that respectively bind to XXX, YYY and ZZZ can be linked to a second zinc finger protein having first, second and third component fingers with binding specificities, AAA, BBB and CCC.
  • the binding specificity of the combined first and second proteins is thus 3′XXXYYYZZZ_AAABBBCCC5′, where the underline indicates a short intervening region (typically 0-5 bases of any type).
  • the target site can be viewed as comprising two target segments separated by an intervening segment.
  • Linkage can be accomplished using any of the following peptide linkers.
  • T G E K P (SEQ. ID. No:2) (Liu et al., 1997, supra.); (G4S) n (SEQ. ID. No:3) (Kim et al., PNAS 93, 1156-1160 (1996.); GGRRGGGS; (SEQ. ID. No:4) LRQRDGERP; (SEQ. ID. No:5) LRQKDGGGSERP; (SEQ. ID. No:6) LRQKD(G3S) 2 ERP (SEQ. ID.
  • flexible linkers can be rationally designed using computer programs capable of modeling both DNA-binding sites and the peptides themselves or by phage display methods .
  • noncovalent linkage can be achieved by fusing two zinc finger proteins with domains promoting heterodimer formation of the two zinc finger proteins.
  • one zinc finger protein can be fused with fos and the other with jun (see Barbas et al., WO 95/119431).
  • Linkage of two zinc finger proteins is advantageous for conferring a unique binding specificity within a mammalian genome.
  • a typical mammalian diploid genome consists of 3 ⁇ 10 9 bp. Assuming that the four nucleotides A, C, G, and T are randomly distributed, a given 9 bp sequence is present ⁇ 23,000 times. Thus a ZFP recognizing a 9 bp target with absolute specificity would have the potential to bind to ⁇ 23,000 sites within the genome. An 18 bp sequence is present once in 3.4 ⁇ 10 10 bp, or about once in a random DNA sequence whose complexity is ten times that of a mammalian genome.
  • a component finger of zinc finger protein typically contains about 30 amino acids and has the following motif (N—C):
  • the two invariant histidine residues and two invariant cysteine residues in a single beta turn are co-ordinated through zinc (see, e.g., Berg & Shi, Science 271, 1081-1085 (1996)).
  • the above motif shows a numbering convention that is standard in the field for the region of a zinc finger conferring binding specificity.
  • the amino acid on the left (N-terminal side) of the first invariant His residues is assigned the number +6, and other amino acids further to the left are assigned successively decreasing numbers.
  • the alpha helix begins at residue 1 and extends to the residue following the second conserved histidine. The entire helix is therefore of variable length, between 11 and 13 residues.
  • the process of designing or selecting a nonmaturally occurring or variant ZFP typically starts with a natural ZFP as a source of framework residues.
  • the process of design or selection serves to define nonconserved positions (i.e., positions ⁇ 1 to +6) so as to confer a desired binding specificity.
  • One suitable ZFP is the DNA binding domain of the mouse transcription factor Zif268.
  • the DNA binding domain of this protein has the amino acid sequence:
  • F2 FQCRICMRNFSRSDHLTTHIRTHTGEKP (F2) (SEQ. ID. No:10)
  • FACDICGRKFARSDERKRHTKIHLRQK (F3) SEQ. ID. No:11)
  • Sp-1 Another suitable natural zinc finger protein as a source of framework residues is Sp-1.
  • the Sp-1 sequence used for construction of zinc finger proteins corresponds to amino acids 531 to 624 in the Sp-1 transcription factor. This sequence is 94 amino acids in length.
  • the amino acid sequence of Sp-1 is as follows:
  • Sp-1 binds to a target site 5′GGG GCG GGG3′ (SEQ ID No:14).
  • YKCPECGKSFSRSDHLSKHQRTHQNKKG (SEQ. ID. No:15) (lower case letters are a leader sequence from Shi & Berg, Chemistry and Biology 1, 83-89. (1995).
  • the optimal binding sequence for the Sp-1 consensus sequence is 5′GGGGCGGGG3′ (SEQ ID No:16).
  • Other suitable ZFPs are described below.
  • a 5′ G in a DNA triplet can be bound by a zinc finger incorporating arginine at position 6 of the recognition helix.
  • Another substitution rule is that a G in the middle of a subsite can be recognized by including a histidine residue at position 3 of a zinc finger.
  • a further substitution rule is that asparagine can be incorporated to recognize A in the middle of triplet, aspartic acid, glutamic acid, serine or threonine can be incorporated to recognize C in the middle of triplet, and amino acids with small side chains such as alanine can be incorporated to recognize T in the middle of triplet.
  • a further substitution rule is that the 3′ base of triplet subsite can be recognized by incorporating the following amino acids at position ⁇ 1 of the recognition helix: arginine to recognize G, glutamine to recognize A, glutamic acid (or aspartic acid) to recognize C, and threonine to recognize T.
  • these substitution rules are useful in designing zinc finger proteins they do not take into account all possible target sites.
  • the assumption underlying the rules namely that a particular amino acid in a zinc finger is responsible for binding to a particular base in a subsite is only approximate. Context-dependent interactions between proximate amino acids in a finger or binding of multiple amino acids to a single base or vice versa can cause variation of the binding specificities predicted by the existing substitution rules.
  • the technique of phage display provides a largely empirical means of generating zinc finger proteins with a desired target specificity (see e.g., Rebar, U.S. Pat. No. 5,789,538; Choo et al., WO 96/06166; Barbas et al., WO 95/19431 and WO 98/543111; Jamieson et al., supra).
  • the method can be used in conjunction with, or as an alternative to rational design.
  • the method involves the generation of diverse libraries of mutagenized zinc finger proteins, followed by the isolation of proteins with desired DNA-binding properties using affinity selection methods. To use this method, the experimenter typically proceeds as follows.
  • a gene for a zinc finger protein is mutagenized to introduce diversity into regions important for binding specificity and/or affinity. In a typical application, this is accomplished via randomization of a single finger at positions ⁇ 1, +2, +3, and +6, and sometimes accessory positions such as +1, +5, +8 and +10.
  • the mutagenized gene is cloned into a phage or phagemid vector as a fusion with gene III of a filamentous phage, which encodes the coat protein pIII.
  • the zinc finger gene is inserted between segments of gene III encoding the membrane export signal peptide and the remainder of pIII, so that the zinc finger protein is expressed as an amino-terminal fusion with pIII or in the mature, processed protein.
  • the mutagenized zinc finger gene may also be fused to a truncated version of gene III encoding, minimally, the C-terminal region required for assembly of pill into the phage particle.
  • the resultant vector library is transformed into E. coli and used to produce filamentous phage which express variant zinc finger proteins on their surface as fusions with the coat protein pIII. If a phagemid vector is used, then the this step requires superinfection with helper phage.
  • the phage library is then incubated with target DNA site, and affinity selection methods are used to isolate phage which bind target with high affinity from bulk phage.
  • the DNA target is immobilized on a solid support, which is then washed under conditions sufficient to remove all but the tightest binding phage. After washing, any phage remaining on the support are recovered via elution under conditions which disrupt zinc finger—DNA binding. Recovered phage are used to infect fresh E. coli ., which is then amplified and used to produce a new batch of phage particles. Selection and amplification are then repeated as many times as is necessary to enrich the phage pool for tight binders such that these may be identified using sequencing and/or screening methods. Although the method is illustrated for pIII fusions, analogous principles can be used to screen ZFP variants as pVIII fusions.
  • the sequence bound by a particular zinc finger protein is determined by conducting binding reactions (see, e.g., conditions for determination of K d , infra) between the protein and a pool of randomized double-stranded oligonucleotide sequences.
  • the binding reaction is analyzed by an electrophoretic mobility shift assay (EMSA), in which protein-DNA complexes undergo retarded migration in a gel and can be separated from unbound nucleic acid.
  • Oligonucleotides which have bound the finger are purified from the gel and amplified, for example, by a polymerase chain reaction.
  • the selection i.e. binding reaction and EMSA analysis
  • Zinc finger proteins are often expressed with a heterologous domain as fusion proteins.
  • Common domains for addition to the ZFP include, e.g., transcription factor domains (activators, repressors, co-activators, co-repressors), silencers, oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (e.g.
  • a preferred domain for fusing with a ZFP when the ZFP is to be used for represssing expression of a target gene is a KRAB repression domain from the human KOX-1 protein (Thiesen et al., New Biologist 2, 363-374 (1990); Margolin et al., Proc. Natl. Acad. Sci.
  • Preferred domains for achieving activation include the HSV VP16 activation domain (see, e.g., Hagmann et al., J. Virol. 71, 5952-5962 (1997)) nuclear hormone receptors (see, e.g., Torchia et al., Curr. Opin. Cell. Biol.
  • polypeptide compounds such as the ZFPs
  • ZFPs polypeptide compounds
  • lipid-protein bilayers that are freely permeable to small, nonionic lipophilic compounds and are inherently impermeable to polar compounds, macromolecules, and therapeutic or diagnostic agents.
  • proteins and other compounds such as liposomes have been described, which have the ability to translocate polypeptides such as ZFPs across a cell membrane.
  • membrane translocation polypeptides have amphiphilic or hydrophobic amino acid subsequences that have the ability to act as membrane-translocating carriers.
  • homeodomain proteins have the ability to translocate across cell membranes.
  • the shortest internalizable peptide of a homeodomain protein, Antennapedia was found to be the third helix of the protein, from amino acid position 43 to 58 (see, e.g., Prochiantz, Current Opinion in Neurobiology 6:629-634 (1996)).
  • Examples of peptide sequences which can be linked to a ZFP, for facilitating uptake of ZFP into cells include, but are not limited to: an 11 amino acid peptide of the tat protein of HIV; a 20 residue peptide sequence which corresponds to amino acids 84-103 of the p16 protein (see Fahraeus et al., Current Biology 6:84 (1996)); the third helix of the 60-amino acid long homeodomain of Antennapedia (Derossi et al., J. Biol. Chem.
  • K-FGF Kaposi fibroblast growth factor
  • VP22 translocation domain from HSV (Elliot & O'Hare, Cell 88:223-233 (1997)).
  • Other suitable chemical moieties that provide enhanced cellular uptake may also be chemically linked to ZFPs.
  • Toxin molecules also have the ability to transport polypeptides across cell membranes. Often, such molecules are composed of at least two parts (called “binary toxins”): a translocation or binding domain or polypeptide and a separate toxin domain or polypeptide. Typically, the translocation domain or polypeptide binds to a cellular receptor, and then the toxin is transported into the cell.
  • Clostridium perfringens iota toxin diphtheria toxin (DT), Pseudomonas exotoxin A (PE), pertussis toxin (PT), Bacillus anthracis toxin, and pertussis adenylate cyclase (CYA)
  • DT diphtheria toxin
  • PE Pseudomonas exotoxin A
  • PT pertussis toxin
  • Bacillus anthracis toxin Bacillus anthracis toxin
  • pertussis adenylate cyclase CYA
  • Such subsequences can be used to translocate ZFPs across a cell membrane.
  • ZFPs can be conveniently fused to or derivatized with such sequences.
  • the translocation sequence is provided as part of a fusion protein.
  • a linker can be used to link the ZFP and the translocation sequence. Any suitable linker can be used, e.g., a peptide linker.
  • a number of the polypeptides disclosed herein have been characterized using the methods disclosed in parent application Ser. No. 09/716,637 (the disclosure of which is hereby incorporated by reference in its entirety); in particular with respect to the effect of their position, within a multi-finger protein, on their sequence specificity.
  • the results of these investigations provide a set of zinc finger sequences that are optimized for recognition of certain triplet target subsites whose 5′-most nucleotide is a G (i.e., GNN triplet subsites).
  • GNN triplet subsites i.e., GNN triplet subsites
  • the optimized, position-specific zinc finger sequences disclosed herein for recognition of GNN target subsites are not limited to use in three-finger proteins.
  • they are also useful in six-finger proteins, which can be made by linkage of two three-finger proteins.
  • GNN subsites A number of zinc finger amino acid sequences which are reported to bind to target subsites in which the 5′-most nucleotide residue is G (i.e., GNN subsites) have recently been disclosed. Segal et al. (1999) Proc. Natl. Acad. Sci. USA 96:2758-2763; Drier et al. (2000) J. Mol. Biol. 303:489-502; U.S. Pat. No. 6,140,081. These GNN-binding zinc fingers were obtained by selection of finger 2 sequences from phage display libraries of three-finger proteins, in which certain amino acid residues of finger 2 had been randomized. Due to the manner in which they were selected, it is not clear whether these sequences would have the same target subsite specificity if they were present in the F1 and/or F3 positions.
  • ZFP polypeptides and nucleic acids encoding the same can be made using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)).
  • nucleic acids less than about 100 bases can be custom ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (http://www.genco.com), ExpressGen Inc.
  • peptides can be custom ordered from any of a variety of sources, such as PeptidoGenic (pkim@ccnet.com), HTI Bio-products, inc. (http://www.htibio.com), BMA Biomedicals Ltd (U.K.), Bio.Synthesis, Inc.
  • Oligonucleotides can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, Tetrahedron Letts. 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter et al., Nucleic Acids Res. 12:6159-6168 (1984). Purification of oligonucleotides is by either denaturing polyacrylamide gel electrophoresis or by reverse phase HPLC.
  • sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace et al., Gene 16:21-26 (1981).
  • Two alternative methods are typically used to create the coding sequences required to express newly designed DNA-binding peptides.
  • One protocol is a PCR-based assembly procedure that utilizes six overlapping oligonucleotides (FIG. 1).
  • Three oligonucleotides (oligos 1, 3, and 5 in FIG. 1) correspond to “universal” sequences that encode portions of the DNA-binding domain between the recognition helices. These oligonucleotides typically remain constant for all zinc finger constructs.
  • the other three “specific” oligonucleotides are designed to encode the recognition helices. These oligonucleotides contain substitutions primarily at positions -1, 2, 3 and 6 on the recognition helices making them specific for each of the different DNA-binding domains.
  • PCR synthesis is carried out in two steps.
  • a double stranded DNA template is created by combining the six oligonucleotides (three universal, three specific) in a four cycle PCR reaction with a low temperature annealing step, thereby annealing the oligonucleotides to form a DNA “scaffold.”
  • the gaps in the scaffold are filled in by high-fidelity thermostable polymerase, the combination of Taq and Pfu polymerases also suffices.
  • the zinc finger template is amplified by external primers designed to incorporate restriction sites at either end for cloning into a shuttle vector or directly into an expression vector.
  • An alternative method of cloning the newly designed DNA-binding proteins relies on annealing complementary oligonucleotides encoding the specific regions of the desired ZFP.
  • This particular application requires that the oligonucleotides be phosphorylated prior to the final ligation step. This is usually performed before setting up the annealing reactions.
  • the “universal” oligonucleotides encoding the constant regions of the proteins (oligos 1, 2 and 3 of above) are annealed with their complementary oligonucleotides.
  • the “specific” oligonucleotides encoding the finger recognition helices are annealed with their respective complementary oligonucleotides.
  • complementary oligos are designed to fill in the region which was previously filled in by polymerase in the above-mentioned protocol.
  • the complementary oligos to the common oligos 1 and finger 3 are engineered to leave overhanging sequences specific for the restriction sites used in cloning into the vector of choice in the following step.
  • the second assembly protocol differs from the initial protocol in the following aspects: the “scaffold” encoding the newly designed ZFP is composed entirely of synthetic DNA thereby eliminating the polymerase fill-in step, additionally the fragment to be cloned into the vector does not require amplification.
  • the design of leaving sequence-specific overhangs eliminates the need for restriction enzyme digests of the inserting fragment.
  • changes to ZFP recognition helices can be created using conventional site-directed mutagenesis methods.
  • Both assembly methods require that the resulting fragment encoding the newly designed ZFP be ligated into a vector.
  • the ZFP-encoding sequence is cloned into an expression vector.
  • Expression vectors that are commonly utilized include, but are not limited to, a modified pMAL-c2 bacterial expression vector (New England BioLabs or an eukaryotic expression vector, pcDNA (Promega). The final constructs are verified by sequence analysis.
  • any suitable method of protein purification known to those of skill in the art can be used to purify ZFPs (see, Ausubel, supra, Sambrook, supra).
  • any suitable host can be used for expression, e.g., bacterial cells, insect cells, yeast cells, mammalian cells, and the like.
  • MBP-ZFP maltose binding protein
  • NEB amylose column
  • High expression levels of the zinc finger chimeric protein can be obtained by induction with IPTG since the MBP-ZFP fusion in the pMal-c2 expression plasmid is under the control of the tac promoter (NEB).
  • Bacteria containing the MBP-ZFP fusion plasmids are inoculated into 2 ⁇ YT medium containing 10 ⁇ M ZnCl2, 0.02% glucose, plus 50 ⁇ g/ml ampicillin and shaken at 37° C.
  • IPTG is added to 0.3 mM and the cultures are allowed to shake. After 3 hours the bacteria are harvested by centrifugation, disrupted by sonication or by passage through a french pressure cell or through the use of lysozyme, and insoluble material is removed by centrifugation.
  • the MBP-ZFP proteins are captured on an amylose-bound resin, washed extensively with buffer containing 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5 mM DTT and 50 ⁇ M ZnC12, then eluted with maltose in essentially the same buffer (purification is based on a standard protocol from NEB). Purified proteins are quantitated and stored for biochemical analysis.
  • the dissociation constants of the purified proteins are typically characterized via electrophoretic mobility shift assays (EMSA) (Buratowski & Chodosh, in Current Protocols in Molecular Biology pp. 12.2.1-12.2.7 (Ausubel ed., 1996)). Affinity is measured by titrating purified protein against a fixed amount of labeled double-stranded oligonucleotide target.
  • the target typically comprises the natural binding site sequence flanked by the 3 bp found in the natural sequence and additional, constant flanking sequences.
  • the natural binding site is typically 9 bp for a three-finger protein and 2 ⁇ 9 bp+intervening bases for a six finger ZFP.
  • the annealed oligonucleotide targets possess a 1 base 5′ overhang which allows for efficient labeling of the target with T4 phage polynucleotide kinase.
  • the target is added at a concentration of 1 nM or lower (the actual concentration is kept at least 10-fold lower than the expected dissociation constant), purified ZFPs are added at various concentrations, and the reaction is allowed to equilibrate for at least 45 min.
  • the reaction mixture also contains 10 mM Tris (pH 7.5), 100 mM KCl, 1 mM MgCl2, 0.1 mM ZnCl2, 5 mM DTT, 10% glycerol, 0.02% BSA.
  • poly d(IC) was also added at 10-100 ⁇ g/ ⁇ l.
  • the equilibrated reactions are loaded onto a 10% polyacrylamide gel, which has been pre-run for 45 min in Tris/glycine buffer, then bound and unbound labeled target is resolved by electrophoresis at 150V. (alternatively, 10-20% gradient Tris-HCl gels, containing a 4% polyacrylamide stacker, can be used)
  • the dried gels are visualized by autoradiography or phosphorimaging and the apparent Kd is determined by calculating the protein concentration that gives half-maximal binding.
  • the assays can also include determining active fractions in the protein preparations. Active fractions are determined by stoichiometric gel shifts where proteins are titrated against a high concentration of target DNA. Titrations are done at 100, 50, and 25% of target (usually at micromolar levels).
  • ZPFs that bind to a particular target gene, and the nucleic acids encoding them can be used for a variety of applications. These applications include therapeutic methods in which a ZFP or a nucleic acid encoding it is administered to a subject and used to modulate the expression of a target gene within the subject. See, for example, co-owned WO 00/41566.
  • the modulation can be in the form of repression, for example, when the target gene resides in a pathological infecting microrganisms, or in an endogenous gene of the patient, such as an oncogene or viral receptor, that is contributing to a disease state.
  • the modulation can be in the form of activation when activation of expression or increased expression of an endogenous cellular gene can ameliorate a diseased state.
  • ZFPs or more typically, nucleic acids encoding them are formulated with a pharmaceutically acceptable carrier as a pharmaceutical composition.
  • Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. (see, e.g., Remington's Pharmaceutical Sciences, 17 th ed. 1985)).
  • the ZFPs alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • Compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally.
  • the formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
  • Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
  • the dose is determined by the efficacy and K d of the particular ZFP employed, the target cell, and the condition of the patient, as well as the body weight or surface area of the patient to be treated.
  • the size of the dose also is determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound or vector in a particular patient
  • ZFPs are used in diagnostic methods for sequence specific detection of target nucleic acid in a sample.
  • ZFPs can be used to detect variant alleles associated with a disease or phenotype in patient samples.
  • ZFPs can be used to detect the presence of particular mRNA species or cDNA in a complex mixtures of mRNAs or cDNAs.
  • ZFPs can be used to quantify copy number of a gene in a sample. For example, detection of loss of one copy of a p53 gene in a clinical sample is an indicator of susceptibility to cancer.
  • ZFPs are used to detect the presence of pathological microorganisms in clinical samples.
  • a suitable format for performing diagnostic assays employs ZFPs linked to a domain that allows immobilization of the ZFP on an ELISA plate.
  • the immobilized ZFP is contacted with a sample suspected of containing a target nucleic acid under conditions in which binding can occur.
  • nucleic acids in the sample are labeled (e.g., in the course of PCR amplification).
  • unlabelled probes can be detected using a second labelled probe. After washing, bound-labelled nucleic acids are detected.
  • ZFPs also can be used for assays to determine the phenotype and function of gene expression.
  • Current methodologies for determination of gene function rely primarily upon either overexpression or removing (knocking out completely) the gene of interest from its natural biological setting and observing the effects. The phenotypic effects observed indicate the role of the gene in the biological system.
  • ZFP-mediated regulation of a gene relative to conventional knockout analysis is that expression of the ZFP can be placed under small molecule control.
  • expression levels of the ZFPs By controlling expression levels of the ZFPs, one can in turn control the expression levels of a gene regulated by the ZFP to determine what degree of repression or stimulation of expression is required to achieve a given phenotypic or biochemical effect.
  • This approach has particular value for drug development.
  • problems of embryonic lethality and developmental compensation can be avoided by switching on the ZFP repressor at a later stage in mouse development and observing the effects in the adult animal.
  • Transgenic mice having target genes regulated by a ZFP can be produced by integration of the nucleic acid encoding the ZFP at any site in trans to the target gene. Accordingly, homologous recombination is not required for integration of the nucleic acid. Further, because the ZFP is trans-dominant, only one chromosomal copy is needed and therefore functional knock-out animals can be produced without backcrossing.
  • PCR products were directly cloned cloning into the Tac promoter vector, pMal-c2 (New England Biolabs, Beverly, Mass.) using the KpnI and BamHI restriction sites.
  • the encoded maltose binding protein-ZFP fusion polypeptides were purified according to the manufacturer's procedures (New England Biolabs, Beverly, Mass.). Binding affinity was measured by gel mobility-shift analysis. All of these procedures are described in detail in co-owned WO 00/41566 and WO 00/42219, as well as in Zhang et al. (2000) J. Biol. Chem. 275:33,850-33,860 and Liu et al. (2001) J. Biol. Chem. 276:11,323-11,334; the disclosures of which are hereby incorporated by reference in their entireties.
  • Designed ZFPs were tested for binding specificity using site selection methods disclosed in parent application U.S. Ser. No. 09/716,637. Briefly, designed proteins were incubated with a population of labeled, double-stranded oligonucleotides comprising a library of all possible 9- or 10-nucleotide target sequences. Five nanomoles of labeled oligonucleotides were incubated with protein, at a protein concentration 4-fold above its K d for its target sequence. The mixture was subjected to gel electrophoresis, and bound oligonucleotides were identified by mobility shift, and extracted from the gel.
  • the purified bound oligonucleotides were amplified, and the amplification products were used for a subsequent round of selection. At each round of selection, the protein concentration was decreased by 2 fold. After 3-5 rounds of selection, amplification products were cloned into the TOPO TA cloning vector (Invitrogen, Carlsbad, Calif.), and the nucleotide sequences of approximately 20 clones were determined. The identities of the target sites bound by a designed protein were determined from the sequences and expressed as a compilation of subsite binding sequences.
  • the second finger of each ZFP preferentially selected subsites other than those to which they were designed to bind (e.g., F2 of ZFP1 was designed to bind TCG, but preferentially selected GTG; F2 of ZFP2 was designed to bind GGT, but preferentially selected GGA).
  • binding affinities of ZFP1 and ZFP2 were measured (see Example 1, supra), both to their original target sequences and to new target sequences reflecting the site selection results.
  • the Mt-1 sequence contains two base changes (compared to the original target sequence for ZFP1) which result in a change in the sequence of the finger 2 subsite to GTG, reflecting the preferred finger 2 subsite sequence obtained by site selection.
  • binding of ZFP1 to the Mt-1 sequence is approximately 4-fold stronger than its binding to the original target sequence (K d of 12.5 nM compared to a K d of 50 nM, see FIG. 1).
  • ZFP2 exhibited the strongest binding affinity for the target sequence containing GGA at the finger 2 subsite (K d of 0.5 nM, FIG. 1), and its affinity for target sequences containing either GGT or GGC at the finger 2 subsite was approximately equal (K d of 1 nM for both targets, FIG. 1). Accordingly, the site selection method, in addition to being useful for iterative optimization of binding specificity, can also be used as a useful indicator of binding affinity.
  • results of these analyses provide optimal position-dependent zinc finger sequences (the sequences shown represent amino acid residues ⁇ 1 through +6 of the recognition helix portion of the finger) for recognition of the 16 GNN target subsites, as well as site selection results for these GNN-specific zinc fingers.
  • Optimal amino acid sequences for recognition of each GNN subsite from each of three positions are thereby provided.
  • the amino acid sequence QSGDLTR ( ⁇ 1 through +6) was tested for its ability to bind the GCA triplet from three positions (F1, F2, and F3) within a three-finger ZFP.
  • FIG. 3A shows that the QSGDLTR sequence bound preferentially to the GCA triplet subsite from the F2 and F3 positions, but not from F1.
  • the presence of QSGDLTR at the F1 position of three different three-finger ZFPs resulted predominantly in selection of GCT. Accordingly, an attempt was made to redesign this sequence to obtain specificity for GCA from the F1 position.
  • the QSGSLTR zinc finger optimized for recognition of the GCA subsite from the F1 position, was tested for its selectivity when located at the F2 position. Accordingly, two ZFPs, one containing QSGSLTR at finger 2 and one containing QSGDLTR at finger 2 (both having identical F1 sequences and identical F3 sequences) were tested by site selection. The results indicated that, when used at the F2 position, QSGSLTR bound preferentially to GTA, rather than GCA. Thus, for optimal binding of a GCA triplet subsite from the F1 position, the amino acid sequence QSGSLTR is required; while, for optimal binding of the same subsite sequence from F2 or F3, QSGDLTR should be used. Accordingly, different zinc finger amino acid sequences may be needed to specify a particular triplet subsite sequence, depending upon the location of the subsite within the target sequence and, hence, upon the position of the finger in the protein.
  • the zinc finger amino acid sequence QSSNLAR ( ⁇ 1 through +6) is expected to bind to GAT, based on design rules. However, this sequence selected GAT only from the F1 position, and not from the F2 and F3 positions, from which the sequence GAA was preferentially bound (FIG. 3B). Similarly, the amino acid sequence QSSHLTR which, based on design rules, should bind GGT, selected GGT at the F1 position, but not at the F2 and F3 positions, from which it preferentially bound GGA (FIG. 3C).
  • TSGHLVR has previously been disclosed to recognize the triplet GGT, based on its selection from a randomized library of zif268 finger 2.
  • TSGHLVR was not specific for the GGT subsite when located at the F1 position (FIG. 3C).
  • the engineered zinc finger protein EP2C binds to a target sequence, GCGGTGGCT with a dissociation constant (K d ) of 2 nM.
  • K d dissociation constant
  • binding affinities of Sp1 and zif268 to their respective targets were also measured under the same conditions, and were determined to be 40 nM for SP1 (target sequence GGGGCGGGG) and 2 nM for zif268 (target sequence GCGTGGGCG).
  • Measurements of binding affinities confirmed that F3 of EP2C bound GTG and GCG equally well (K d s of 2 nM), but bound GAG with a two-fold lower affinity (FIG. 4B).
  • Finger 2 was very specific for the GTG triplet, binding 15-fold less tightly to a GGG triplet (compare 2C0 and 2C3 in FIG. 4B).
  • Finger 1 was also very specific for the GCT triplet, it bound with 4-fold lower affinity to a GAT triplet (2C4) and with 2-fold lower affinity to a GCG triplet (2C5). This example shows, once again, the high degree of correlation between site selection results and binding affinities.
  • Luciferase reporter assays were performed by co-transfection of luciferase reporter construct (200 ng) and pCMV- ⁇ gal (100 ng, used as an internal control) into the EP2C cells seeded in 6-well plates. Expression of the EP2C-VP16 transcriptional activator was induced with doxycycline (0.05 ug/ml) 24 h after transfection of reporter constructs.
  • the target sequences to which EP2C bound with greatest affinity (2C0 and 2C2, K d of 2 nM for each) both stimulated the highest levels of luciferase activity, when used to drive luciferase expression in the reporter construct (FIG. 4B).
  • Target sequences to which EP2C bound with 2-fold lower affinity 2C1 and 2C5 (K d of 4 nM for each), stimulated roughly half the luciferase activity of the 2C0 and 2C2 targets.
  • the 2C3 and 2C4 sequences, for which EP2C showed the lowest in vitro binding affinities also yielded the lowest levels of in vivo activity when used to drive luciferase expression.
  • Target 3B a sequence to which EP2C does not bind, yielded background levels of luciferase activity, similar to those obtained with a luciferase-encoding vector lacking EP2C target sequences (pGL3).
  • binding affinity as determined by K d measurement
  • binding specificity as determined by site selection

Abstract

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5′-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • The present application is a continuation-in-part of copending U.S. patent application Ser. No. 09/535,008, filed Mar. 23, 2000, which application claims the benefit of U.S. provisional applications No. 60/126,238, filed Mar. 24, 1999, No. 60/126,239 filed Mar. 24, 1999, No. 60/146,595 filed Jul. 30, 1999 and No. 60/146,615 filed Jul. 30, 1999. The present application is also a continuation-in-part of copending U.S. patent application Ser. No. 09/716,637, filed Nov. 20, 2000. The disclosures of all of the aforementioned applications are hereby incorporated by reference in their entireties for all purposes.[0001]
  • BACKGROUND
  • Zinc finger proteins (ZFPs) are proteins that can bind to DNA in a sequence-specific manner. Zinc fingers were first identified in the transcription factor TFIIIA from the oocytes of the African clawed toad, [0002] Xenopus laevis. An exemplary motif characterizing one class of these protein (C2H2 class) is -Cys-(X)2-4-Cys-(X)12-His-(X)3-5-His (where X is any amino acid) (SEQ. ID. No:1). A single finger domain is about 30 amino acids in length, and several structural studies have demonstrated that it contains an alpha helix containing the two invariant histidine residues and two invariant cysteine residues in a beta turn co-ordinated through zinc. To date, over 10,000 zinc finger sequences have been identified in several thousand known or putative transcription factors. Zinc finger domains are involved not only in DNA-recognition, but also in RNA binding and in protein-protein binding. Current estimates are that this class of molecules will constitute about 2% of all human genes.
  • The x-ray crystal structure of Zif268, a three-finger domain from a murine transcription factor, has been solved in complex with a cognate DNA sequence and shows that each finger can be superimposed on the next by a periodic rotation. The structure suggests that each finger interacts independently with DNA over 3 base-pair intervals, with side-chains at positions −1, 2 , 3 and 6 on each recognition helix making contacts with their respective DNA triplet subsites. The amino terminus of Zif268 is situated at the 3′ end of the DNA strand with which it makes most contacts. Some zinc fingers can bind to a fourth base in a target segment. If the strand with which a zinc finger protein makes most contacts is designated the target strand, some zinc finger proteins bind to a three base triplet in the target strand and a fourth base on the nontarget strand. The fourth base is complementary to the base immediately 3′ of the three base subsite. [0003]
  • The structure of the Zif268-DNA complex also suggested that the DNA sequence specificity of a zinc finger protein might be altered by making amino acid substitutions at the four helix positions (−1, 2, 3 and 6) on each of the zinc finger recognition helices. Phage display experiments using zinc finger combinatorial libraries to test this observation were published in a series of papers in 1994 (Rebar et al., [0004] Science 263, 671-673 (1994); Jamieson et al., Biochemistry 33, 5689-5695 (1994); Choo et al, PNAS 91, 11163-11167 (1994)). Combinatorial libraries were constructed with randomized side-chains in either the first or middle finger of Zif268 and then used to select for an altered Zif268 binding site in which the appropriate DNA sub-site was replaced by an altered DNA triplet. Further, correlation between the nature of introduced mutations and the resulting alteration in binding specificity gave rise to a partial set of substitution rules for design of ZFPs with altered binding specificity.
  • Greisman & Pabo, [0005] Science 275, 657-661 (1997) discuss an elaboration of the phage display method in which each finger of a Zif268 was successively randomized and selected for binding to a new triplet sequence. This paper reported selection of ZFPs for a nuclear hormone response element, a p53 target site and a TATA box sequence.
  • A number of papers have reported attempts to produce ZFPs to modulate particular target sites. For example, Choo et al., [0006] Nature 372, 645 (1994), report an attempt to design a ZFP that would repress expression of a bcr-abl oncogene. The target segment to which the ZFPs would bind was a nine, base sequence 5′GCA GAA GCC3′ chosen to overlap the junction created by a specific oncogenic translocation fusing the genes encoding bcr and abl. The intention was that a ZFP specific to this target site would bind to the oncogene without binding to abl or bcr component genes. The authors used phage display to screen a mini-library of variant ZFPs for binding to this target segment. A variant ZFP thus isolated was then reported to repress expression of a stably transfected bcr-able construct in a cell line.
  • Pomerantz et al., [0007] Science 267, 93-96 (1995) reported an attempt to design a novel DNA binding protein by fusing two fingers from Zif268 with a homeodomain from Oct-1. The hybrid protein was then fused with a transcriptional activator for expression as a chimeric protein. The chimeric protein was reported to bind a target site representing a hybrid of the subsites of its two components. The authors then constructed a reporter vector containing a luciferase gene operably linked to a promoter and a hybrid site for the chimeric DNA binding protein in proximity to the promoter. The authors reported that their chimeric DNA binding protein could activate expression of the luciferase gene.
  • Liu et al., [0008] PNAS 94, 5525-5530 (1997) report forming a composite zinc finger protein by using a peptide spacer to link two component zinc finger proteins each having three fingers. The composite protein was then further linked to transcriptional activation domain. It was reported that the resulting chimeric protein bound to a target site formed from the target segments bound by the two component zinc finger proteins. It was further reported that the chimeric zinc finger protein could activate transcription of a reporter gene when its target site was inserted into a reporter plasmid in proximity to a promoter operably linked to the reporter.
  • Choo et al., WO 98/53058, WO98/53059, and WO 98/53060 (1998) discuss selection of zinc finger proteins to bind to a target site within the HIV Tat gene. Choo et al. also discuss selection of a zinc finger protein to bind to a target site encompassing a site of a common mutation in the oncogene ras. The target site within ras was thus constrained by the position of the mutation. [0009]
  • Previously-disclosed methods for the design of sequence-specific zinc finger proteins have often been based on modularity of individual zinc fingers; i.e., the ability of a zinc finger to recognize the same target subsite regardless of the location of the finger in a multi-finger protein. Although, in many instances, a zinc finger retains the same sequence specificity regardless of its location within a multi-finger protein; in certain cases, the sequence specificity of a zinc finger depends on its position. For example, it is possible for a finger to recognize a particular triplet sequence when it is present as [0010] finger 1 of a three-finger protein, but to recognize a different triplet sequence when present as finger 2 of a three-finger protein.
  • Attempts to address situations in which a zinc finger behaves in a non-modular fashion (i.e., its sequence specificity depends upon its location in a multi-finger protein) have, to date, involved strategies employing randomization of key binding residues in multiple adjacent zinc fingers, followed by selection. See, for example, Isalan et al. (2001) [0011] Nature Biotechnol. 19:656-660. However, methods for rational design of polypeptides containing non-modular zinc fingers have not heretofore been described.
  • SUMMARY
  • The present disclosure provides compositions comprising and methods involving position dependent recognition of GNN nucleotide triplets by zinc fingers. [0012]
  • Thus, provided herein is a zinc finger protein that binds to a target site, said zinc finger protein comprising a first (F1), a second (F2), and a third (F3) zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, said target site comprising, in 3′ to 5′ direction, a first (S1), a second (S2), and a third (S3) target subsite, each target subsite having the nucleotide sequence GNN, wherein if S1 comprises GAA, F1 comprises the amino acid sequence QRSNLVR; if S2 comprises GAA, β2 comprises the amino acid sequence QSGNLA R; if S3 comprises GAA, F3 comprises the amino acid sequence QSGNLAR; if S1 comprises GAG , F1 comprises the amino acid sequence RSDNLAR; if S2 comprises GAG, F2 comprises the amino acid sequence RSDNLAR; if S3 comprises GAG, F3 comprises the amino acid sequence RSDNLTR; if S1 comprises GAC, F1 comprises the amino acid sequence DRSNLTR; if S2 comprises GAC, F2 comprises the amino acid sequence DRSNLTR; if S3 comprises GAC, F3 comprises the amino acid sequence DRSNLTR; if S comprises GAT , F1 comprises the amino acid sequence QSSNLAR; if S2 comprises GAT, F2 comprises the amino acid sequence TSGNLVR; if S3 comprises GAT, F3 comprises the amino acid sequence TSANLSR; if S1 comprises GGA, F1 comprises the amino acid sequence QSGHLAR; if S2 comprises GGA, F2 comprises the amino acid sequence QSGHLQR; if S3 comprises GGA, F3 comprises the amino acid sequence QSGHLQR; if S1 comprises GGG, F1 comprises the amino acid sequence RSDHLAR; if S2 comprises GGG, F2 comprises the amino acid sequence RSDHLSR; if S3 comprises GGG, F3 comprises the amino acid sequence RSDHLSR; if S1 comprises GGC, F1 comprises the amino acid sequence DRSHLRT; if S2 comprises GGC, F2 comprises the amino acid sequence DRSHLAR; if S1 comprises GGT, F1 comprises the amino acid sequence QSSHLTR; if S2 comprises GGT, F2 comprises the amino acid sequence TSGHLSR; if S3 comprises GGT, F3 comprises the amino acid sequence TSGHLVR; if S1 comprises GCA, F1 comprises the amino acid sequence QSGSLTR; if S2 comprises GCA, F2 comprises QSGDLTR; if S3 comprises GCA, F3 comprises QSGDLTR; if S1 comprises GCG, F1 comprises the amino acid sequence RSDDLTR; if S2 comprises GCG, F2 comprises the amino acid sequence RSDDLQR; if S3 comprises GCG, F3 comprises the amino acid sequence RSDDLTR; if S1 comprises GCC, F1 comprises the amino acid sequence ERGTLAR; if S2 comprises GCC, F2 comprises the amino acid sequence DRSDLTR; if S3 comprises GCC, F3 comprises the amino acid sequence DRSDLTR; if S1 comprises GCT, F1 comprises the amino acid sequence QSSDLTR; if S2 comprises GCT, F2 comprises the amino acid sequence QSSDLTR; if S3 comprises GCT, F3 comprises the amino acid sequence QSSDLQR; if S1 comprises GTA, F1 comprises the amino acid sequence QSGALTR; if S2 comprises GTA, F2 comprises the amino acid sequence QSGALAR; if S1 comprises GTG, F1 comprises the amino acid sequence RSDALTR; if S2 comprises GTG, F2 comprises the amino acid sequence RSDALSR; if S3 comprises GTG, F3 comprises the amino acid sequence RSDALTR; if S1 comprises GTC, F1 comprises the amino acid sequence DRSALAR; if S2 comprises GTC, F2 comprises the amino acid sequence DRSALAR; and if S3 comprises GTC, F3 comprises the amino acid sequence DRSALAR. [0013]
  • Also provided are methods of designing a zinc finger protein comprising a first (F1), a second (F2), and a third (F3) zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus that binds to a target site comprising, in 3′ to 5′ direction, a first (S1), a second (S2), and a third (S3) target subsite, each target subsite having the nucleotide sequence GNN, the method comprising the steps of (a) selecting the F1 zinc finger such that it binds to the S1 target subsite, wherein if S1 comprises GAA, F1 comprises the amino acid sequence QRSNLVR; if S1 comprises GAG, F1 comprises the amino acid sequence RSDNLAR; if S1 comprises GAC, F1 comprises the amino acid sequence DRSNLTR; if S1 comprises GAT, F1 comprises the amino acid sequence QSSNLAR; if S1 comprises GGA, F1 comprises the amino acid sequence QSGHLAR; if S1 comprises GGG, F1 comprises the amino acid sequence RSDHLAR; if S1 comprises GGC, F1 comprises the amino acid sequence DRSHLRT; if S1 comprises GGT, F1 comprises the amino acid sequence QSSHLTR; if S1 comprises GCA, F1 comprises QSGSLTR; if S1 comprises GCG, F1 comprises RSDDLTR; if S2 comprises GCG, F2 comprises RSDDLQR; if S1 comprises GCC, F1 comprises ERGTLAR; if S1 comprises GCT, F1 comprises the amino acid sequence QSSDLTR; if S1 comprises GTA, F1 comprises the amino acid sequence QSGALTR; if S1 comprises GTG, F1 comprises the amino acid sequence RSDALTR; if S1 comprises GTC, F1 comprises the amino acid sequence DRSALAR; (b) selecting the F2 zinc finger such that it binds to the S2 target subsite, wherein S2 comprises GAA, F2 comprises the amino acid sequence QSGNLAR; if S2 comprises GAG, F2 comprises the amino acid sequence RSDNLAR; if S2 comprises GAC, F2 comprises the amino acid sequence DRSNLTR; if S2 comprises GAT, F2 comprises the amino acid sequence TSGNLVR; if S2 comprises GGA, F2 comprises the amino acid sequence QSGHLQR; if S2 comprises GGG, F2 comprises the amino acid sequence RSDHLSR; if S2 comprises GGC, F2 comprises the amino acid sequence DRSHLAR; if S2 comprises GGT, F2 comprises the amino acid sequence TSGHLSR; if S2 comprises GCA, F2 comprises the amino acid sequence QSGDLTR; if S2 comprises GCC, F2 comprises the amino acid sequence DRSDLTR; if S2 comprises GCT, F2 comprises the amino acid sequence QSSDLTR; if S2 comprises GTA, F2 comprises the amino acid sequence QSGALAR; if S2 comprises GTG, F2 comprises the amino acid sequence RSDALSR; if S2 comprises GTC, F2 comprises the amino acid sequence DRSALAR; and (c) selecting the F3 zinc finger such that it binds to the S3 target subsite, wherein if S3 comprises GAA, F3 comprises the amino acid sequence QSGNLAR; if S3 comprises GAG, F3 comprises the amino acid sequence RSDNLTR; if S3 comprises GAC, F3 comprises the amino acid sequence DRSNLTR; if S3 comprises GAT, F3 comprises the amino acid sequence TSANLSR; if S3 comprises GGA, F3 comprises the amino acid sequence QSGHLQR; if S3 comprises GGG, F3 comprises RSDHLSR; if S3 comprises GGT, F3 comprises the amino acid sequence TSGHLVR; if S3 comprises GCA, F3 comprises the amino acid sequence QSGDLTR; if S3 comprises GCG, F3 comprises the amino acid sequence RSDDLTR; if S3 comprises GCC, F3 comprises the amino acid sequence DRSDLTR; if S3 comprises GCT, F3 comprises the amino acid sequence QSSDLQR; if S3 comprises GTG, F3 comprises RSDALTR; and if S3 comprises GTC, F3 comprises the amino acid sequence DRSALAR; [0014]
  • thereby designing a zinc finger protein that binds to a target site. [0015]
  • In certain embodiments of the zinc finger proteins and methods described herein, S1 comprises GAA and F1 comprises the amino acid sequence QRSNLVR. In other embodiments, S2 comprises GAA and F2 comprises the amino acid sequence QSGNLAR. In other embodiments, S3 comprises GAA and F3 comprises the amino acid sequence QSGNLAR. In other embodiments, S1 comprises GAG and F1 comprises the amino acid sequence RSDNLAR. In other embodiments, S2 comprises GAG and F2 comprises the amino acid sequence RSDNLAR. In other embodiments, S3 comprises GAG and F3 comprises the amino acid sequence RSDNLTR. In other embodiments, S1 comprises GAC and F1 comprises the amino acid sequence DRSNLTR. In other embodiments, S2 comprises GAC and F2 comprises the amino acid sequence DRSNLTR. In other embodiments, S3 comprises GAC and F3 comprises the amino acid sequence DRSNLTR . In other embodiments, S1 comprises GAT and F1 comprises the amino acid sequence QSSNLAR. In other embodiments, S2 comprises GAT and F2 comprises the amino acid sequence TSGNLVR . In other embodiments, S3 comprises GAT and F3 comprises the amino acid sequence TSANLSR. In other embodiments, S1 comprises GGA and F1 comprises the amino acid sequence QSGHLAR. In other embodiments, S2 comprises GGA and F2 comprises the amino acid sequence QSGHLQR. In other embodiments, S3 comprises GGA and F3 comprises the amino acid sequence QSGHLQR. In other embodiments, S1 comprises GGG and F1 comprises the amino acid sequence RSDHLAR. In other embodiments, S2 comprises GGG and F2 comprises the amino acid sequence RSDHLSR. In other embodiments, S3 comprises GGG and F3 comprises the amino acid sequence RSDHLSR. In other embodiments, S1 comprises GGC and F1 comprises the amino acid sequence DRSHLTR. In other embodiments, S2 comprises GGC and F2 comprises the amino acid sequence DRSHLAR. In other embodiments, S1 comprises GGT and F1 comprises the amino acid sequence QSSHLTR. In other embodiments, S2 comprises GGT and F2 comprises the amino acid sequence TSGHLSR. In other embodiments, S3 comprises GGT and F3 comprises the amino acid sequence TSGHLVR. In other embodiments, S1 comprises GCA and F1 comprises the amino acid sequence QSGSLTR. In other embodiments, S2 comprises GCA and F2 comprises the amino acid sequence QSGDLTR. In other embodiments, S3 comprises GCA and F3 comprises the amino acid sequence QSGDLTR. In other embodiments, S1 comprises GCG and F1 comprises the amino acid sequence RSDDLTR. In other embodiments, S2 comprises GCG and F2 comprises the amino acid sequence RSDDLQR. In other embodiments, S3 comprises GCG and F3 comprises the amino acid sequence RSDDLTR. In other embodiments, S1 comprises GCC and F1 comprises the amino acid sequence ERGTLAR. In other embodiments, S2 comprises GCC and F2 comprises the amino acid sequence DRSDLTR. In other embodiments, S3 comprises GCC and F3 comprises the amino acid sequence DRSDLTR. in other embodiments, S1 comprises GCT and F1 comprises the amino acid sequence QSSDLTR. In other embodiments, S2 comprises GCT and F2 comprises the amino acid sequence QSSDLTR. In other embodiments, S3 comprises GCT and F3 comprises the amino acid sequence QSSDLQR. In other embodiments, S1 comprises GTA and F1 comprises the amino acid sequence QSGALTR . In other embodiments, S2 comprises GTA and F2 comprises the amino acid sequence QSGALAR . In other embodiments, S1 comprises GTG and F1 comprises the amino acid sequence RSDALTR. In other embodiments, S2 comprises GTG and F2 comprises the amino acid sequence RSDALSR. In other embodiments, S3 comprises GTG and F3 comprises the amino acid sequence RSDALTR. In other embodiments, S1 comprises GTC and F1 comprises the amino acid sequence DRSALAR. In other embodiments, S2 comprises GTC and F2 comprises the amino acid sequence DRSALAR . In other embodiments, S3 comprises GTC and p3 comprises the amino acid sequence DRSALAR. [0016]
  • Also provided are polypeptides comprising any of zinc finger proteins described herein. In certain embodiments, the polypeptide further comprises at least one functional domain. Also provided are polynucleotides encoding any of the polypeptides described herein. Thus, also provided are nucleic acid encoding zinc fingers, including all of the zinc fingers described above. [0017]
  • Also provided are segments of a zinc finger comprising a sequence of seven contiguous amino acids as shown herein. Also provided are nucleic acids encoding any of these segments and zinc fingers comprising the same. [0018]
  • Also provided are zinc finger proteins comprising first, second and third zinc fingers. The first, second and third zinc fingers comprise respectively first, second and third segments of seven contiguous amino acids as shown herein. Also provided are nucleic acids encoding such zinc finger proteins.[0019]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows results of site selection analysis of two representative zinc finger proteins (leftmost 4 columns) and measurements of binding affinity for each of these proteins to their intended target sequences and to variant target sequences. (rightmost 3 columns). Analysis of ZFP1 is shown in the upper portion of the figure and analysis of ZFP2 is shown in the lower portion of the figure. For the site selection analyses, the amino acid sequences of residues −1 through +6 of the recognition helix of each of the three component zinc fingers (F3, F2 and F1) are shown across the top row; the intended target sequence (divided into finger-specific target subsites) is shown across the second row, and a summary of the sequences bound is shown in the third row. Data for F3 is shown in the second column, data for F2 is shown in the third column, and data for F1 is shown in the third column. [0020]
  • For the binding affinity analyses, the designed target sequence for each ZFP (“cognate”) and two related sequences (“Mt”) are shown (column 6), along with the K[0021] d for binding of the ZFP to each of these sequences (column 7).
  • FIG. 2 shows amino acid sequences of zinc finger recognition regions (amino acids −1 through +6 of the recognition helix) that bind to each of the 16 GNN triplet subsites. Three amino acid sequences are shown for each trinucleotide subsite; these correspond to optimal amino acid sequences for recognition of the subsite from each of the three positions ([0022] finger 1, F1; finger 2, F2; or finger 3, F3) in a three-finger zinc finger protein. Amino acid sequences are from N-terminal to C-terminal; nucleotide sequences are from 5′ to 3′.
  • Also shown are site selection results for each of the 48 position-dependent GNN-recognizing zinc fingers. These show the number of times a particular nucleotide was present, at a given position, in a collection of oligonucleotide sequences bound by the finger. For example, out of 15 oligonucleotides bound by a zinc finger protein with the amino acid sequence QSGHLAR present at the finger 1 (F1) position, 15 contained a G in the 5′-most position of the subsite, 15 contained a G in the middle position of the subsite, while, at the 3′-most position of the subsite, 10 contained an A, 3 contained a G and 2 contained a T. Accordingly, this particular amino acid sequence is optimal for binding a GGA triplet from the F1 position. [0023]
  • FIGS. 3A, 3B and [0024] 3C show site selection data indicating positional dependence of GCA-, GAT- and GGT-binding zinc fingers. The first and fourth (where applicable) rows of each figure show portions of the amino acid sequence of a designed zinc finger protein. Amino acid residues −1 through +6 of each α-helix are listed from left to right. The second and fifth (where applicable) rows show the target sequence, divided into three triplet subsites, one for each finger of the protein shown in the first and fourth (where applicable) rows, respectively. The third and sixth (where applicable) rows show the distribution of nucleotides in the oligonucleotides obtained by site selection with the proteins shown in the first and fourth (where applicable) rows, respectively. FIG. 3A shows data for fingers designed to bind GCA; FIG. 3B shows data for fingers designed to bind GAT; FIG. 3C shows data for fingers designed to bind GGT.
  • FIGS. 4A and 4B show properties of the engineered ZFP EP2C. FIG. 4A shows site selection data. The first row provides the amino acid sequences of residues −1 through +6 of the recognition helices for each of the three zinc fingers of the EP2C protein. The second row shows the target sequence (5′ to 3′); with the distribution of nucleotides in the oligonucleotides obtained by site selection indicated below the target sequence. [0025]
  • FIG. 4B shows in vitro and in vivo assays for the binding specificity of EP2C. The first three columns show in vitro measurements of binding affinity of EP2C to its intended target sequence and several related sequences. The first column gives the name of each sequence (2C0 is the intended target sequence, compare to FIG. 4A). The second column shows the nucleotide sequence of various target sequences, with differences from the intended target sequence (2C0) highlighted. The third column shows the K[0026] d (in nM) for binding of EP2C to each of the target sequences. Kds were determined by gel shift assays, using 2-fold dilution series of EP2C. The right side of the figure (fourth column and bar graph) shows relative luciferase activities (normalized to β-galactosidase levels) in stable cell lines in which expression of EP2C is inducible. Cells were co-transfected with a vector containing a luciferase coding region under the transcriptional control of the target sequence shown in the same row of the figure, and a control vector encoding β-galactosidase. Luciferase and β-galactosidase levels were measured after induction of EP2C expression. Triplicate samples were assayed and the standard deviations are shown in the bar graph. pGL3 is a luciferase-encoding vector lacking EP2C target sequences. 3B is another negative control, in which luciferase expression is under transcriptional control of sequences (3B) unrelated to the EP2C target sequence.
  • DEFINITIONS
  • A zinc finger DNA binding protein is a protein or segment within a larger protein that binds DNA in a sequence-specific manner as a result of stabilization of protein structure through coordination of a zinc ion. The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP. [0027]
  • Zinc finger proteins can be engineered to recognize a selected target sequence in a nucleic acid. Any method known in the art or disclosed herein can be used to construct an engineered zinc finger protein or a nucleic acid encoding an engineered zinc finger protein. These include, but are not limited to, rational design, selection methods (e.g., phage display) random mutagenesis, combinatorial libraries, computer design, affinity selection, use of databases matching zinc finger amino acid sequences with target subsite nucleotide sequences, cloning from cDNA and/or genomic libraries, and synthetic constructions. An engineered zinc finger protein can comprise a new combination of naturally-occurring zinc finger sequences. Methods for engineering zinc finger proteins are disclosed in co-owned WO 00/41566 and WO 00/42219; as well as in WO 98/53057; WO 98/53058; WO 98/53059 and WO 98/53060; the disclosures of which are hereby incorporated by reference in their entireties. Methods for identifying preferred target sequences, and for engineering zinc finger proteins to bind to such preferred target sequences, are disclosed in co-owned WO 00/42219. [0028]
  • A designed zinc finger protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data. [0029]
  • A selected zinc finger protein is a protein not found in nature whose production results primarily from an empirical process such as phage display. [0030]
  • The term naturally-occurring is used to describe an object that can be found in nature as distinct from being artificially produced by man. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring. Generally, the term naturally-occurring refers to an object as present in a non-pathological (undiseased) individual, such as would be typical for the species. [0031]
  • A nucleic acid is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it increases the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by up to several kilobases or more and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous. [0032]
  • A specific binding affinity between, for example, a ZFP and a specific target site means a binding affinity of at least 1×10[0033] 6 M−1.
  • The terms “modulating expression” “inhibiting expression” and “activating expression” of a gene refer to the ability of a zinc finger protein to activate or inhibit transcription of a gene. Activation includes prevention of subsequent transcriptional inhibition (i.e., prevention of repression of gene expression) and inhibition includes prevention of subsequent transcriptional activation (i.e., prevention of gene activation). Modulation can be assayed by determining any parameter that is indirectly or directly affected by the expression of the target gene. Such parameters include, e.g., changes in RNA or protein levels, changes in protein activity, changes in product levels, changes in downstream gene expression, changes in reporter gene transcription (luciferase, CAT, beta-galactosidase, GFP (see, e.g., Mistili & Spector, [0034] Nature Biotechnology 15:961-964 (1997)); changes in signal transduction, phosphorylation and dephosphorylation, receptor-ligand interactions, second messenger concentrations (e.g., cGMP, cAMP, IP3, and Ca2+), cell growth, neovascularization, in vitro, in vivo, and ex vivo. Such functional effects can be measured by any means known to those skilled in the art, e.g., measurement of RNA or protein levels, measurement of RNA stability, identification of downstream or reporter gene expression, e.g., via chemiluminescence, fluorescence, calorimetric reactions, antibody binding, inducible markers, ligand binding assays; changes in intracellular second messengers such as cGMP and inositol triphosphate (IP3); changes in intracellular calcium levels; cytokine release, and the like.
  • A “regulatory domain” refers to a protein or a protein subsequence that has transcriptional modulation activity. Typically, a regulatory domain is covalently or non-covalently linked to a ZFP to modulate transcription. Alternatively, a ZFP can act alone, without a regulatory domain, or with multiple regulatory domains to modulate transcription. [0035]
  • A D-able subsite within a target site has the [0036] motif 5′NNGK3′. A target site containing one or more such motifs is sometimes described as a D-able target site. A zinc finger appropriately designed to bind to a D-able subsite is sometimes referred to as a D-able finger. Likewise a zinc finger protein containing at least one finger designed or selected to bind to a target site including at least one D-able subsite is sometimes referred to as a D-able zinc finger protein.
  • DETAILED DESCRIPTION
  • I. General [0037]
  • Tables 1-5 list a collection of nonnaturally occurring zinc finger protein sequences and their corresponding target sites. The first column of each table is an internal reference number. The second column lists a 9 or 10 base target site bound by a three-finger zinc finger protein, with the target sites listed in 5′ to 3′ orientation. The third column provides SEQ ID NOs for the target site sequences listed in [0038] column 2. The fourth, sixth and eighth columns list amino acid residues from the first, second and third fingers, respectively, of a zinc finger protein which recognizes the target sequence listed in the second column. For each finger, seven amino acids, occupying positions −1 to +6 of the finger, are listed. The numbering convention for zinc fingers is defined below. Columns 5, 7 and 9 provide SEQ ID NOs for the amino acid sequences listed in columns 4, 6 and 8, respectively. The final column of each table lists the binding affinity (i.e., the Kd in nM) of the zinc finger protein for its target site. Binding affinities are measured as described below.
  • Each finger binds to a triplet of bases within a corresponding target sequence. The first finger binds to the first triplet starting from the 3′ end of a target site, the second finger binds to the second triplet, and the third finger binds the third (i.e., the 5′-most) triplet of the target sequence. For example, the RSDSLTS finger (SEQ ID NO:646) of SBS# 201 (Table 2) binds to 5′TTG3′, the ERSTLTR finger (SEQ ID NO:851) binds to 5′GCC3′ and the QRADLRR finger (SEQ ID NO:1056) binds to 5′GCA3′. [0039]
  • Table 6 lists a collection of consensus sequences for zinc fingers and the target sites bound by such sequences. Conventional one letter amino acid codes are used to designate amino acids occupying consensus positions. The symbol “X” designates a nonconsensus position that can in principle be occupied by any amino acid. In most zinc fingers of the C[0040] 2H2 type, binding specificity is principally conferred by residues −1, +2, +3 and +6. Accordingly, consensus sequence determining binding specificity typically include at least these residues. Consensus sequences are useful for designing zinc fingers to bind to a given target sequence. Residues occupying other positions can be selected based on sequences in Tables 1-5, or other known zinc finger sequences. Alternatively, these positions can be randomized with a plurality of candidate amino acids and screened against one or more target sequences to refine binding specificity or improve binding specificity. In general, the same consensus sequence can be used for design of a zinc finger regardless of the relative position of that finger in a multi-finger zinc finger protein. For example, the sequence RXDNXXR can be used to design a N-terminal, central or C-terminal finger of three finger protein. However, some consensus sequences are most suitable for designing a zinc finger to occupy a particular position in a multi-finger protein. For example, the consensus sequence RXDHXXQ is most suitable for designing a C-terminal finger of a three-finger protein.
  • II. Characteristics of Zinc Finger Proteins [0041]
  • Zinc finger proteins are formed from zinc finger components. For example, zinc finger proteins can have one to thirty-seven fingers, commonly having 2, 3, 4, 5 or 6 fingers. A zinc finger protein recognizes and binds to a target site (sometimes referred to as a target segment) that represents a relatively small subsequence within a target gene. Each component finger of a zinc finger protein can bind to a subsite within the target site. The subsite includes a triplet of three contiguous bases all on the same strand (sometimes referred to as the target strand). The subsite may or may not also include a fourth base on the opposite strand that is the complement of the base immediately 3′ of the three contiguous bases on the target strand. In many zinc finger proteins, a zinc finger binds to its triplet subsite substantially independently of other fingers in the same zinc finger protein. Accordingly, the binding specificity of zinc finger protein containing multiple fingers is usually approximately the aggregate of the specificities of its component fingers. For example, if a zinc finger protein is formed from first, second and third fingers that individually bind to triplets XXX, YYY, and ZZZ, the binding specificity of the zinc finger protein is 3′XXX YYY ZZZ5′. [0042]
  • The relative order of fingers in a zinc finger protein from N-terminal to C-terminal determines the relative order of triplets in the 3′ to 5′ direction in the target. For example, if a zinc finger protein comprises from N-terminal to C-terminal first, second and third fingers that individualy bind, respectively, to [0043] triplets 5′ GAC3′, 5′GTA3′ and 5″GGC3′ then the zinc finger protein binds to the target segment 3′CAGATGCGG5′. If the zinc finger protein comprises the fingers in another order, for example, second finger, first finger, third finger, then the zinc finger protein binds to a target segment comprising a different permutation of triplets, in this example, 3′ATGCAGCGG5′ (see Berg & Shi, Science 271, 1081-1086 (1996)). The assessment of binding properties of a zinc finger protein as the aggregate of its component fingers may, in some cases, be influenced by context-dependent interactions of multiple fingers binding in the same protein.
  • Two or more zinc finger proteins can be linked to have a target specificity that is the aggregate of that of the component zinc finger proteins (see e.g., Kim & Pabo, [0044] PNAS 95, 2812-2817 (1998)). For example, a first zinc finger protein having first, second and third component fingers that respectively bind to XXX, YYY and ZZZ can be linked to a second zinc finger protein having first, second and third component fingers with binding specificities, AAA, BBB and CCC. The binding specificity of the combined first and second proteins is thus 3′XXXYYYZZZ_AAABBBCCC5′, where the underline indicates a short intervening region (typically 0-5 bases of any type). In this situation, the target site can be viewed as comprising two target segments separated by an intervening segment.
  • Linkage can be accomplished using any of the following peptide linkers. T G E K P: (SEQ. ID. No:2) (Liu et al., 1997, supra.); (G4S)[0045] n (SEQ. ID. No:3) (Kim et al., PNAS 93, 1156-1160 (1996.); GGRRGGGS; (SEQ. ID. No:4) LRQRDGERP; (SEQ. ID. No:5) LRQKDGGGSERP; (SEQ. ID. No:6) LRQKD(G3S)2 ERP (SEQ. ID. No:7) Alternatively, flexible linkers can be rationally designed using computer programs capable of modeling both DNA-binding sites and the peptides themselves or by phage display methods . In a further variation, noncovalent linkage can be achieved by fusing two zinc finger proteins with domains promoting heterodimer formation of the two zinc finger proteins. For example, one zinc finger protein can be fused with fos and the other with jun (see Barbas et al., WO 95/119431).
  • Linkage of two zinc finger proteins is advantageous for conferring a unique binding specificity within a mammalian genome. A typical mammalian diploid genome consists of 3×10[0046] 9 bp. Assuming that the four nucleotides A, C, G, and T are randomly distributed, a given 9 bp sequence is present ˜23,000 times. Thus a ZFP recognizing a 9 bp target with absolute specificity would have the potential to bind to ˜23,000 sites within the genome. An 18 bp sequence is present once in 3.4×1010 bp, or about once in a random DNA sequence whose complexity is ten times that of a mammalian genome.
  • A component finger of zinc finger protein typically contains about 30 amino acids and has the following motif (N—C): [0047]
  • Cys-(X)2-4-Cys-X.X.X.X.X.X.X.X.X.X.X.X.-His-(x)3-5-His   (SEQ. ID. No. 8)
  • The two invariant histidine residues and two invariant cysteine residues in a single beta turn are co-ordinated through zinc (see, e.g., Berg & Shi, [0048] Science 271, 1081-1085 (1996)). The above motif shows a numbering convention that is standard in the field for the region of a zinc finger conferring binding specificity. The amino acid on the left (N-terminal side) of the first invariant His residues is assigned the number +6, and other amino acids further to the left are assigned successively decreasing numbers. The alpha helix begins at residue 1 and extends to the residue following the second conserved histidine. The entire helix is therefore of variable length, between 11 and 13 residues.
  • The process of designing or selecting a nonmaturally occurring or variant ZFP typically starts with a natural ZFP as a source of framework residues. The process of design or selection serves to define nonconserved positions (i.e., positions −1 to +6) so as to confer a desired binding specificity. One suitable ZFP is the DNA binding domain of the mouse transcription factor Zif268. The DNA binding domain of this protein has the amino acid sequence: [0049]
  • YACPVESCDRRFSRSDELTRHIRIHTGQKP (F1) (SEQ. ID No:9) [0050]
  • FQCRICMRNFSRSDHLTTHIRTHTGEKP (F2) (SEQ. ID. No:10) [0051]
  • FACDICGRKFARSDERKRHTKIHLRQK (F3) SEQ. ID. No:11) [0052]
  • and binds to a [0053] target 5′ GCG TGG GCG 3′ (SEQ ID No:12).
  • Another suitable natural zinc finger protein as a source of framework residues is Sp-1. The Sp-1 sequence used for construction of zinc finger proteins corresponds to amino acids 531 to 624 in the Sp-1 transcription factor. This sequence is 94 amino acids in length. The amino acid sequence of Sp-1 is as follows: [0054]
  • PGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERP [0055]
  • FMCTWSYCGKRFTRSDELQRHKRTHTGEKK [0056]
  • FACPECPKRFMRSDHLSKHIKTHQNKKG (SEQ. ID. No:13) [0057]
  • Sp-1 binds to a [0058] target site 5′GGG GCG GGG3′ (SEQ ID No:14).
  • An alternate form of Sp-1, an Sp-1 consensus sequence, has the following amino acid sequence: [0059]
  • meklngsgd [0060]
  • PGKKKQHACPECGKSFSKSSHLRAHQRTHTGERP [0061]
  • YKCPECGKSFSRSDELQRHQRTHTGEKP [0062]
  • YKCPECGKSFSRSDHLSKHQRTHQNKKG (SEQ. ID. No:15) (lower case letters are a leader sequence from Shi & Berg, [0063] Chemistry and Biology 1, 83-89. (1995). The optimal binding sequence for the Sp-1 consensus sequence is 5′GGGGCGGGG3′ (SEQ ID No:16). Other suitable ZFPs are described below.
  • There are a number of substitution rules that assist rational design of some zinc finger proteins (see Desjarlais & Berg, [0064] PNAS 90, 2256-2260 (1993); Choo & Klug, PNAS 91, 11163-11167 (1994); Desjarlais & Berg, PNAS 89, 7345-7349 (1992); Jamieson et al., supra; Choo et al., WO 98/53057, WO 98/53058; WO 98/53059; WO 98/53060). Many of these rules are supported by site-directed mutagenesis of the three-finger domain of the ubiquitous transcription factor, Sp-1 (Desjarlais and Berg, 1992; 1993). One of these rules is that a 5′ G in a DNA triplet can be bound by a zinc finger incorporating arginine at position 6 of the recognition helix. Another substitution rule is that a G in the middle of a subsite can be recognized by including a histidine residue at position 3 of a zinc finger. A further substitution rule is that asparagine can be incorporated to recognize A in the middle of triplet, aspartic acid, glutamic acid, serine or threonine can be incorporated to recognize C in the middle of triplet, and amino acids with small side chains such as alanine can be incorporated to recognize T in the middle of triplet. A further substitution rule is that the 3′ base of triplet subsite can be recognized by incorporating the following amino acids at position −1 of the recognition helix: arginine to recognize G, glutamine to recognize A, glutamic acid (or aspartic acid) to recognize C, and threonine to recognize T. Although these substitution rules are useful in designing zinc finger proteins they do not take into account all possible target sites. Furthermore, the assumption underlying the rules, namely that a particular amino acid in a zinc finger is responsible for binding to a particular base in a subsite is only approximate. Context-dependent interactions between proximate amino acids in a finger or binding of multiple amino acids to a single base or vice versa can cause variation of the binding specificities predicted by the existing substitution rules.
  • The technique of phage display provides a largely empirical means of generating zinc finger proteins with a desired target specificity (see e.g., Rebar, U.S. Pat. No. 5,789,538; Choo et al., WO 96/06166; Barbas et al., WO 95/19431 and WO 98/543111; Jamieson et al., supra). The method can be used in conjunction with, or as an alternative to rational design. The method involves the generation of diverse libraries of mutagenized zinc finger proteins, followed by the isolation of proteins with desired DNA-binding properties using affinity selection methods. To use this method, the experimenter typically proceeds as follows. First, a gene for a zinc finger protein is mutagenized to introduce diversity into regions important for binding specificity and/or affinity. In a typical application, this is accomplished via randomization of a single finger at positions −1, +2, +3, and +6, and sometimes accessory positions such as +1, +5, +8 and +10. Next, the mutagenized gene is cloned into a phage or phagemid vector as a fusion with gene III of a filamentous phage, which encodes the coat protein pIII. The zinc finger gene is inserted between segments of gene III encoding the membrane export signal peptide and the remainder of pIII, so that the zinc finger protein is expressed as an amino-terminal fusion with pIII or in the mature, processed protein. When using phagemid vectors, the mutagenized zinc finger gene may also be fused to a truncated version of gene III encoding, minimally, the C-terminal region required for assembly of pill into the phage particle. The resultant vector library is transformed into [0065] E. coli and used to produce filamentous phage which express variant zinc finger proteins on their surface as fusions with the coat protein pIII. If a phagemid vector is used, then the this step requires superinfection with helper phage. The phage library is then incubated with target DNA site, and affinity selection methods are used to isolate phage which bind target with high affinity from bulk phage. Typically, the DNA target is immobilized on a solid support, which is then washed under conditions sufficient to remove all but the tightest binding phage. After washing, any phage remaining on the support are recovered via elution under conditions which disrupt zinc finger—DNA binding. Recovered phage are used to infect fresh E. coli., which is then amplified and used to produce a new batch of phage particles. Selection and amplification are then repeated as many times as is necessary to enrich the phage pool for tight binders such that these may be identified using sequencing and/or screening methods. Although the method is illustrated for pIII fusions, analogous principles can be used to screen ZFP variants as pVIII fusions.
  • In certain embodiments, the sequence bound by a particular zinc finger protein is determined by conducting binding reactions (see, e.g., conditions for determination of K[0066] d, infra) between the protein and a pool of randomized double-stranded oligonucleotide sequences. The binding reaction is analyzed by an electrophoretic mobility shift assay (EMSA), in which protein-DNA complexes undergo retarded migration in a gel and can be separated from unbound nucleic acid. Oligonucleotides which have bound the finger are purified from the gel and amplified, for example, by a polymerase chain reaction. The selection (i.e. binding reaction and EMSA analysis) is then repeated as many times as desired, with the selected oligonucleotide sequences. In this way, the binding specificity of a zinc finger protein having a particular amino acid sequence is determined.
  • Zinc finger proteins are often expressed with a heterologous domain as fusion proteins. Common domains for addition to the ZFP include, e.g., transcription factor domains (activators, repressors, co-activators, co-repressors), silencers, oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (e.g. kinases, acetylases and deacetylases); and DNA modifying enzymes (e.g., methyltransferases, topoisomerases, helicases, ligases, kinases, phosphatases, polymerases, endonucleases) and their associated factors and modifiers. A preferred domain for fusing with a ZFP when the ZFP is to be used for represssing expression of a target gene is a KRAB repression domain from the human KOX-1 protein (Thiesen et al., [0067] New Biologist 2, 363-374 (1990); Margolin et al., Proc. Natl. Acad. Sci. USA 91, 4509-4513 (1994); Pengue et al., Nucl. Acids Res. 22:2908-2914 (1994); Witzgall et al., Proc. Natl. Acad. Sci. USA 91, 4514-4518 (1994). Preferred domains for achieving activation include the HSV VP16 activation domain (see, e.g., Hagmann et al., J. Virol. 71, 5952-5962 (1997)) nuclear hormone receptors (see, e.g., Torchia et al., Curr. Opin. Cell. Biol. 10:373-383 (1998)); the p65 subunit of nuclear factor kappa B (Bitko & Barik, J. Virol. 72:5610-5618 (1998)and Doyle & Hunt, Neuroreport 8:2937-2942 (1997)); Liu et al., Cancer Gene Ther. 5:3-28 (1998)), or artificial chimeric functional domains such as VP64 (Seifpal et al., EMBO J. 11, 4961-4968 (1992)).
  • An important factor in the administration of polypeptide compounds, such as the ZFPs, is ensuring that the polypeptide has the ability to traverse the plasma membrane of a cell, or the membrane of an intra-cellular compartment such as the nucleus. Cellular membranes are composed of lipid-protein bilayers that are freely permeable to small, nonionic lipophilic compounds and are inherently impermeable to polar compounds, macromolecules, and therapeutic or diagnostic agents. However, proteins and other compounds such as liposomes have been described, which have the ability to translocate polypeptides such as ZFPs across a cell membrane. [0068]
  • For example, “membrane translocation polypeptides” have amphiphilic or hydrophobic amino acid subsequences that have the ability to act as membrane-translocating carriers. In one embodiment, homeodomain proteins have the ability to translocate across cell membranes. The shortest internalizable peptide of a homeodomain protein, Antennapedia, was found to be the third helix of the protein, from amino acid position 43 to 58 (see, e.g., Prochiantz, [0069] Current Opinion in Neurobiology 6:629-634 (1996)). Another subsequence, the h (hydrophobic) domain of signal peptides, was found to have similar cell membrane translocation characteristics (see, e.g., Lin et al., J. Biol. Chem. 270:14255-14258 (1995)).
  • Examples of peptide sequences which can be linked to a ZFP, for facilitating uptake of ZFP into cells, include, but are not limited to: an 11 amino acid peptide of the tat protein of HIV; a 20 residue peptide sequence which corresponds to amino acids 84-103 of the p16 protein (see Fahraeus et al., [0070] Current Biology 6:84 (1996)); the third helix of the 60-amino acid long homeodomain of Antennapedia (Derossi et al., J. Biol. Chem. 269:10444 (1994)); the h region of a signal peptide such as the Kaposi fibroblast growth factor (K-FGF) h region (Lin et al., supra); or the VP22 translocation domain from HSV (Elliot & O'Hare, Cell 88:223-233 (1997)). Other suitable chemical moieties that provide enhanced cellular uptake may also be chemically linked to ZFPs.
  • Toxin molecules also have the ability to transport polypeptides across cell membranes. Often, such molecules are composed of at least two parts (called “binary toxins”): a translocation or binding domain or polypeptide and a separate toxin domain or polypeptide. Typically, the translocation domain or polypeptide binds to a cellular receptor, and then the toxin is transported into the cell. Several bacterial toxins, including [0071] Clostridium perfringens iota toxin, diphtheria toxin (DT), Pseudomonas exotoxin A (PE), pertussis toxin (PT), Bacillus anthracis toxin, and pertussis adenylate cyclase (CYA), have been used in attempts to deliver peptides to the cell cytosol as internal or amino-terminal fusions (Arora et al., J. Biol. Chem., 268:3334-3341 (1993); Perelle et al., Infect. Immun., 61:5147-5156 (1993); Stenmark et al., J. Cell Biol. 113:1025-1032 (1991); Donnelly et al., PNAS 90:3530-3534 (1993); Carbonetti et al., Abstr. Annu. Meet. Am. Soc. Microbiol. 95:295 (1995); Sebo et al., Infect. Immun. 63:3851-3857 (1995); Klimpel et al., PNAS U.S.A. 89:10277-10281 (1992); and Novak et al., J. Biol. Chem. 267:17186-17193 1992)).
  • Such subsequences can be used to translocate ZFPs across a cell membrane. ZFPs can be conveniently fused to or derivatized with such sequences. Typically, the translocation sequence is provided as part of a fusion protein. Optionally, a linker can be used to link the ZFP and the translocation sequence. Any suitable linker can be used, e.g., a peptide linker. [0072]
  • III. Position Dependence of Subsite Recognition by Zinc Fingers [0073]
  • A number of the polypeptides disclosed herein have been characterized using the methods disclosed in parent application Ser. No. 09/716,637 (the disclosure of which is hereby incorporated by reference in its entirety); in particular with respect to the effect of their position, within a multi-finger protein, on their sequence specificity. The results of these investigations provide a set of zinc finger sequences that are optimized for recognition of certain triplet target subsites whose 5′-most nucleotide is a G (i.e., GNN triplet subsites). Thus, particular zinc finger sequences which recognize each of the GNN triplet subsites, from each position of a three-finger zinc finger protein, are provided. See FIG. 2. It will be clear to those of skill in the art that the optimized, position-specific zinc finger sequences disclosed herein for recognition of GNN target subsites are not limited to use in three-finger proteins. For example, they are also useful in six-finger proteins, which can be made by linkage of two three-finger proteins. [0074]
  • A number of zinc finger amino acid sequences which are reported to bind to target subsites in which the 5′-most nucleotide residue is G (i.e., GNN subsites) have recently been disclosed. Segal et al. (1999) [0075] Proc. Natl. Acad. Sci. USA 96:2758-2763; Drier et al. (2000) J. Mol. Biol. 303:489-502; U.S. Pat. No. 6,140,081. These GNN-binding zinc fingers were obtained by selection of finger 2 sequences from phage display libraries of three-finger proteins, in which certain amino acid residues of finger 2 had been randomized. Due to the manner in which they were selected, it is not clear whether these sequences would have the same target subsite specificity if they were present in the F1 and/or F3 positions.
  • Use of the methods and compositions disclosed herein has now allowed identification of specific zinc finger sequences that bind each of the 16 GNN triplet subsites, and for the first time, provides zinc finger sequences that are optimized for recognition of these triplet subsites in a position-dependent fashion. Moreover, in vivo studies of these optimized designs reveal that the functionality of a ZFP is correlated with its binding affinity to its target sequence. See Example 6, infra. [0076]
  • As a result of the discovery, disclosed herein, that sequence recognition by zinc fingers is position-dependent, it is clear that existing design rules will not, in and of themselves, be applicable to every situation in which it is necessary to construct a sequence-specific ZFP. The results disclosed herein show that many zinc fingers that are constructed based on design rules exhibit the sequence specificity predicted by those design rules only at certain finger positions. The position-specific zinc fingers disclosed herein are likely to function more efficiently in vivo and in cultured cells, with fewer nonspecific effects. Highly specific ZFPs, made using position-specific zinc fingers, will be useful tools in studying gene function and will find broad applications in areas as diverse as human therapeutics and plant engineering. [0077]
  • IV. Production of Zinc Finger Proteins [0078]
  • ZFP polypeptides and nucleic acids encoding the same can be made using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods include Sambrook et al., [0079] Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)). In addition, nucleic acids less than about 100 bases can be custom ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (http://www.genco.com), ExpressGen Inc. (www.expressgen.com), Operon Technologies Inc. (Alameda, Calif.). Similarly, peptides can be custom ordered from any of a variety of sources, such as PeptidoGenic (pkim@ccnet.com), HTI Bio-products, inc. (http://www.htibio.com), BMA Biomedicals Ltd (U.K.), Bio.Synthesis, Inc.
  • Oligonucleotides can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, [0080] Tetrahedron Letts. 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter et al., Nucleic Acids Res. 12:6159-6168 (1984). Purification of oligonucleotides is by either denaturing polyacrylamide gel electrophoresis or by reverse phase HPLC. The sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace et al., Gene 16:21-26 (1981).
  • Two alternative methods are typically used to create the coding sequences required to express newly designed DNA-binding peptides. One protocol is a PCR-based assembly procedure that utilizes six overlapping oligonucleotides (FIG. 1). Three oligonucleotides ([0081] oligos 1, 3, and 5 in FIG. 1) correspond to “universal” sequences that encode portions of the DNA-binding domain between the recognition helices. These oligonucleotides typically remain constant for all zinc finger constructs. The other three “specific” oligonucleotides ( oligos 2, 4, and 6 in FIG. 1) are designed to encode the recognition helices. These oligonucleotides contain substitutions primarily at positions -1, 2, 3 and 6 on the recognition helices making them specific for each of the different DNA-binding domains.
  • The PCR synthesis is carried out in two steps. First, a double stranded DNA template is created by combining the six oligonucleotides (three universal, three specific) in a four cycle PCR reaction with a low temperature annealing step, thereby annealing the oligonucleotides to form a DNA “scaffold.” The gaps in the scaffold are filled in by high-fidelity thermostable polymerase, the combination of Taq and Pfu polymerases also suffices. In the second phase of construction, the zinc finger template is amplified by external primers designed to incorporate restriction sites at either end for cloning into a shuttle vector or directly into an expression vector. [0082]
  • An alternative method of cloning the newly designed DNA-binding proteins relies on annealing complementary oligonucleotides encoding the specific regions of the desired ZFP. This particular application requires that the oligonucleotides be phosphorylated prior to the final ligation step. This is usually performed before setting up the annealing reactions. In brief, the “universal” oligonucleotides encoding the constant regions of the proteins ([0083] oligos 1, 2 and 3 of above) are annealed with their complementary oligonucleotides. Additionally, the “specific” oligonucleotides encoding the finger recognition helices are annealed with their respective complementary oligonucleotides. These complementary oligos are designed to fill in the region which was previously filled in by polymerase in the above-mentioned protocol. The complementary oligos to the common oligos 1 and finger 3 are engineered to leave overhanging sequences specific for the restriction sites used in cloning into the vector of choice in the following step. The second assembly protocol differs from the initial protocol in the following aspects: the “scaffold” encoding the newly designed ZFP is composed entirely of synthetic DNA thereby eliminating the polymerase fill-in step, additionally the fragment to be cloned into the vector does not require amplification. Lastly, the design of leaving sequence-specific overhangs eliminates the need for restriction enzyme digests of the inserting fragment. Alternatively, changes to ZFP recognition helices can be created using conventional site-directed mutagenesis methods.
  • Both assembly methods require that the resulting fragment encoding the newly designed ZFP be ligated into a vector. Ultimately, the ZFP-encoding sequence is cloned into an expression vector. Expression vectors that are commonly utilized include, but are not limited to, a modified pMAL-c2 bacterial expression vector (New England BioLabs or an eukaryotic expression vector, pcDNA (Promega). The final constructs are verified by sequence analysis. [0084]
  • Any suitable method of protein purification known to those of skill in the art can be used to purify ZFPs (see, Ausubel, supra, Sambrook, supra). In addition, any suitable host can be used for expression, e.g., bacterial cells, insect cells, yeast cells, mammalian cells, and the like. [0085]
  • Expression of a zinc finger protein fused to a maltose binding protein (MBP-ZFP) in bacterial strain JM109 allows for straightforward purification through an amylose column (NEB). High expression levels of the zinc finger chimeric protein can be obtained by induction with IPTG since the MBP-ZFP fusion in the pMal-c2 expression plasmid is under the control of the tac promoter (NEB). Bacteria containing the MBP-ZFP fusion plasmids are inoculated into 2×YT medium containing 10 μM ZnCl2, 0.02% glucose, plus 50 μg/ml ampicillin and shaken at 37° C. At mid-exponential growth IPTG is added to 0.3 mM and the cultures are allowed to shake. After 3 hours the bacteria are harvested by centrifugation, disrupted by sonication or by passage through a french pressure cell or through the use of lysozyme, and insoluble material is removed by centrifugation. The MBP-ZFP proteins are captured on an amylose-bound resin, washed extensively with buffer containing 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5 mM DTT and 50 μM ZnC12, then eluted with maltose in essentially the same buffer (purification is based on a standard protocol from NEB). Purified proteins are quantitated and stored for biochemical analysis. [0086]
  • The dissociation constants of the purified proteins, e.g., Kd, are typically characterized via electrophoretic mobility shift assays (EMSA) (Buratowski & Chodosh, in [0087] Current Protocols in Molecular Biology pp. 12.2.1-12.2.7 (Ausubel ed., 1996)). Affinity is measured by titrating purified protein against a fixed amount of labeled double-stranded oligonucleotide target. The target typically comprises the natural binding site sequence flanked by the 3 bp found in the natural sequence and additional, constant flanking sequences. The natural binding site is typically 9 bp for a three-finger protein and 2×9 bp+intervening bases for a six finger ZFP. The annealed oligonucleotide targets possess a 1 base 5′ overhang which allows for efficient labeling of the target with T4 phage polynucleotide kinase. For the assay the target is added at a concentration of 1 nM or lower (the actual concentration is kept at least 10-fold lower than the expected dissociation constant), purified ZFPs are added at various concentrations, and the reaction is allowed to equilibrate for at least 45 min. In addition the reaction mixture also contains 10 mM Tris (pH 7.5), 100 mM KCl, 1 mM MgCl2, 0.1 mM ZnCl2, 5 mM DTT, 10% glycerol, 0.02% BSA. B: in earlier assays poly d(IC) was also added at 10-100 μg/μl.)
  • The equilibrated reactions are loaded onto a 10% polyacrylamide gel, which has been pre-run for 45 min in Tris/glycine buffer, then bound and unbound labeled target is resolved by electrophoresis at 150V. (alternatively, 10-20% gradient Tris-HCl gels, containing a 4% polyacrylamide stacker, can be used) The dried gels are visualized by autoradiography or phosphorimaging and the apparent Kd is determined by calculating the protein concentration that gives half-maximal binding. [0088]
  • The assays can also include determining active fractions in the protein preparations. Active fractions are determined by stoichiometric gel shifts where proteins are titrated against a high concentration of target DNA. Titrations are done at 100, 50, and 25% of target (usually at micromolar levels). [0089]
  • V. Applications of Engineered Zinc Finger Proteins [0090]
  • ZPFs that bind to a particular target gene, and the nucleic acids encoding them, can be used for a variety of applications. These applications include therapeutic methods in which a ZFP or a nucleic acid encoding it is administered to a subject and used to modulate the expression of a target gene within the subject. See, for example, co-owned WO 00/41566. The modulation can be in the form of repression, for example, when the target gene resides in a pathological infecting microrganisms, or in an endogenous gene of the patient, such as an oncogene or viral receptor, that is contributing to a disease state. Alternatively, the modulation can be in the form of activation when activation of expression or increased expression of an endogenous cellular gene can ameliorate a diseased state. For such applications, ZFPs, or more typically, nucleic acids encoding them are formulated with a pharmaceutically acceptable carrier as a pharmaceutical composition. [0091]
  • Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. (see, e.g., [0092] Remington's Pharmaceutical Sciences, 17th ed. 1985)). The ZFPs, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • The dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose is determined by the efficacy and K[0093] d of the particular ZFP employed, the target cell, and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also is determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound or vector in a particular patient
  • In other applications, ZFPs are used in diagnostic methods for sequence specific detection of target nucleic acid in a sample. For example, ZFPs can be used to detect variant alleles associated with a disease or phenotype in patient samples. As an example, ZFPs can be used to detect the presence of particular mRNA species or cDNA in a complex mixtures of mRNAs or cDNAs. As a further example, ZFPs can be used to quantify copy number of a gene in a sample. For example, detection of loss of one copy of a p53 gene in a clinical sample is an indicator of susceptibility to cancer. In a further example, ZFPs are used to detect the presence of pathological microorganisms in clinical samples. This is achieved by using one or more ZFPs specific to genes within the microorganism to be detected. A suitable format for performing diagnostic assays employs ZFPs linked to a domain that allows immobilization of the ZFP on an ELISA plate. The immobilized ZFP is contacted with a sample suspected of containing a target nucleic acid under conditions in which binding can occur. Typically, nucleic acids in the sample are labeled (e.g., in the course of PCR amplification). Alternatively, unlabelled probes can be detected using a second labelled probe. After washing, bound-labelled nucleic acids are detected. [0094]
  • ZFPs also can be used for assays to determine the phenotype and function of gene expression. Current methodologies for determination of gene function rely primarily upon either overexpression or removing (knocking out completely) the gene of interest from its natural biological setting and observing the effects. The phenotypic effects observed indicate the role of the gene in the biological system. [0095]
  • One advantage of ZFP-mediated regulation of a gene relative to conventional knockout analysis is that expression of the ZFP can be placed under small molecule control. By controlling expression levels of the ZFPs, one can in turn control the expression levels of a gene regulated by the ZFP to determine what degree of repression or stimulation of expression is required to achieve a given phenotypic or biochemical effect. This approach has particular value for drug development. By putting the ZFP under small molecule control, problems of embryonic lethality and developmental compensation can be avoided by switching on the ZFP repressor at a later stage in mouse development and observing the effects in the adult animal. Transgenic mice having target genes regulated by a ZFP can be produced by integration of the nucleic acid encoding the ZFP at any site in trans to the target gene. Accordingly, homologous recombination is not required for integration of the nucleic acid. Further, because the ZFP is trans-dominant, only one chromosomal copy is needed and therefore functional knock-out animals can be produced without backcrossing. [0096]
  • All references cited above are hereby incorporated by reference in their entirety for all purposes. [0097]
  • EXAMPLES Example 1 Initial Design of Zinc Finger Proteins and Determination of Binding Affinity
  • Initial ZFP designs were based on existing design rules, correspondence regimes and ZFP directories, including those disclosed herein (see Tables 1-5) and also in WO 98/53058; WO 98/530059; WO 98/53060 and co-owned U.S. patent application Ser. No. 09/444,241. See also WO 00/42219. Amino acid sequences were conceptually designed using amino acids 532-624 of the human transcription factor Sp1 as a backbone. Polynucleotides encoding designed ZFPs were assembled using a Polymerase Chain Reaction (PCR)-based procedure that utilizes six overlapping oligonucleotides. PCR products were directly cloned cloning into the Tac promoter vector, pMal-c2 (New England Biolabs, Beverly, Mass.) using the KpnI and BamHI restriction sites. The encoded maltose binding protein-ZFP fusion polypeptides were purified according to the manufacturer's procedures (New England Biolabs, Beverly, Mass.). Binding affinity was measured by gel mobility-shift analysis. All of these procedures are described in detail in co-owned WO 00/41566 and WO 00/42219, as well as in Zhang et al. (2000) [0098] J. Biol. Chem. 275:33,850-33,860 and Liu et al. (2001) J. Biol. Chem. 276:11,323-11,334; the disclosures of which are hereby incorporated by reference in their entireties.
  • Example 2 Optimization of Binding Specificity by Site Selection
  • Designed ZFPs were tested for binding specificity using site selection methods disclosed in parent application U.S. Ser. No. 09/716,637. Briefly, designed proteins were incubated with a population of labeled, double-stranded oligonucleotides comprising a library of all possible 9- or 10-nucleotide target sequences. Five nanomoles of labeled oligonucleotides were incubated with protein, at a protein concentration 4-fold above its K[0099] d for its target sequence. The mixture was subjected to gel electrophoresis, and bound oligonucleotides were identified by mobility shift, and extracted from the gel. The purified bound oligonucleotides were amplified, and the amplification products were used for a subsequent round of selection. At each round of selection, the protein concentration was decreased by 2 fold. After 3-5 rounds of selection, amplification products were cloned into the TOPO TA cloning vector (Invitrogen, Carlsbad, Calif.), and the nucleotide sequences of approximately 20 clones were determined. The identities of the target sites bound by a designed protein were determined from the sequences and expressed as a compilation of subsite binding sequences.
  • Example 3 Comparison of Site Selection Results With Binding Affinity
  • To test the correlation between site selection results and the affinity of binding of a ZFP to various related targets, site selection experiments were conducted on 2 three-finger ZFPs, denoted ZFP1 and ZFP2, and the site selection results were compared with K[0100] d measurements obtained from quantitative gel-mobility shift assays using the same ZFPs and target sites. Each ZFP was constructed, based on design rules, to bind to a particular nine-nucleotide target sequence (comprising 3 three-nucleotide subsites), as shown in FIG. 1. Site selection results and affinity measurements are also shown in FIG. 1. The site selection results showed that fingers 1 and 3 of both the ZFP1 and ZFP2 proteins preferentially selected their intended target sequences. However, the second finger of each ZFP preferentially selected subsites other than those to which they were designed to bind (e.g., F2 of ZFP1 was designed to bind TCG, but preferentially selected GTG; F2 of ZFP2 was designed to bind GGT, but preferentially selected GGA).
  • To confirm the site selection results, binding affinities of ZFP1 and ZFP2 were measured (see Example 1, supra), both to their original target sequences and to new target sequences reflecting the site selection results. For example, the Mt-1 sequence contains two base changes (compared to the original target sequence for ZFP1) which result in a change in the sequence of the [0101] finger 2 subsite to GTG, reflecting the preferred finger 2 subsite sequence obtained by site selection. In agreement with the site selection results, binding of ZFP1 to the Mt-1 sequence is approximately 4-fold stronger than its binding to the original target sequence (Kd of 12.5 nM compared to a Kd of 50 nM, see FIG. 1).
  • For ZFP2, the specificity of [0102] finger 2 for the 3′ base of its target subsite was tested, since, although this finger was designed to bind GGT, site selection indicated that it bound preferentially to GGA. Moreover, the site selection results predicted that finger 2 of ZFP2 would bind with approximately equal affinity to GGT and GGC. Accordingly, target sequences containing GGA (Mt-3) and GGC (Mt-4) at the finger 2 subsite were constructed, and binding affinities of ZFP2 to these target sequences, and to its original target sequence (containing GGT at the finger 2 subsite), were compared. In complete agreement with the site selection results, ZFP2 exhibited the strongest binding affinity for the target sequence containing GGA at the finger 2 subsite (Kd of 0.5 nM, FIG. 1), and its affinity for target sequences containing either GGT or GGC at the finger 2 subsite was approximately equal (Kd of 1 nM for both targets, FIG. 1). Accordingly, the site selection method, in addition to being useful for iterative optimization of binding specificity, can also be used as a useful indicator of binding affinity.
  • Example 4 Use of Site Selection to Identify Position-Dependent, GNN-Binding Zinc Fingers
  • A large number of engineered ZFPs have been evaluated, by site selection, to identify zinc fingers that bind to GNN target subsites. In the course of these studies, it became apparent that the binding specificity of a particular zinc finger sequence is, in some instances, dependent upon the position of the zinc finger in the protein, and hence upon the location of the target subsite within the target sequence. For example, if one wishes to design a three-finger zinc finger protein to bind to a target sequence containing the triplet subsite GAT, it is necessary to know whether this subsite is the first, second or third subsite in the target sequence (i.e., whether the GAT subsite will be bound by the first, second or third finger of the protein). Accordingly, over 110 three-finger zinc finger proteins, containing potential GNN-recognizing zinc fingers in various locations, have been evaluated by site selection experiments. Generally, several zinc finger sequences were designed to recognize each GNN triplet, and each design was tested in each of the F1, F2 and F3 positions through 4 to 6 rounds of selection. [0103]
  • The results of these analyses, shown in FIG. 2, provide optimal position-dependent zinc finger sequences (the sequences shown represent amino acid residues −1 through +6 of the recognition helix portion of the finger) for recognition of the 16 GNN target subsites, as well as site selection results for these GNN-specific zinc fingers. Optimal amino acid sequences for recognition of each GNN subsite from each of three positions ([0104] finger 1, finger 2 or finger 3) are thereby provided.
  • GNG-Binding Finger Designs [0105]
  • The amino acid sequence RSDXLXR (position −1 to +6 of the recognition helix) was found to be optimal for binding to the four GNG triplets, with Asn[0106] +3 specifying A as the middle nucleotide; His+3 specifying G as the middle nucleotide; Ala+3 specifying T as the middle nucleotide; and Asp+3 specifying cytosine as the middle nucleotide. At the +5 position, Ala, Thr, Ser, and Gln, were tested, and all showed similar specificity profiles by site selection. Interestingly, and in contrast to a previous report (Swirnoff et al. (1995) Mol. Cell. Biol. 15:2275-2287), site selection results indicated that three naturally-occurring GCG-binding fingers from zif268 and Sp1, having the amino acid sequences RSDELTR, RSDELQR, and RSDERKR, were not GCG-specific. Rather, each of these fingers selected almost equal numbers of GCG and GTG sequences. Analysis of binding affinity by gel-shift experiments confirmed that finger 3 of zif268, having the sequence RSDERKR, binds GCG and GTG with approximately equal affinity.
  • Position Dependence of GCA-, GAT-, GGT-, GAA- and GCC-Binding Fingers [0107]
  • Based on existing design rules, the amino acid sequence QSGDLTR (−1 through +6) was tested for its ability to bind the GCA triplet from three positions (F1, F2, and F3) within a three-finger ZFP. FIG. 3A shows that the QSGDLTR sequence bound preferentially to the GCA triplet subsite from the F2 and F3 positions, but not from F1. In fact, the presence of QSGDLTR at the F1 position of three different three-finger ZFPs resulted predominantly in selection of GCT. Accordingly, an attempt was made to redesign this sequence to obtain specificity for GCA from the F1 position. Since the sequence Q[0108] −1G+2S+3R+6 had previously been selected from a randomized F1 library using GCA as target (Rebar et al. (1994) Science 263:671-673), a D (asp) to S (ser) change was made at the +3 residue of this finger. The resulting sequence, QSGSLTR, was tested for its binding specificity by site selection and found to preferentially bind GCA, from the F1 position, in three different ZFPs (see FIG. 2).
  • The QSGSLTR zinc finger, optimized for recognition of the GCA subsite from the F1 position, was tested for its selectivity when located at the F2 position. Accordingly, two ZFPs, one containing QSGSLTR at [0109] finger 2 and one containing QSGDLTR at finger 2 (both having identical F1 sequences and identical F3 sequences) were tested by site selection. The results indicated that, when used at the F2 position, QSGSLTR bound preferentially to GTA, rather than GCA. Thus, for optimal binding of a GCA triplet subsite from the F1 position, the amino acid sequence QSGSLTR is required; while, for optimal binding of the same subsite sequence from F2 or F3, QSGDLTR should be used. Accordingly, different zinc finger amino acid sequences may be needed to specify a particular triplet subsite sequence, depending upon the location of the subsite within the target sequence and, hence, upon the position of the finger in the protein.
  • Positional effects were also observed for zinc fingers recognizing GAT and GGT subsites. The zinc finger amino acid sequence QSSNLAR (−1 through +6) is expected to bind to GAT, based on design rules. However, this sequence selected GAT only from the F1 position, and not from the F2 and F3 positions, from which the sequence GAA was preferentially bound (FIG. 3B). Similarly, the amino acid sequence QSSHLTR which, based on design rules, should bind GGT, selected GGT at the F1 position, but not at the F2 and F3 positions, from which it preferentially bound GGA (FIG. 3C). Conversely, the amino acid sequence TSGHLVR has previously been disclosed to recognize the triplet GGT, based on its selection from a randomized library of [0110] zif268 finger 2. U.S. Pat. No. 6,140,081. However, TSGHLVR was not specific for the GGT subsite when located at the F1 position (FIG. 3C). These results indicate that the binding specificity of many fingers is position dependent, and particularly point out that the sequence specificity of a zinc finger selected from a F2 library may be positionally limited.
  • The results shown in FIG. 2 indicate that recognition of at least GAA and GCC triplets by zinc fingers is also position dependent. [0111]
  • These positional dependences stand in contrast to earlier published work, which suggested that zinc fingers behaved as independent modules with respect to the sequence specificity of their binding to DNA. Desjarlais et al. (1993) [0112] Proc. Natl. Acad. Sci. USA 90:2256-2260.
  • Example 5 Characterization of EP2C
  • The engineered zinc finger protein EP2C binds to a target sequence, GCGGTGGCT with a dissociation constant (K[0113] d) of 2 nM. Site selection results indicated that fingers 1 and 2 are highly specific for their target subsites, while finger 3 selects GCG (its intended target subsite) and GTG at approximately equal frequencies (FIG. 4A). To confirm these observations, the binding affinities of EP2C to its cognate target sequence, and to variant target sequences, was measured by standard gel-shift analyses (see Example 1, supra). As standards for comparison, the binding affinities of Sp1 and zif268 to their respective targets were also measured under the same conditions, and were determined to be 40 nM for SP1 (target sequence GGGGCGGGG) and 2 nM for zif268 (target sequence GCGTGGGCG). Measurements of binding affinities confirmed that F3 of EP2C bound GTG and GCG equally well (Kds of 2 nM), but bound GAG with a two-fold lower affinity (FIG. 4B). Finger 2 was very specific for the GTG triplet, binding 15-fold less tightly to a GGG triplet (compare 2C0 and 2C3 in FIG. 4B). Finger 1 was also very specific for the GCT triplet, it bound with 4-fold lower affinity to a GAT triplet (2C4) and with 2-fold lower affinity to a GCG triplet (2C5). This example shows, once again, the high degree of correlation between site selection results and binding affinities.
  • Example 6 Evaluation of Engineered ZFPs by in vivo Functional Assays
  • To determine whether a correlation exists between the binding affinity of a engineered ZFP to its target sequence and its functionality in vivo, cell-based reporter gene assays were used to analyze the functional properties of the engineered ZFP EP2C (see Example 5, supra). For these assays, a plasmid encoding the EP2C ZFP, fused to a VP16 transcriptional activation domain, was used to construct a stable cell line (T-Rex-293™, Invitrogen, Carlsbad, Calif.) in which expression of EP2C-VP16 is inducible, as described in Zhang et al., supra. To generate reporter constructs, three tandem copies of the EP2C target site, or its variants (see FIG. 4B, column 2), were inserted between the Mlu I and BglII sites of the pGL3 luciferase-encoding vector (Promega, Madison, Wis.), upstream of the SV40 promoter. Structures of all reporter constructs were confirmed by DNA sequencing. [0114]
  • Luciferase reporter assays were performed by co-transfection of luciferase reporter construct (200 ng) and pCMV-βgal (100 ng, used as an internal control) into the EP2C cells seeded in 6-well plates. Expression of the EP2C-VP16 transcriptional activator was induced with doxycycline (0.05 ug/ml) 24 h after transfection of reporter constructs. Cell lysates were harvested 40 hours post-transfection, luciferase and β-galactosidase activities were measured by the Dual-Light Reporter Assay System (Tropix, Bedford, Mass.), and luciferase activities were normalized to the co-transfected β-galactosidase activities. The results, shown on the right side of FIG. 4B, showed that the normalized luciferase activity for each reporter construct was well correlated with the in vitro binding affinity of EP2C to the target sequence present in the construct. For example, the target sequences to which EP2C bound with greatest affinity (2C0 and 2C2, K[0115] d of 2 nM for each) both stimulated the highest levels of luciferase activity, when used to drive luciferase expression in the reporter construct (FIG. 4B). Target sequences to which EP2C bound with 2-fold lower affinity, 2C1 and 2C5 (Kd of 4 nM for each), stimulated roughly half the luciferase activity of the 2C0 and 2C2 targets. The 2C3 and 2C4 sequences, for which EP2C showed the lowest in vitro binding affinities, also yielded the lowest levels of in vivo activity when used to drive luciferase expression. Target 3B, a sequence to which EP2C does not bind, yielded background levels of luciferase activity, similar to those obtained with a luciferase-encoding vector lacking EP2C target sequences (pGL3). Thus there exist good correlations between binding affinity (as determined by Kd measurement), binding specificity (as determined by site selection) and in vivo functionality for engineered zinc finger proteins.
    TABLE 1
    SEQ SEQ SEQ SEQ Kd
    SBS# TARGET ID F1 ID F2 ID F3 ID (nM)
    249 GCGGGGGCG 17 RSDELTR 123 RSDHLSR 229 RSDELRR 335 20
    250 GCGGGGGCG 18 RSDELTR 124 RSDHLSR 230 RSDTLKK 336 70
    251 GCGGAGGCG 19 RSDELTR 125 RSDNLTR 231 RSDELRR 337 27.5
    252 GCGGCCGCG 20 RSDELTR 126 DRSSLTR 232 RSDELRR 338 100
    253 GGATGGGGG 21 RSDHLAR 127 RSDHLTT 233 QRAHLAR 339 0.75
    256 GCGGGGTCC 22 ERGDLTT 128 RSDHLSR 234 RSDELRR 340 800
    258 GCGGGCGGG 23 RSDHLTR 129 ERGHLTR 235 RSDELRR 341 15
    259 GCAGAGGAG 24 RSDNLAR 130 RSDNLAR 236 QSGSLTR 342 250
    261 GAGGTGGCC 25 ERGTLAR 131 RSDALSR 237 RSDNLSR 343 0.5
    262 GCGGGGGCT 26 QSSDLQR 132 RSDHLSR 238 RSDELRR 344 20
    263 GCGGGGGCT 27 QSSDLQR 133 RSDHLSR 239 RSDTLKK 345 1
    264 GTGGCTGCC 28 DRSSLTR 134 QSSDLQR 240 RSDALAR 346 27
    265 GTGGCTGCC 29 ERGTLAR 135 QSSDLQR 241 RSDALAR 347 600
    269 GGGGCCGGG 30 RSDHLTR 136 DRSSLTR 242 RSDHLTR 348 5
    270 GGGGCCGGG 31 RSDHLTR 137 ERGTLAR 243 RSDHLTR 349 52.5
    272 GCAGGGGCC 32 DRSSLTR 138 RSDHLSR 244 QSGSLTR 350 20
    337 TGCGGGGCAA 33 RSADLTR 139 RSDHLTR 245 ERQHLAT 351 24
    338 TGCGGGGCAA 34 RSADLTR 140 RSDHLTR 246 ERDHLRT 352 8
    339 TGCGGGGCAA 35 RSADLTR 141 RSDHLTT 247 ERQHLAT 353 64
    340 TGCGGGGCAA 36 RSADLTR 142 RSDHLTT 248 ERDHLRT 354 48
    341 TGCGGGGCAA 37 RSADLTR 143 RGDHLKD 249 ERQHLAT 355 1000
    342 TGCGGGGCAA 38 RSADLTR 144 RGDHLKD 250 ERDHLRT 356 1000
    343 TGCGGGGCAA 39 QSGSLTR 145 RSDHLTR 251 ERQHLAT 357 8
    344 TGCGGGGCAA 40 QSGSLTR 146 RSDHLTR 252 ERDHLRT 358 6
    345 TGCGGGGCAA 41 QSGSLTR 147 RSDHLTT 253 ERQHLAT 359 96
    346 TGCGGGGCAA 42 QSGSLTR 148 RSDHLTT 254 ERDHLRT 360 64
    347 TGCGGGGCAA 43 QSGSLTR 149 RGDHLKD 255 ERQHLAT 361 1000
    348 TGCGGGGCAA 44 QSGSLTR 150 RGDHLKD 256 ERDHLRT 362 1000
    367 GGGGGCGGG 45 RSDHLTR 151 DSGHLTR 257 RSDHLQR 363 60
    368 GAGGGGGCG 46 RSDELTR 152 RSDHLTR 258 RSDNLTR 364 3.5
    369 GTAGTTGTG 47 RSDALTR 153 TGGSLAR 259 QSGSLTR 365 95
    370 GTAGTTGTG 48 RSDALTR 154 NRATLAR 260 QSASLTR 366 300
    371 GTAGTTGTG 49 RSDALTR 155 NRATLAR 261 QSGSLTR 367 175
    372 GTAGTTGTG 50 RSDSLLR 156 TGGSLAR 262 QSASLTR 368 112.5
    373 GTAGTTGTG 51 RSDSLLR 157 NRATLAR 263 QSASLTR 369 320
    374 GCTGAGGAA 52 QRSNLVR 158 RSDNLTR 264 TSSELQR 370 3.3
    375 GAGGAAGAT 53 QQSNLAR 159 QSGNLQR 265 RSDNLTR 371 85
    401 GTAGTTGTG 54 RSDALTR 160 TGGSLAR 266 QSASLTR 372 80
    403 GTAGTTGTG 55 RSDSLLR 161 NRATLAR 267 QSGSLTR 373 750
    421 GTAGTTGTG 56 DSDSLLR 162 TGGSLAR 268 QSGSLTR 374 500
    422 GTAGTTGTG 57 RSDSLLR 163 TGGSLTR 269 QSGSLTR 375 200
    423 GTAGTTGTG 58 RSDALTR 164 TGGSLAR 270 QRSALAR 376 1000
    424 GATGCTGAG 59 RSDNLTR 165 TSSELQR 271 TSANLSR 377 100
    425 GATGCTGAG 60 RSDNLTR 166 QSSDLQR 272 QQSNLAR 378 25
    426 GATGCTGAG 61 RSDNLTR 167 QSSDLQR 273 TSANLSR 379 5.5
    427 GCTGAGGAA 62 QRSNLVR 168 RSDNLTR 274 QSSDLQR 380 1
    428 GAAGATGAC 63 DSSNLTR 169 QQSNLAR 275 QRSNLVR 381 120
    429 GAAGATGAC 64 DSSNLTR 170 TSANLSR 276 QRSNLVR 382 50
    430 GATGACGAC 65 EKANLTR 171 DSSNLTR 277 QQSNLAR 383 250
    431 GACGACGGC 66 DSGHLTR 172 DRSNLER 278 DSSNLTR 384 100
    432 GACGACGGC 67 DSGHLTR 173 DHANLAR 279 DSSNLTR 385 1000
    433 GACGACGGC 68 DSGNLTR 174 DHANLAR 280 DSSNLTR 386 1000
    434 GACGGCGTA 69 QSASLTR 175 DSGHLTR 281 EKANLTR 387 152.5
    435 GACGGCGTA 70 QSASLTR 176 DSGHLTR 282 ERGNLTR 388 150
    436 GACGGCGTA 71 QRSALAR 177 DSGHLTR 283 EKANLTR 389 95
    437 GACGGCGTA 72 QRSALAR 178 DSGHLTR 284 ERGNLTR 390 117.5
    438 GAGGGGGCG 73 RSDELTR 179 RSDHLTT 285 RSDNLTR 391 62.5
    440 GCCGAGGTGC 74 RSDSLLR 180 RSKNLQR 286 ERGTLAR 392 40
    441 GGTGGAGTCA 75 DSGSLTR 181 QSGHLQR 287 TSGHLTR 393 250
    445 GTCGCAGTGA 76 RSDSLRR 182 QSSDLQK 288 DSGSLTR 394 1000
    450 GACTTGGTGC 77 RSDTLAR 183 RGDALTS 289 DRSNLTR 395 130
    453 GGTGGAGTCA 78 DRSALAR 184 QSGHLQR 290 DSSKLSR 396 150
    461 GAGTACTGTA 79 QRSHLTT 185 DRSNLRT 291 RSDNLAR 397 120
    463 GTGGAGGAGA 80 RSDNLTR 186 RSDNLAR 292 RSDALAR 398 0.5
    464 GTGGAGGAGA 81 RSDNLTR 187 RSDNLAR 293 RSDSLAR 399 0.4
    466 CAGGCTGCGC 82 RSDDLTR 188 QSSDLQR 294 RSDNLRE 400 65
    467 CAGGCTGCGC 83 RSDELTR 189 QSSDLQR 295 RGDHLKD 401 800
    468 CAGGCTGCGC 84 RSDDLTR 190 QSSDLQR 296 RGDHLKD 402 42
    469 GAAGAGGTCT 85 DRSALAR 191 RSDNLAR 297 QSGNLTR 403 13.5
    472 GAGGTCTGGA 86 RSSHLTT 192 DRSALAR 298 RSDNLAR 404 80
    476 GGAGAGGATG 87 TTSNLRR 193 RSDNLAR 299 QSDHLTR 405 80
    477 GGAGAGGATG 88 TTSNLRR 194 RSDNLAR 300 QRAHLAR 406 100
    478 GGAGAGGATG 89 TTSNLRR 195 RSDNLAR 301 QSGHLRR 407 60
    479 GTGGCGGACC 90 DSSNLTR 196 RSDELQR 302 RSDALAR 408 8.5
    480 GTGGCGGACC 91 DSSNLTR 197 RADTLRR 303 RSDALAR 409 5
    483 GAGGGCGAAG 92 QSANLAR 198 ESSKLKR 304 RSDNLAR 410 130
    484 GAGGGCGAAG 93 QSDNLAR 199 ESSKLKR 305 RSDNLAR 411 1000
    485 GGAGAGGTTT 94 QSSALAR 200 RSDNLAR 306 QRAHLAR 412 110
    487 GGAGAGGTTT 95 NRATLAR 201 RSDNLAR 307 QSGHLAR 413 76.9
    488 TGGTAGGGGG 96 RSDHLAR 202 RSDNLTT 308 RSDHLTT 414 35
    490 TAGGGGGTGG 97 RSDSLLR 203 RSDHLTR 309 RSDNLTT 415 1.5
    503 GCCGAGGTGC 98 RSDSLLR 204 RSDNLAR 310 ERGTLAR 416 50
    504 GCCGAGGTGC 99 RSDSLLR 205 RSDNLAR 311 DRSDLTR 417 25
    505 GCCGAGGTGC 100 RSDSLLR 206 RSDNLAR 312 DCRDLAR 418 65
    526 GCGGGCGGGC 101 RSDHLTR 207 ERGHLTR 313 RSDTLKK 419 8
    543 GAGTGTGTGA 102 RSDLLQR 208 MSHHLKE 314 RSDHLSR 420 50
    544 GAGTGTGTGA 103 RSDSLLR 209 MSHHLKE 315 RSDNLAR 421 125
    545 GAGTGTGTGA 104 RKDSLVR 210 TSDHLAS 316 RSDNLTR 422 32
    546 GAGTGTGTGA 105 RSDLLQR 211 MSHHLKT 317 RLDGLRT 423 500
    547 GAGTGTGTGA 106 RKDSLVR 212 TSGHLTS 318 RSDNLTR 424 500
    548 GAGTGTGTGA 107 RSSLLQR 213 MSHHLKT 319 RSDHLSR 425 500
    549 GAGTGTGTGA 108 RSSLLQR 214 MSHHLKE 320 RSDHLSR 426 500
    550 GAGTGTGTGA 109 RKDSLVR 215 TKDHLAS 321 RSDNKLTR 427 20
    551 GAGTGTGTGA 110 RSDLLQR 216 MSHHLKT 322 RSDHLSR 428 50
    552 GAGTGTGTGA 111 RKDSLVR 217 MSHHLKT 323 RSDNLTR 429 31
    553 GAGTGTGTGA 112 RSDSLLR 218 MSHHLKE 324 RSDNLTR 430 125
    554 GAGTGTGTGA 113 RKDSLVR 219 TSDHLAS 325 RSDNLAR 431 62.5
    558 TGCGGGGCA 114 QSGDLTR 220 RSDHLTR 326 DSGHLAS 432 21
    559 GAGTGTGTGA 115 RSDSLLR 221 TSDHLAS 327 RSDNLAR 433 1000
    560 GAGTGTGTGA 116 RSSLLQR 222 MSHHLKT 328 RSDHLSR 434 500
    561 GAGTGTGTGA 117 RKDSLVR 223 MSHHLKE 329 RSDNLAR 435 1000
    562 GAGTGTGTGA 118 RSDSLLR 224 TSGHLTS 330 RSDNLAR 436 1000
    565 GATGCTGAG 119 RSDNLTR 225 TSSELQR 331 QQSNLAR 437 100
    567 GAAGATGAC 120 EKANLTR 226 TSANLSR 332 QRSNLVR 438 47.5
    568 GATGACGAC 121 EKANLTR 227 DSSNLTR 333 TSANLSR 439 300
    569 GTAGTTGTG 122 RSDSLLR 228 TGGSLAR 334 QRSALTR 440 52
  • [0116]
    TABLE 2
    SEQ SEQ SEQ SEQ Kd
    SBS# TARGET ID F1 ID F2 ID F3 ID (nM)
    201 GCAGCCTTG 441 RSDSLTS 646 ERSTLTR 851 QRADLRR 1056 1000
    202 GCAGCCTTG 442 RSDSLTS 647 ERSTLTR 852 QRADLAR 1057 1000
    203 GCAGCCTTG 443 RSDSLTS 648 ERSTLTR 853 QRATLRR 1058 1000
    204 GCAGCCTTG 444 RSDSLTS 649 ERSTLTR 854 QRATLAR 1059 1000
    205 GAGGTAGAA 445 QSANLAR 650 QSATLAR 855 RSDNLSR 1060 80
    206 GAGGTAGAA 446 QSANLAR 651 QSAVLAR 856 RSDNLSR 1061 1000
    207 GAGTGGTTA 447 QRASLAS 652 RSDHLTT 857 RSDNLAR 1062 70
    208 TAGGTCTTA 448 QRASLAS 653 DRSALAR 858 RSDNLAS 1063 1000
    209 GGAGTGGTT 449 QSSALAR 654 RSDALAR 859 QRAHLAR 1064 35
    210 GGAGTGGTT 450 NRDTLAR 655 RSDALAR 860 QRAHLAR 1065 65
    211 GGAGTGGTT 451 QSSALAR 656 RSDALAS 861 QRAHLAR 1066 140
    212 GGAGTGGTT 452 NRDTLAR 657 RSDALAS 862 QRAHLAR 1067 400
    213 GTTGCTGGA 453 QRAHLAR 658 QSSTLAR 863 QSSALAR 1068 1000
    214 GTTGCTGGA 454 QRAHLAR 659 QSSTLAR 864 NRDTLAR 1069 1000
    215 GAAGTCTGT 455 NRDHLMV 660 DRSALAR 865 QSANLSR 1070 1000
    216 GAAGTCTGT 456 NRDHLTT 661 DRSALAR 866 QSANLSR 1071 1000
    217 GAGGTCGTA 457 QRSALAR 662 DRSALAR 867 RSDNLAR 1072 40
    219 GATGTTGAT 458 QQSNLAR 663 NRDTLAR 868 NRDNLSR 1073 1000
    220 GATGTTGAT 459 QQSNLAR 664 NRDTLAR 869 QQSNLSR 1074 1000
    221 GATGAGTAC 460 DRSNLRT 665 RSDNLAR 870 NRDNLAR 1075 1000
    222 GATGAGTAC 461 ERSNLRT 666 RSDNLAR 871 NRDNLAR 1076 1000
    223 GATGAGTAC 462 DRSNLRT 667 RSDNLAR 872 QQSNLAR 1077 105
    224 GATGAGTAC 463 ERSNLRT 668 RSDNLAR 873 QQSNLAR 1078 1000
    225 TGGGAGGTC 464 DRSALAR 669 RSDNLAR 874 RSDHLTT 1079 6
    226 GCAGCCTTG 465 RGDALTS 670 ERGTLAR 875 QSGSLTR 1080 1000
    227 GCAGCCTTG 466 RGDALTV 671 ERGTLAR 876 QSGSLTR 1081 1000
    228 GCAGCCTTG 467 RGDALTM 672 ERGTLAR 877 QSGSLTR 1082 1000
    229 GCAGCCTTG 468 RGDALTS 673 ERGTLAR 878 RSDELTR 1083 1000
    230 GCAGCCTTG 469 RGDALTV 674 ERGTLAR 879 RSDELTR 1084 1000
    231 GCAGCCTTG 470 RGDALTM 675 ERGTLAR 880 RSDELTR 1085 1000
    232 GGTGTGGTG 471 RSDALTR 676 RSDALAR 881 NRSHLAR 1086 50
    233 GGTGTGGTG 472 RSDALTR 677 RSDALAR 882 QASHLAR 1087 100
    235 GTAGAGGTG 473 RSDALTR 678 RSDNLAR 883 QRGALAR 1088 80
    236 GGGGAGGGG 474 RSDHLAR 679 RSDNLAR 884 RSDHLSR 1089 0.3
    237 GGGGAGGCC 475 ERGTLAR 680 RSDNLAR 885 RSDHLSR 1090 0.3
    238 GGGGAGGCC 476 ERGTLAR 681 RSDNLQR 886 RSDHLSR 1091 0.8
    239 GGCGGGGAG 477 RSDNLTR 682 RSDHLTR 887 DRSHLAR 1092 0.4
    240 GCAGGGGAG 478 RSDNLTR 683 RSDHLSR 888 QSGSLTR 1093 1
    242 GGGGGTGCT 479 QSSDLRR 684 QSSHLAR 889 RSDHLSR 1094 1
    243 GTGGGCGCT 480 QSSDLRR 685 DRSHLAR 890 RSDALAR 1095 75
    244 TAAGAAGGG 481 RSDHLAR 686 QSGNLTR 891 QSGNLRT 1096 100
    245 TAAGAAGGG 482 RSDHLAR 687 QSANLTR 892 QSGNLRT 1097 235
    246 GAAGGGGAG 483 RSDNLAR 688 RSDHLAR 893 QSGNLTR 1098 2
    247 GAAGGGGAG 484 RSDNLAR 689 RSDHLAR 894 QSGNLRR 1099 2
    276 GCGGCCGCG 485 RSDELTR 690 ERGTLAR 895 RSDERKR 1100 90
    277 GCGGCCGCG 486 RSDELTR 691 DRSSLTR 896 RSDERKR 1101 107
    278 GCGGCCGCG 487 QSWELTR 692 ERGTLAR 897 RSDERKR 1102 190
    279 GCGGCCGCG 488 QSWELTR 693 DRSSLTR 898 RSDERKR 1103 260
    280 GCGGCCGCG 489 QSGSLTR 694 ERGTLAR 899 RSDERKR 1104 160
    281 GCGGCCGCG 490 QSGSLTR 695 DRSSLTR 900 RSDERKR 1105 225
    282 GCAGAAGTG 491 RGDALTR 696 QSANLTR 901 QSADLAR 1106 1000
    283 GCAGAAGTG 492 RSDALTR 697 QSGNLTR 902 QSGSLTR 1107 2
    284 GCGGCCGCG 493 QSGSLTR 698 RSDHLTT 903 RSDERKR 1108 1000
    285 TGTGCGGCC 494 ERGTLRG 699 RSDELTR 904 SRDHLQS 1109 1000
    287 GCAGAAGCG 495 RGPDLAR 700 QSANLTR 905 QSGSLTR 1110 1000
    288 GCAGAAGCG 496 RGPDLAR 701 QSANLTR 906 QSGSLTR 1111 1000
    289 GCAGAAGCG 497 RGPDLAR 702 QSGNLQR 907 QSGSLTR 1112 800
    290 GCAGAAGCG 498 RSDELAR 703 QSANLTR 908 QSADLAR 1113 1000
    292 GCAGAAGCG 499 RSDELTR 704 QSANLQR 909 QSGSLTR 1114 1000
    293 GTGTGCGGC 500 DRSHLTR 705 ERHSLQT 910 RSDALTR 1115 320
    296 TGCGCGGCC 501 ERGTLAR 706 RSDELTR 911 DRDHLQS 1116 1000
    297 TGCGCGGCC 502 ERGTLAR 707 RSDELRR 912 DRSHLQT 1117 500
    298 GCTTAGGCA 503 QTGELRR 708 RSDNLQK 913 TSGDLSR 1118 4000
    299 GCTTAGGCA 504 QTSDLRR 709 RSDNLQK 914 QSSDLQR 1119 4000
    300 GCTTAGGCA 505 QTADLRR 710 RSDNLQR 915 QSSDLSR 1120 400
    301 GCTTAGGCA 506 QSADLRR 711 RSDNLQT 916 QSSDLSR 1121 350
    302 GCTTAGGCA 507 QSGSLTR 712 RSDNLQT 917 QSSDLSR 1122 75
    303 GCTTAGGCA 508 QTGSLTR 713 RSDNLQT 918 QSSDLSR 1123 135
    304 GCTTAGGCA 509 QTADLTR 714 RSDNLQT 919 QSSDLSR 1124 230
    305 GCTTAGGCA 510 QTGDLTR 715 RSDNLQT 920 QSSDLSR 1125 230
    306 GCTTAGGCA 511 QTASLTR 716 RSDNLQT 921 QSSDLSR 1126 280
    307 GAAGAAGCG 512 RSDELRR 717 QSGNLQR 922 QSGNLSR 1127 50.5
    308 GAAGAAGCG 513 RSDELRR 718 QSANLQR 923 QSANLQR 1128 1000
    309 GGAGATGCC 514 ERSDLRR 719 QSSNLQR 924 QSGHLSR 1129 4000
    310 GGAGATGCC 515 DRSDTTR 720 NRDNLQT 925 QSGHLSR 1130 1000
    311 GGAGATGCC 516 DRSTLTR 721 NRDNLQR 926 QSGHLSR 1131 170
    312 GGAGATGCC 517 ERGTLAR 722 NRDNLQR 927 QSGHLSR 1132 2000
    313 GGAGATGCC 518 DRSDLTR 723 QRSNLQR 928 QSGHLSR 1133 1000
    314 GGAGATGCC 519 DRSSLTR 724 QSSNLQR 929 QSGHLSR 1134 117.5
    315 GGAGATGCC 520 ERGTLAR 725 QSSNLQR 930 QSGHLSR 1135 265
    316 GGAGATGCC 521 ERGTLAR 726 QRDNLQR 931 QSGHLSR 1136 3000
    318 TAGGAGATGC 522 RSDALTS 727 RSDNLAR 932 RSDNLAS 1137 100
    319 GGGGAAGGG 523 KTSHLRA 728 QSGNLSR 933 RSDHLSR 1138 125
    320 GGGGAAGGG 524 RSDHLTR 729 QSGNLSR 934 RSDHLSR 1139 5
    321 GGCGGAGAT 525 TTSNLRR 730 QSGHLQR 93S DRSHLTR 1140 200
    323 GGCGGAGAT 526 TTSNLRR 731 QSGHLQR 936 DRDHLTR 1141 600
    324 GGCGGAGAT 527 TTSNLRR 732 QSGHLQR 937 DRDHLTR 1142 200
    325 GTATCTGCT 528 NSSDLTR 733 NSDVLTS 938 QSDVLTR 1143 1000
    326 GTATCTGTT 529 NSDALTR 734 NSDVLTS 939 QSDVLTR 1144 1000
    327 TCTGCTGGG 530 RSDHLTR 735 NSADLTR 940 NSDDLTR 1145 1000
    328 TCTGTTGGG 531 RSDHLTR 736 NSSALTS 941 NSDDLTR 1146 1000
    349 GGTGTCGCC 532 DCRDLAR 737 DSGSLTR 942 TSGHLTR 1147 1000
    350 TCCGAGGGT 533 TSGHLTR 738 RSDNLTR 943 DCRDLTT 1148 332
    351 GCTGGTGTC 534 DSGSLTR 739 TSGHLTR 944 TLHTLTR 1149 1000
    352 GGAGGGGTG 535 RSDSLLR 740 RSDHLTR 945 QSDHLTR 1150 26
    353 GTTGGAGCC 536 DCRDLAR 741 QSDHLTR 946 TSGALTR 1151 1000
    354 GAAGAGGAC 537 DSSNLTR 742 RSDNLTR 947 QRSNLVR 1152 28
    355 GAAGAGGAC 538 EKANLTR 743 RSDNLTR 948 QRSNLVR 1153 20
    356 GGCTGGGCG 539 RSDELRR 744 RSDHLTK 949 DSDHLSR 1154 1000
    357 GGCTGGGCG 540 RSDELRR 745 RSDHLTK 950 DSDHLSR 1155 1000
    358 GGCTGGGCG 541 RSDELRR 746 RSDHLTK 951 DSSHLSR 1156 225
    361 GGGTTTGGG 542 RSDHLTR 747 QSSALTR 952 RSDHLTR 1157 130
    363 GGGTTTGGG 543 RSDHLTR 748 QSSVLTR 953 RSDHLTR 1158 200
    364 GTGTCCGAAG 544 RSDNLTR 749 DSAVLTT 954 RSDSLTR 1159 1000
    365 GGTGCTGGT 545 QASHLTR 750 QASVLTR 955 QASHLTR 1160 600
    366 GAGGGTGCT 546 QASVLTR 751 QASHLTR 956 RSDNLTR 1161 1000
    367 GGGGGCGGG 547 RSDHLTR 752 DSGHLTR 957 RSDHLQR 1162 60
    368 GAGGGGGCG 548 RSDELTR 753 RSDHLTR 958 RSDNLTR 1163 3.5
    369 GTAGTTGTG 549 RSDALTR 754 TGGSLAR 959 QSGSLTR 1164 95
    370 GTAGTTGTG 550 RSDALTR 755 NRATLAR 960 QSASLTR 1165 300
    371 GTAGTTGTG 551 RSDALTR 756 NRATLAR 961 QSGSLTR 1166 175
    372 GTAGTTGTG 552 RSDSLLR 757 TGGSLAR 962 QSASLTR 1167 112.5
    373 GTAGTTGTG 553 RSDSLLR 758 NRATLAR 963 QSASLTR 1168 320
    374 GCTGAGGAA 554 QRSNLVR 759 RSDNLTR 964 TSSELQR 1169 3.3
    375 GAGGAAGAT 555 QQSNLAR 760 QSGNLQR 965 RSDNLTR 1170 85
    377 GTGTTGGCAG 556 QSGSLTR 761 RGDALTS 966 RSDALTR 1171 89
    378 GCCGAGGAGA 557 RSDNLTR 762 RSDNLTR 967 DRSSLTR 1172 31
    379 GCCGAGGAGA 558 RSDNLTR 763 RSDNLTR 968 ERGTLAR 1173 3
    380 GAGTCGCAAG 559 QSANLAR 764 RSDELTT 969 RSDNLAR 1174 1000
    381 GCAGCTGCGC 560 RSDELTR 765 QSSDLQR 970 QSGDLTR 1175 1.5
    383 TGGTTGGTAT 561 QSATLAR 766 RGDALTS 971 RSDHLTT 1176 1000
    384 GTGGGCTTCA 562 DRSALTT 767 DRSHLAR 972 RSDALAR 1177 60
    385 GGGGCGGAGC 563 RSDNLTR 768 RSDTLKK 973 RSDHLSR 1178 1.2
    386 GGGGCGGAGC 564 RSDNLTR 769 RSDELQR 974 RSDHLSR 1179 0.4
    387 GGCGAGGCAA 565 QSGSLTR 770 RSDNLAR 975 DRSHLAR 1180 2.5
    388 GGCGAGGCAA 566 QSGDLTR 771 RSDNLAR 976 DRSHLAR 1181 28
    390 GTGGCAGCGG 567 RSDTLKK 772 QSSDLQK 977 RSDALAR 1182 20
    392 GTGGCAGCGG 568 RSDELTR 773 QSSDLQK 978 RSDALAR 1183 1000
    396 GCGGGAGCAG 569 QSGSLTR 774 QSGHLQR 979 RSDTLKK 1184 18.8
    397 GCGGGAGCAG 570 QSGDLTR 775 QSGHLQR 980 RSDTLKK 118 525
    400 TCAGTGGTGG 571 RSDALAR 776 RSDSLAR 981 QSGDLRT 1186 40
    405 GCGGCCGCA 572 RSDELTR 777 ERGTLAR 982 RSDERKR 1187 110
    406 GCGGCCGCA 573 RSDELTR 778 DRSSLTR 983 RSDERKR 1188 110
    407 GCGGCCGCA 574 QSWELTR 779 ERGTLAR 984 RSDERKR 1189 410
    408 GCGGCCGCA 575 QSWELTR 780 DRSSLTR 985 RSDERKR 1190 380
    409 GCGGCCGCA 576 QSGSLTR 781 ERGTLAR 986 RSDERKR 1191 50
    410 GCAGAAGTC 577 RSDALTR 782 QSGNLTR 987 QSGSLTR 1192 3
    411 GCGGCCGCA 578 QSGSLTR 783 RSDHLTT 988 RSDERKR 1193 1000
    412 GCGTGGGCG 579 QSGSLTR 784 RSDHLTT 989 RSDERKR 1194 5
    413 GCGTGGGCA 580 QSGSLTR 785 RSDHLTT 990 RSDERKR 1195 5
    414 GCAGAAGCA 581 RSDELTR 786 QSANLQR 991 QSGSLTR 1196 1000
    415 GTGTGCGGA 582 DRSHLTR 787 ERHSLQT 992 RSDALTR 1197 1000
    416 TGTGCGGCC 583 ERGTLAR 788 RSDELRR 993 DRSHLQT 1198 1000
    493 GGGGTGGCGG 584 RSDTLKK 789 RSDSLAR 994 RSDHLSR 1199 300
    494 GCCGAGGAGA 585 RSDNLTR 790 RSDNLTR 995 DRSSLTR 1200 90
    496 GGTGGTGGC 586 DTSHLRR 791 TSGHLQR 996 TSGHLSR 1201 1000
    497 GTTTGCGTC 587 ETASLRR 792 DSAHLQR 997 TSSALSR 1202 1000
    498 GAAGAGGCA 588 QTGELRR 793 RSDNLQR 998 QSGNLSR 1203 30
    499 GCTTGTGAG 589 RTSNLRR 794 TSSHLQK 999 DTDHLRR 1204 1000
    500 GCTTGTGAG 590 RSDNLTR 795 QSSNLQT 1000 DRSHLAR 1205 1000
    501 GTGGGGGTT 591 NRATLAR 796 RSDHLSR 1001 RSDALAR 1206 8
    502 GGGGTGGGA 592 QSAHLAR 797 RSDALAR 1002 RSDHLSR 1207 60
    507 GAGGTAGAGG 593 RSDNLAR 798 QRSALAR 1003 RSDNLAR 1208 10
    508 GAGGTAGAGG 594 RSDNLAR 799 QSATLR 1004 RSDNLAR 1209 10
    509 GTCGTGTGGC 595 RSDHLTT 800 RSDALAR 1005 DRSALAR 1210 100
    510 GTTGAGGAAG 596 QSGNLAR 801 RSDNLAR 1006 NRATLAR 1211 100
    511 GTTGAGGAAG 597 QSGNLAR 802 RSDNLAR 1007 QSSALAR 1212 100
    512 GAGGTGGAAG 598 QSGNLAR 803 RSDALAR 1008 RSDNLAR 1213 10
    513 GAGGTGGAAG 599 QSANLAR 804 RSDALAR 1009 RSDNLAR 1214 1.5
    514 TAGGTGGTGG 600 RSDALTR 805 RSDALAR 1010 RSDNLTT 1215 10
    515 TGGGAGGAGT 601 RSDNLTR 806 RSDNLTR 1011 RSDHLTT 1216 0.5
    516 GGAGGAGCT 602 TTSELRR 807 QSGHLQR 1012 QSGHLSR 1217 700
    517 GGAGCTGGGG 603 RTDHLRR 808 TSSELQR 1013 QSGHLSR 1218 50
    518 GGGGGAGGAG 604 QTGHLRR 809 QSGHLQR 1014 RSDHLSR 1219 30
    519 GGGGAGGAGA 605 RSDNLAR 810 RSDNLSR 1015 RSDHLSR 1220 0.3
    520 GGAGGAGAT 606 TTANLRR 811 QSGHLQR 1016 QSGHLSR 1221 300
    521 GCAGCAGGA 607 QTGHLRR 812 QSGELQR 1017 QSGELSR 1222 1000
    522 GATGAGGCA 608 QTGELRR 813 RSDNLQR 1018 TSANLSR 1223 200
    527 GGGGAGGATC 609 TTSNLRR 814 RSSNLQR 1019 RSDHLSR 1224 2
    528 GGGGAGGATC 610 TTSNLRR 815 RSSNLQR 1020 RSDHLSR 1225 10
    529 GAGGCTTGGG 611 RTDHLRK 816 TSAELQR 1021 RSSNLSR 1226 1000
    531 GCGGAGGCTT 612 TTGELRR 817 RSSNLQR 1022 RSDELSR 1227 160
    532 GCGGAGGCTT 613 QSSDLQR 818 RSSNLQR 1023 RSDELSR 1228 100
    533 GCGGAGGCTT 614 QSSDLQR 819 RSDNLAR 1024 RSADLSR 1229 7
    534 GCGGAGGCTT 615 QSSDLQR 820 RSDNLAR 1025 RSDDLRR 1230 10
    535 GCAGCCGGG 616 RTDHLRR 821 ESSDLQR 1026 QSGELSR 1231 1000
    538 GCAGAGGCTT 617 QSSDLQR 822 RSDNLAR 1027 QSGSLTR 1232 70
    540 TGGGCAGGCC 618 DRSHLTR 823 QSGSLTR 1028 RSDHLTT 1233 55
    541 GGGGAGGAT 619 TTSNLRR 824 RSSNLQR 1029 RSDHLSR 1234 3
    570 GGGGAAGGCT 620 DSGHLTR 825 QRSNLVR 1030 RSDHLTR 1235 20
    571 GTGTGTGTGT 621 RSDSLTR 826 QRSNLVR 1031 RSDSLLR 1236 1000
    572 GCATACGTGG 622 RSDSLLR 827 DKGNLQS 1032 QSDDLTR 1237 1000
    573 GCATACGTG 623 RSDSLLR 828 DKGNLQS 1033 QSGDLTR 1238 1000
    574 TACGTGGGGT 624 RSDHLTR 829 RSDHLTR 1034 DKGNLQT 1239 25
    575 TACGTGGGCT 625 DFSHLTR 830 RSDHLTR 1035 DKGNLQT 1240 472
    576 GAGGGTGTTG 626 NSDTLAR 831 TSGHLTR 1036 RSDNLTR 1241 200
    577 GGAGCGGGGA 627 RSDHLSR 832 RSDELQR 1037 QSDHLTR 1242 200
    579 GGGGTTGAGG 628 RSDNLTR 833 NRDTLAR 1038 TSGHLTR 1243 200
    580 GGTGTTGGAG 629 QRAHLAR 834 NRDTLAR 1039 TSGHLTR 1244 1000
    581 TACGTGGGTT 630 QSSHLTR 835 RSDSLLR 1040 DKGNLQT 1245 382
    583 GTAGGGGTTG 631 NSSALTR 836 RSDHLTR 1041 QSASLTR 1246 46
    584 GAAGGCGGAG 632 QAGHLTR 837 DKSHLTR 1042 QSGNLTR 1247 1000
    585 GAAGGCGGAG 633 QAGHLTR 838 DSGHLTR 1043 QSGNLTR 1248 1000
    587 GGGGGTTACG 634 DKGNLQT 839 TSGHLTR 1044 RSDHLSK 1249 500
    588 GGGGGGGGGG 635 RSDHLSR 840 RSDHLTR 1045 RSDHLSK 1250 30
    589 GGAGTATGCT 636 DSGHLAS 841 QSATLAR 1046 QSDHLTR 1251 1000
    595 TGGTTGGTAT 637 QRGSLAR 842 RGDALTR 1047 RSDHLTT 1252 73.3
    597 TGGTTGGTA 638 QNSAMRK 843 RGDALTS 1048 RSDHLTT 1253 1000
    598 TGGTTGGTA 639 QRGSLAR 844 RDGSLTS 1049 RSDHLTT 1254 1000
    599 TGGTTGGTA 640 QNSAMRK 845 RDGSLTS 1050 RSDHLTT 1255 1000
    600 GAGTCGGAA 641 QSANLAR 846 RSDELRT 1051 RSDNLAR 1256 206.7
    601 GAGTCGGAA 642 RSANLTR 847 RLDGLRT 1052 RSDNLAR 1257 606.7
    602 GAGTCGGAA 643 RSANLTR 848 RQDTLVG 1053 RSDNLAR 1258 616.7
    603 GAGTCGGAA 644 QSGNLAR 849 RSDELRT 1054 RSDNLAR 1259 166.7
    606 GGGGAGGATC 645 TTSNLRR 850 RSDNLQR 1055 RSDHLSR 1260 0.2
  • [0117]
    TABLE 3
    SEQ SEQ SEQ SEQ Kd
    SBS# TARGET ID F1 ID F2 ID F3 ID (nM)
    897 GAGGAGGTGA 1261 RSDALAR 1347 RSDNLAR 1433 RSDNLVR 1519 0.07
    828 GCGGAGGACC 1262 EKANLTR 1348 RSDNLAR 1434 RSDERKR 1520 0.1
    884 GAGGAGGTGA 1263 RSDSLTR 1349 RSDNLAR 1435 RSDNLVR 1521 0.15
    817 GAGGAGGTGA 1264 RSDSLTR 1350 RSDNLAR 1436 RSDNLAR 1522 0.31
    666 GCGGAGGCGC 1265 RSDDLTR 1351 RSDNLTR 1437 RSDTLKK 1523 0.5
    829 GCGGAGGACC 1266 EKANLTR 1352 RSDNLAR 1438 RSDTLKK 1524 0.52
    670 GACGTGGAGG 1267 RSDNLAR 1353 RSDALAR 1439 DRSNLTR 1525 0.57
    801 AAGGAGTCGC 1268 RSADLRT 1354 RSDNLAR 1440 RSDNLTQ 1526 0.85
    668 GTGGAGGCCA 1269 ERGTLAR 13S5 RSDNLAR 1441 RSDALAR 1527 1.13
    895 ATGGATTCAG 1270 QSHDLTK 1356 TSGNLVR 1442 RSDALTQ 1528 1.4
    799 GGGGGAGCTG 1271 QSSDLQR 1357 QRAHLER 1443 RSDHLSR 1529 1.85
    798 GGGGGAGCTG 1272 QSSDLQR 1358 QSGHLER 1444 RSDHLSR 1530 3
    842 GAGGTGGGCT 1273 DRSHLTR 1359 RSDALAR 1445 RSDNLAR 1531 5.4
    894 TCAGTGGTAT 1274 QRSALAR 1360 RSDALSR 1446 QSHDLTK 1532 6.15
    892 ATGGATTCAG 1275 QSHDLTK 1361 QQSNLVR 1447 RSDALTQ 1533 6.2
    888 TCAGTGGTAT 1276 QSSSLVR 1362 RSDALSR 1448 QSHDLTK 1534 14
    739 GCGGGCGGGC 1277 RSDHLTR 1363 ERGHLTR 1449 RSDDLRR 1535 16.5
    850 CAGGCTGTGG 1278 RSDALTR 1364 QSSDLTR 1450 RSDNLRE 1536 17
    797 GCAGAGGCTG 1279 QSSDLQR 1365 RSDNLAR 1451 QSGDLTR 1537 17.5
    891 TCAGTGGTAT 1280 QSSSLVR 1366 RSDALSR 1452 QSGSLRT 1538 18.5
    887 TCAGTGGTAT 1281 QRSALAR 1367 RSDALSR 1453 QSGDLRT 1539 23.75
    672 TCGGACGTGG 1282 RSDALAR 1368 DRSNLTR 1454 RSDELRT 1540 24
    836 GGGGAGGCCC 1283 ERGTLAR 1369 RSDNLAR 1455 RSDHLSR 1541 24.25
    674 GCGGCGTCGG 1284 RSDELRT 1370 RADTLRR 1456 RSDTLKK 1542 27.5
    849 GGGGCCCTGG 1285 RSDALRE 1371 DRSSLTR 1457 RSDHLTQ 1543 29.05
    825 GAATGGGCAG 1286 QSGSLTR 1372 RSDHLTT 1458 QSGNLTR 1544 37.3
    673 GCGGGTGTCT 1287 DRSALAR 1373 QSSHLAR 1459 RSDTLKK 1545 48.33
    848 GGGGAGGCCC 1288 DRSSLTR 1374 RSDNLAR 1460 RSDHLSR 1546 49.5
    662 AGAGCGGCAC 1289 QTGSLTR 1375 RSDELQR 1461 QSGHLNQ 1547 50
    667 GAGTCGGACG 1290 DRSNLTR 1376 RSDELRT 1462 RSDNLAR 1548 50
    803 GCAGCGGCTC 1291 QSSDLQR 1377 RSDELQR 1463 QSGSLTR 1549 57.5
    671 TCGGACGAGT 1292 RSDNLAR 1378 DRSNLTR 1464 RSDELRT 1550 64
    851 GAGATGGATC 1293 QSSNLQR 1379 RRDVLMN 1465 RLHNLQR 1551 74
    804 GCAGCGGCTC 1294 QSSDLQR 1380 RSDDLNR 1466 QSGSLTR 1552 82.5
    669 GACGAGTCGG 1295 RSDELRT 1381 RSDNLAR 1467 DRSNLTR 1553 90
    682 GCTGCAGGAG 1296 RSDHLAR 1382 QSGDLTR 1468 QSSDLSR 1554 90
    845 GAGATGGATC 1297 QSSNLQR 1383 RSDALRQ 1469 RLHNLQR 1S5S 112.5
    663 AGAGCGGCAC 1298 QTGSLTR 1384 RSDELQR 1470 KNWKLQA 1556 115
    738 GCGGGGTCCG 1299 ERGTLTT 1385 RSDHLSR 1471 RSDDLRR 1557 120
    664 AGAGCGGCAC 1300 QTGSLTR 1386 RADTLRR 1472 ASSRLAT 1558 125
    833 GACTAGGACC 1301 EKANLTR 1387 RSDNLTK 1473 DRSNLTR 1559 136
    685 GCTGCAGGAG 1302 RSDHLAR 1388 QSGSLTR 1474 QSSDLSR 1560 150
    835 TAGGGAGCGT 1303 RADTLRR 1389 QSGHLTR 1475 RSDNLTT 1561 150
    847 TAGGGAGCGT 1304 RSDDLTR 1390 QSGHLTR 1476 RSDNLTT 1562 150
    818 GAATGGGCAG 1305 QSGSLTR 1391 RSDHLTT 1477 QSSNLVR 1563 167
    834 GACTAGGACC 1306 EKANLTR 1392 RSDHLTT 1478 DRSNLTR 1564 186
    837 GGGGCCCTGG 1307 RSDALRE 1393 DRSSLTR 1479 RSDHLSR 1565 222
    764 GCAGAGGCTG 1308 TSGELVR 1394 RSDNLAR 1480 QSGDLTR 1566 255
    774 GCAGCGGTAG 1309 QRSALAR 1395 RSDELQR 1481 QSGDLTR 1567 258
    765 GCCGAGGCCG 1310 ERGTLAR 1396 RSDNLAR 1482 ERGTLAR 1568 262.5
    766 GCCGAGGCCG 1311 ERGTLAR 1397 RSDNLAR 1483 DRSDLTR 1569 262.5
    775 GCAGCGGTAG 1312 QSGALTR 1398 RSDELQR 1484 QSGDLTR 1570 265
    763 GCAGAGGCTG 1313 TSGELVR 1399 RSDNLAR 1485 QSGSLTR 1571 275
    838 GGGGCCCTGG 1314 RSDALRE 1400 DRSSLTR 1486 RSDHLTA 1572 300
    841 GAGTGTGAGG 1315 RSDNLAR 1401 QSSHLAS 1487 RSDNLAR 1573 300
    770 TTGGCAGCCT 1316 DRSSLTR 1402 QSGSLTR 1488 RSDSLTK 1574 325
    767 GGGGGAGCTG 1317 QSSDLAR 1403 QSGHLQR 1489 RSDHLSR 1575 335
    800 TTGGCAGCCT 1318 ERGTLAR 1404 QSGSLTR 1490 RSDSLTK 1576 400
    832 GACTAGGACC 1319 EKANLTR 1405 RSDNLTT 1491 DRSNLTR 1577 408
    844 GAGATGGATC 1320 QSSNLQR 1406 RSDALRQ 1492 RSDNLQR 1578 444
    683 GCTGCAGGAG 1321 QSGHLAR 1407 QSGSLTR 1493 QSSDLSR 1579 500
    805 GCAGCGGTAG 1322 QRSALAR 1408 RSDELQR 1494 QSGSLTR 1580 500
    839 GAGTGTGAGG 1323 RSDNLAR 1409 TSDHLAS 1495 RSDNLAR 1581 625
    840 GAGTGTGAGG 1324 RSDNLAR 1410 MSHHLKT 1496 RSDNLAR 1582 625
    830 GGAGAGTCGG 1325 RSDELRT 1411 RSDNLAR 1497 QRAHLAR 1583 683
    831 GGAGAGTCGG 1326 RSDDLTK 1412 RSDNLAR 1498 QRAHLAR 1584 700
    684 GCTGCAGGAG 1327 RSAHLAR 1413 QSGSLTR 1499 QSSDLSR 1585 850
    846 GAGATGGATC 1328 QSSNLQR 1414 RRDVLMN 1500 RSDNLQR 1586 889.5
    819 AAGTAGGGTG 1329 QSSHLTR 1415 RSDNLTT 1501 RSDNLTQ 1587 1000
    820 ACGGTAGTTA 1330 QSSALTR 1416 QRSALAR 1502 RSDTLTQ 1588 1000
    821 ACGGTAGTTA 1331 NRATLAR 1417 QRSALAR 1503 RSDTLTQ 1589 1000
    822 GTGTGCTGGT 1332 RSDHLTT 1418 ERQHLAT 1504 RSDALAR 1590 1000
    823 GTGTGCTGGT 1333 RSDHLTK 1419 ERQHLAT 1505 RSDALAR 1591 1000
    824 GTGTGCTGGT 1334 RSDHLTT 1420 DRSHLRT 1506 RSDALAR 1592 1000
    885 GTGTGCTGGT 1335 RSDHLTK 1421 DRSHLRT 1507 RSDALAR 1593 1000
    886 TCAGTGGTAT 1336 QSSSLVR 1422 RSDALSR 1508 QSGDLRT 1594 1000
    889 ATGGATTCAG 1337 QSGSLTT 1423 QQSNLVR 1509 RSDALTQ 1595 1000
    890 CTGGTATGTC 1338 QRSHLTT 1424 QRSALAR 1510 RSDALRE 1596 1000
    896 AAGTAGGGTG 1339 TSGHLVR 1425 RSDNLTT 1511 RSDNLTQ 1597 1000
    898 ACGGTAGTTA 1340 NRATLAR 1426 QSSSLVR 1512 RSDTLTQ 1598 1000
    899 CTGGTATGTC 1341 QRSHLTT 1427 QSSSLVR 1513 RSDALRE 1599 1000
    900 CTGGTATGTC 1342 MSHHLKE 1428 QSSSLVR 1514 RSDALRE 1600 1000
    901 CTGGTATGTC 1343 MSHHLKE 1429 QRSALAR 1515 RSDALRE 1601 1000
    773 GCAGCGGTAG 1344 QSQALTR 1430 RSDELQR 1516 QSGSLTR 1602 1250
    768 GGGGGAGCTG 1345 QSSDLAR 1431 QRAHLER 1517 RSDHLSR 1603 2000
    681 GCTGCAGGAG 1346 RSAHLAR 1432 QSGDLTR 1518 QSSDLSR 1604 3000
  • [0118]
    TABLE 4
    SEQ F1 SEQ F2 SEQ F3 SEQ Kd
    SBS# TARGET ID ID ID ID (nM)
    607 AAGGTGGCAG 1605 QSGDLTR 1707 RSDSLAR 1809 RLDNRTA 1911 6.5
    608 TTGGCTGGGC 1606 GSWHLTR 1708 QSSDLQR 1810 RSDSLTK 1912 8
    611 GTGGCTGCAG 1607 QSGDLTR 1709 QSSDLQR 1811 RSDALAR 1913 11.5
    612 GTGGCTGCAG 1608 QSGTLTR 1710 QSSDLQR 1812 RSDALAR 1914 0.38
    613 TTGGCTGGGC 1609 RSDHLAR 1711 QSSDLQR 1813 RGDALTS 1915 1.45
    614 TTGGCTGGGC 1610 RSDHLAR 1712 QSSDLQR 1814 RSDSLTK 1916 2
    616 GAGGAGGATG 1611 QSSNLQR 1713 RSDNLAR 1815 RSDNLQR 1917 0.08
    617 AAGGGGGGG 1612 RSDHLSR 1714 RSDHLTR 1816 RKDNMTA 1918 1
    618 AAGGGGGGG 1613 RSDHLSR 1715 RSDHLTR 1817 RKDNMTQ 1919 0.55
    619 AAGGGGGGG 1614 RSDHLSR 1716 RSDHLTR 1818 RKDNMTN 1920 1.34
    620 AAGGGGGGG 1615 RSDHLSR 1717 RSDHLTR 1819 RLDNRTA 1921 0.54
    621 AAGGGGGGG 1616 RSDHLSR 1718 RSDHLTR 1820 RLDNRTQ 1922 0.75
    624 ACGGATGTCT 1617 DRSALAR 1719 TSANLAR 1821 RSDTLRS 1923 7
    628 TTGTAGGGGA 1618 RSDHLTR 1720 RSDNLTT 1822 RGDALTS 1924 130
    629 TTGTAGGGGA 1619 RSSHLTR 1721 RSDNLTT 1823 RGDALTS 1925 150
    630 CGGGGAGAGT 1620 RSDNLAR 1722 QSGHLQR 1824 RSDHLRE 1926 37.5
    646 TTGGTGGAAG 1621 QSGNLAR 1723 RSDALAR 1825 RGDALTS 1927 35
    647 TTGGTGGAAG 1622 QSANLAR 1724 RSDALAR 1826 RGDALTS 1928 40
    651 GTTGTGGAAT 1623 QSGNLSR 1725 RSDALAR 1827 NRATLAR 1929 67.5
    652 TAGGAGGCTG 1624 QSSDLQR 1726 RSDNLAR 1828 RSDNLTT 1930 1.5
    653 TAGGAGGCTG 1625 TTSDLTR 1727 RSDNLAR 1829 RSDNLTT 1931 5.5
    654 TAGGCATAAA 1626 QSGNLRT 1728 QSGSLTR 1830 RSDNLTT 1932 105
    655 TAGGCATAAA 1627 QSGNLRT 1729 QSSTLRR 1831 RSDNLTT 1933 1000
    656 TAGGCATAAA 1628 QSGNLRT 1730 QSGSLTR 1832 RSDNLTS 1934 540
    657 TAGGCATAAA 1629 QSGNLRT 1731 QSSTLRR 1833 RSDNLTS 1935 300
    660 GAGGGAGTTC 1630 NRATLAR 1732 QSGHLTR 1834 RSDNLAR 1936 8.25
    661 GAGGGAGTTC 1631 TTSALTR 1733 QSGHLTR 1835 RSDNLAR 1937 1.73
    665 GCGGAGGCGC 1632 RSDDVTR 1734 RSDNLTR 1836 RSDDLRR 1938 12.5
    689 AAGGCGGAGA 1633 RSDNLTR 1735 RSDELQR 1837 RLDNRTA 1939 82.5
    692 AAGGCGGAGA 1634 RSDNLTR 1736 RSDELQR 1838 RSDNLTQ 1940 51
    693 AAGGCGGAGA 1635 RSDNLTR 1737 RADTLRR 1839 RLDNRTA 1941 95
    694 AAGGCGGAGA 1636 RSDNLTR 1738 RADTLRR 1840 RSDNLTQ 1942 28.5
    695 GGGGGCGAGC 1637 RSSNLTR 1739 DRSHLAR 1841 RSDHLTR 1943 850
    697 TGAGCGGCGG 1638 RSDELTR 1740 RSDELSR 1842 QSGHLTK 1944 200
    698 TGAGCGGCGG 1639 RSDELTR 1741 RSDELSR 1843 QSHGLTS 1945 300
    699 GCGGCGGCAG 1640 QSGSLTR 1742 RSDDLQR 1844 RSDERKR 1946 21.5
    700 GCGGCGGCAG 1641 QSGDLTR 1743 RSDDLQR 1845 RSDERKR 1947 45
    701 GCAGCGGAGC 1642 RSDNLAR 1744 RSDELQR 1846 QSGSLTR 1948 50.5
    702 GCAGCGGAGC 1643 RSDNLAR 1745 RSDELQR 1847 QSGDLTR 1949 73.5
    704 AAGGTGGCAG 1644 QSGDLTR 1746 RSDSLAR 1848 RSDNLTQ 1950 5
    705 GGGGTGGGGC 1645 RSDHLAR 1747 RSDSLAR 1849 RSDHLSR 1951 0.01
    706 GGGGTGGGGC 1646 RSDHLAR 1748 RSDSLLR 1850 RSDHLSR 1952 0.05
    708 GAGTCGGAA 1647 QSANLAR 1749 RQDTLVG 1851 RSDNLAR 1953 300
    709 GAGTCGGAA 1648 QSANLAR 1750 RKDVLVS 1852 RSDNLAR 1954 400
    710 GAGTCGGAA 1649 QSGNLAR 1751 RLDGLRT 1853 RSDNLAR 1955 400
    711 GAGTCGGAA 1650 QSGNLAR 1752 RQDTLVG 1854 RSDNLAR 1956 400
    712 GGTGAGGAGT 1651 RSDNLAR 1753 RSDNLAR 1855 MSDHLSR 1957 9.5
    713 GGTGAGGAGT 1652 RSDNLAR 1754 RSDNLAR 1856 MSHHLSR 1958 0.15
    714 TGGGTCGCGG 1653 RSDELRR 1755 DRSALAR 1857 RSDHLTT 1959 200
    715 TGGGTCGCGG 1654 RADTLRR 1756 DRSALAR 1858 RSDHLTT 1960 0.46
    716 TTGGGAGCAC 1655 QSGSLTR 1757 QSGHLQR 1859 RGDALTS 1961 200
    717 TTGGGAGCAC 1656 QSGSLTR 1758 QSGHLQR 1860 RSDALTK 1962 150
    718 TTGGGAGCAC 1657 QSGSLTR 1759 QSGHLQR 1861 RSDALTR 1963 107.5
    719 GGCATGGTGG 1658 RSDALTR 1760 RSDALTS 1862 DRSHLAR 1964 20
    720 GAAGAGGATG 1659 TTSNLAR 1761 RSDNLAR 1863 QSGNLTR 1965 1.6
    722 ATGGGGGTGG 1660 RSDALTR 1762 RSDHLTR 1864 RSDALRQ 1966 0.7
    724 GGCATGGTGG 1661 RSDALTR 1763 RSDALRQ 1865 DRSHLAR 1967 2.5
    725 GCTTGAGTTA 1662 QSSALAR 1764 QSGHLQK 1866 QSSDLQR 1968 3000
    726 GAAGAGGATG 1663 QSSNLAR 1765 RSDNLAR 1867 QSGNLTR 1969 1.5
    727 GCGGTGGCTC 1664 QSSDLTR 1766 RSDALSR 1868 RSDTLKK 1970 0.1
    728 GGTGAGGAGT 1665 RSDNLAR 1767 RSDNLAR 1869 DSSKLSR 1971 15
    729 GGAGGGGAGT 1666 RSDNLAR 1768 RSDHLSR 1870 QSGHLAR 1972 1000
    730 TGGGTCGCGG 1667 RSDDLTR 1769 DRSALAR 1871 RSDHLTT 1973 1000
    731 GTGGGGGAGA 1668 RSDNLAR 1770 RSDHLSR 1872 RSDALAR 1974 12
    732 GCGGGTGGGG 1669 RSDHLAR 1771 QSSHLAR 1873 RSDDLTR 1975 22.5
    733 GCGGGTGGGG 1670 RSDHLAR 1772 QSSHLAR 1874 RSDTLKK 1976 0.32
    734 GGGGCTGGGT 1671 RSDHLAR 1773 QSSDLSR 1875 RSDHLSR 1977 0.25
    735 GCGGTGGCTC 1672 QSSDLTR 1774 RSDALSR 1876 RSDERKR 1978 0.05
    736 GAGGTGGGGA 1673 RSDHLAR 1775 RSDALSR 1877 RSDNLSR 1979 0.47
    737 GGAGGGGAGT 1674 RSDNLAR 1776 RSDHLSR 1878 QRGHLSR 1980 1000
    740 AAGGTGGCAG 1675 QSGSLTR 1777 RSDALAR 1879 RSDNRTA 1981 12.5
    741 AAGGCTGAGA 1676 RSDNLTR 1778 QSSDLQR 1880 RSDNLTQ 1982 15
    742 ACGGGGTTAT 1677 QRGALAS 1779 RSDHLSR 1881 RSDTLKQ 1983 29
    743 ACGGGGTTAT 1678 QRGALAS 1780 RSDHLSR 1882 RSDTLTQ 1984 10
    744 ACGGGGTTAT 1679 QRSALAS 1781 RSDHLSR 1883 RSDTLKQ 1985 8.33
    745 ACGGGGTTAT 1680 QRSALAS 1782 RSDHLSR 1884 RSDTLTQ 1986 12.5
    746 CTGGAAGCAT 1681 QSGSLTR 1783 QSGNLAR 1885 RSDALRE 1987 2.07
    747 CTATTTTGGG 1682 RSDHLTT 1784 QSSALRT 1886 QSGALRE 1988 2000
    748 TTGGACGGCG 1683 DSGHLTR 1785 DRSNLER 1887 RGDALTS 1989 112.3
    749 TTGGACGGCG 1684 DRSHLTR 1786 DSSNLTR 1888 RGDALTS 1990 11.33
    750 GAGGGAGCGA 1685 RSDELTR 1787 QSAHLAR 1889 RSDNLAR 1991 52
    751 GGTGAGGAGT 1686 RSDNLAR 1788 RSDNLAR 1890 NRSHTAR 1992 7
    752 GAGGTGGGGA 1687 RSHHLAR 1789 RSDALSR 1891 RSDNLSR 1993 31
    757 CGGGCGGCTG 1688 QSSDLRR 1790 RSDELQR 1892 RSDHLRE 1994 14.5
    758 CGGGCGGCTG 1689 QSSDLRR 1791 RADTLRR 1893 RSDHLRE 1995 16.5
    759 TTGGACGGCG 1690 DSGHLTR 1792 DSSNLTR 1894 RGDALTS 1996 37
    760 TTGGACGGCG 1691 DRSHLTR 1793 DRSNLER 1895 RGDALTS 1997 148.5
    761 GCGGTGGCTC 1692 QSSDLQR 1794 RSDALSR 1896 RSDERKR 1998 6
    762 GCGGTGGCTC 1693 QSSDLQR 1795 RSDALSR 1897 RSDTLKK 1999 18
    776 ATGGACGGGT 1694 RSDHLAR 1796 DRSNLER 1898 RSDSLNQ 2000 0.4
    777 ATGGACGGGT 1695 RSDHLAR 1797 DRSNLTR 1899 RSDALSA 2001 3.4
    779 CGGGGAGCAG 1696 QSGSLTR 1798 QSGHLTR 1900 RSDHLAE 2002 0.5
    780 CGGGGAGCAG 1697 QSGSLTR 1799 QSGHLTR 1901 RSDHLRA 2003 0.5
    781 GGGGAGCAGC 1698 RSSNLRE 1800 RSDNLAR 1902 RSDHLTR 2004 4.25
    783 TTGGGAGCGG 1699 RSDELTR 1801 QSGHLQR 1903 RGDALTS 2005 2000
    785 TTGGGAGCGG 1700 RSDTLKK 1802 QSGHLQR 1904 RSDALTS 2006 50
    786 TTGGGAGCGG 1701 RSDTLKK 1803 QSGHLQR 1905 RGDALRS 2007 2000
    787 AGGGAGGATG 1702 QSDNLAR 1804 RSDNLAR 1906 RSDHLTQ 2008 4
    826 GAGGGAGCGA 1703 RSDELTR 1805 QSGHLAR 1907 RSDNLAR 2009 2.75
    827 GAGGGAGCGA 1704 RADTLRR 1806 QSGHLAR 1908 RSDNLAR 2010 1.2
    882 GCGTGGGCGT 1705 RSDELTR 1807 RSDHLTT 1909 RSDERKR 2011 0.01
    883 GCGTGGGCGT 1706 RSDELTR 1808 RSDHLTT 1910 RSDERKR 2012 1
  • [0119]
    TABLE 5
    SEQ SEQ SEQ SEQ Kd
    SBS# TARGET ID F1 ID F2 ID F3 ID (nM)
    903 ATGGAAGGG 2013 RSDHLAR 2513 QSGNLAR 3013 RSDALRQ 3513 1.027
    904 AAGGGTGAC 2014 DSSNLTR 2514 QSSHLAR 3014 RSDNLTQ 3514 1
    905 GTGGTGGTG 2015 RSSALTR 2515 RSDSLAR 3015 RSDSLAR 3515 1.15
    908 AAGGTCTCA 2016 QSGDLRT 2516 DRSALAR 3016 RSDNLRQ 3516 50
    909 GTGGAAGAA 2017 QSGNLSR 2517 QSGNLQR 3017 RSDALAR 3517 16.4
    910 ATGGAAGAT 2018 QSSNLAR 2518 QSGNLQR 3018 RSDALAQ 3518 0.03
    911 ATGGGTGCA 2019 QSGSLTR 2519 QSSHLAR 3019 RSDALAQ 3519 0.91
    912 TCAGAGGTG 2020 RSDSLAR 2520 RSDNLTR 3020 QSGDLRT 3520 0.135
    914 CAGGAAAAG 2021 RSDNLTQ 2521 QSGNLAR 3021 RSDNLRE 3521 1.26
    915 CAGGAAAAG 2022 RSDNLRQ 2522 QSGNLAR 3022 RSDNLRE 3522 45.15
    916 GAGGAAGGA 2023 QSGHLAR 2523 QSGNLAR 3023 RSDNLQR 3523 1.3
    919 TCATAGTAG 2024 RSDNLTT 2524 RSDNLRT 3024 QSGDLRT 3524 250
    920 GATGTGGTA 2025 QSSSLVR 2525 RSDSLAR 3025 TSANLSR 3525 4
    921 AAGGTCTCA 2026 QSGDLRT 2526 DPGALVR 3026 RSDNLRQ 3526 11
    922 AAGGTCTCA 2027 QSHDLTK 2527 DRSALAR 3027 RSDNLRQ 3527 4
    923 AAGGTCTCA 2028 QSHDLTK 2528 DPGALVR 3028 RSDNLRQ 3528 2
    926 GTGGTGGTG 2029 RSDALTR 2529 RSDSLAR 3029 RSDSLAR 3529 7.502
    927 CAGGTTGAG 2030 RSDNLAR 2530 TSGSLTR 3030 RSDNLRE 3530 3.61
    928 CAGGTTGAG 2031 RSDNLAR 2531 QSSALTR 3031 RSDNLRE 3531 25
    929 CAGGTAGAT 2032 QSSNLAR 2532 QSATLAR 3032 RSDNLRE 3532 1.3
    931 GAGGAAGAG 2033 RSDNLAR 2533 QSSNLVR 3033 RSDNLAR 3533 2
    932 ATGGAAGGG 2034 RSDHLAR 2534 QSSNLVR 3034 RSDALRQ 3534 797
    933 GACGAGGAA 2035 QSANLAR 2535 RSDNLAR 3035 DRSNLTR 3535 500
    934 ATGGAAGAT 2036 QSSNLAR 2536 QSGNLQR 3036 RSDALTS 3536 0.07
    935 ATGGGTGCA 2037 QSGSLTR 2537 QSSHLAR 3037 RSDALTS 3537 0.91
    937 GTGGGGGCT 2038 QSSDLTR 2538 RSDHLTR 3038 RSDSLAR 3538 0.03
    938 GTGGGGGCT 2039 QSSDLRR 2539 RSDHLTR 3039 RSDSLAR 3539 0.049
    939 GGGGGCTGG 2040 RSDHLTT 2540 DRSHLAR 3040 RSDHLSK 3540 0.352
    940 GGGGGCTGG 2041 RSDHLTK 2541 DRSHLAR 3041 RSDHLSK 3541 1.5
    941 GGGGCTGGG 2042 RSDHLAR 2542 QSSDLRR 3042 RSDKLSR 3542 0.077
    942 GGGGCTGGG 2043 RSDHLAR 2543 QSSDLRR 3043 RSDHLSK 3543 0.13
    943 GGGGCTGGG 2044 RSDHLAR 2544 TSGELVR 3044 RSDKLSR 3544 0.067
    944 GGGGCTGGG 2045 RSDHLAR 2545 TSGELVR 3045 RSDHLSK 3545 0.027
    945 GGTGCGGTG 2046 RSDSLTR 2546 RADTLRR 3046 MSHHLSR 3546 0.027
    946 GGTGCGGTG 2047 RSDSLTR 2547 RSDVLQR 3047 MSHHLSR 3547 0.027
    947 GGTGCGGTG 2048 RSDSLTR 2548 RSDELQR 3048 QSSHLAR 3548 0.013
    948 GGTGCGGTG 2049 RSDSLTR 2549 RSDVLQR 3049 QSSHLAR 3549 0.017
    962 GAGGCGGCA 2050 QSGSLTR 2550 RSDELQR 3050 RSDNLAR 3550 0.015
    963 GAGGCGGCA 2051 QSGSLTR 2551 RSDDLQR 3051 RSDNLAR 3551 0.015
    964 GCGGCGGTG 2052 RSDALAR 2552 RSDELQR 3050 RSDERKR 3552 0.041
    965 GCGGCGGCC 2053 ERGDLTR 2553 RSDELQR 3053 RSDERKR 3553 3.1
    966 GAGGAGGCC 2054 ERGTLAR 2554 RSDNLSR 3054 RSDNLAR 3554 0.028
    967 GAGGAGGCC 2055 DRSSLTR 2555 RSDNLSR 3055 RSDNLAR 3555 0.055
    968 GAGGCCGCA 2056 QSGSLTR 2556 DRSSLTR 3056 RSDNLAR 3556 1.4
    969 GAGGCCGCA 2057 QSGSLTR 2557 DRSDLTR 3057 RSDNLAR 3557 0.275
    970 GTGGGCGCC 2058 ERGTLAR 2558 DRSHLAR 3058 RSDALAR 3558 1.859
    971 GTGGGCGCC 2059 DRSSLTR 2559 DRSHLAR 3059 RSDALAR 3559 0.144
    972 GTGGGCGCC 2060 ERGDLTR 2560 DRSHLAR 3060 RSDALAR 3560 1.748
    973 GCCGCGGTC 2061 DRSALTR 2561 RSDELQR 3061 ERGTLAR 3561 0.6
    974 GCCGCGGTC 2062 DRSALTR 2562 RSDELQR 3062 DRSDLTR 3562 0.038
    975 CAGGCCGCT 2063 QSSDLTR 2563 DRSSLTR 3063 RSDNLRE 3563 1.1
    976 CAGGCCGCT 2064 QSSDLTR 2564 DRSDLTR 3064 RSDNLRE 3564 4.12
    977 CTGGCAGTG 2065 RSDSLTR 2565 QSGSLTR 3065 RSDALRE 3565 0.017
    978 CTGGCAGTG 2066 RSDSLTR 2566 QSGDLTR 3066 RSDALRE 3566 1.576
    979 CTGGCGGCG 2067 RSSDLTR 2567 RSDELQR 3067 RSDALRE 3567 1.59
    980 CTGGCGGCG 2068 RSDDLTR 2568 RSDELQR 3068 RSDALRE 3568 2.2
    981 CAGGCGGCG 2069 RSDDLTR 2569 RSDELQR 3069 RSDNLRE 3569 0.375
    982 CCGGGCTGG 2070 RSDHLTT 2570 DRSHLAR 3070 RSDELRE 3570 0.03
    983 CCGGGCTGG 2071 RSDHLTK 2571 DRSHLAR 3071 RSDELRE 3571 1.385
    984 GACGGCGAG 2072 RSDNLAR 2572 DRSHLAR 3072 DRSNLTR 3572 1.6
    985 GACGGCGAG 2073 RSDNLAR 2573 DRSHLAR 3073 EKANLTR 3573 0.965
    986 GGTGCTGAT 2074 QSSNLQR 2574 QSSDLQR 3074 MSHHLSR 3574 1.6
    987 GGTGCTGAT 2075 QSSNLQR 2575 QSSDLQR 3075 TSGHLVR 3575 33.55
    988 GGTGCTGAT 2076 TSGNLVR 2576 QSSDLQR 3076 MSHHLSR 3576 0.15
    989 GGTGAGGGG 2077 RSDHLAR 2577 RSDNLAR 3077 MSHHLSR 3577 1.9
    990 AAGGTGGGC 2078 DRSHLTR 2578 RSDSLAR 3078 RSDNLTQ 3578 5.35
    991 AAGGTGGGC 2079 DRSHLTR 2579 SSGSLVR 3079 RSDNLTQ 3579 0.06
    993 GGGGCTGGG 2080 RSDHLAR 2580 TSGELVR 3080 RSDHLSR 3580 3.1
    994 GGGGGCTGG 2081 RSDHLTK 2581 DRSHLAR 3081 RSDHLSR 3581 0.03
    995 GGGGAGGAA 2082 QSANLAR 2582 RSDNLAR 3082 RSDHLSK 3582 0.08
    996 CAGTTGGTC 2083 DRSALAR 2583 RSDALTS 3083 RSDNLRE 3583 9.6
    997 AGAGAGGCT 2084 QSSDLTR 2584 RSDNLAR 3084 QSGHLNQ 584 1.65
    998 ACGTAGTAG 2085 RSANLRT 2585 RSDNLTK 3085 RSDTLKQ 3585 0.23
    999 AGAGAGGCT 2086 QSSDLTR 2586 RSDNLAR 3086 QSGKLTQ 3586 0.6
    1000 CAGTTGGTC 2087 DRSALAR 2587 RSDALTR 3087 RSDNLRE 3587 11.15
    1001 GGAGCTGAC 2088 EKANLTR 2588 QSSDLSR 3088 QRAHLAR 3588 1.8
    1002 GCGGAGGAG 2089 RSDNLVR 2589 RSDNLAR 3089 RSDERKR 3589 0.028
    1003 ACGTAGTAG 2090 RSANLRT 2590 RSDNLTK 3090 RSDTLRS 3590 0.118
    1004 ACGTAGTAG 2091 RSDNLTT 2591 RSDNLTK 3091 RSDTLRS 3591 1.4
    1006 GTAGGGGCG 2092 RSDDLTR 2592 RSDHLTR 3092 QRASLTR 3592 0.898
    1007 GAGAGAGAT 2093 QSSNLQR 2593 QSGHLTR 3093 RLHNLAR 3593 167
    1008 GAGATGGAG 2094 RSDNLSR 2594 RSDSLTQ 3094 RLHNLAR 3594 0.4
    1009 GAGATGGAG 2095 RSDNLSR 2595 RSDSLTQ 3095 RSDNLSR 3595 1.9
    1010 GAGAGAGAT 2096 QSSNLQR 2596 QSGHLTR 3096 RSDNLAR 3596 8.2
    1011 TTGGTGGCG 2097 RSADLTR 2597 RSDSLAR 3097 RSDSLTK 3597 0.03
    1012 GACGTAGGG 2098 RSDHLTR 2598 QSSSLVR 3098 DRSNLTR 3598 0.032
    1013 GAGAGAGAT 2099 QSSNLQR 2599 QSGHLNQ 3099 RSDNLAR 3599 0.15
    1014 GACGTAGGG 2100 RSDHLTR 2600 QSGSLTR 3100 DRSNLTR 3600 0.01
    1015 GCGGAGGAG 2101 RSDNLVR 2601 RSDNLAR 3101 RSDTLKK 3601 0.008
    1016 CAGTTGGTC 2102 DRSALAR 2602 RSDSLTK 3102 RSDNLRE 3602 0.09
    1017 CTGGATGAC 2103 EKANLTR 2603 TSGNLVR 3103 RSDALRE 3603 0.233
    1018 GTAGTAGAA 2104 QSANLAR 2604 QSSSLVR 3104 QRASLAR 3604 7.2
    1019 AGGGAGGAG 2105 RSDNLAR 2605 RSDNLAR 3105 RSDHLTQ 3605 0.022
    1020 ACGTAGTAG 2106 RSDNLTT 2606 RSDNLTK 3106 RSDTLKQ 3606 0.69
    1022 GAGGAGGTG 2107 RSDALAR 2607 RSDNLAR 3107 RSDNLAR 3607 0.01
    1024 GGGGAGGAA 2108 QSANLAR 2608 RSDNLAR 3108 RSDHLSR 3608 0.08
    1025 GAGGAGGTG 2109 QSSALTR 2609 QSSSLVR 3109 RSDTLTQ 3609 0.115
    1026 GTGGCTTGT 2110 MSHHLKE 2610 QSSDLSR 3110 RSDALAR 3610 0.076
    1027 GCGGCGGTG 2111 RSDALAR 2611 RSDELQR 3111 RSDELQR 3611 0.054
    1032 GGTGCTGAT 2112 TSGNLVR 2612 QSSDLQR 3112 TSGHLVR 3612 0.52
    1033 GTGTTCGTG 2113 RSDALAR 2613 DRSALTT 3113 RSDALAR 3613 685.2
    1034 GTGTTCGTG 2114 RSDALAR 2614 DRSALTK 3114 RSDALAR 3614 14.55
    1035 GTGTTCGTG 2115 RSDALAR 2615 DRSALRT 3115 RSDALAR 3615 56
    1037 GTAGGGGCA 2116 QSGSLTR 2616 RSDHLSR 3116 QRASLAR 3616 0.05
    1038 GTAGGGGCA 2117 QTGELRR 2617 RSDHLSR 3117 QRASLAR 3617 0.152
    1039 GGGGCTGGG 2118 RSDHLSR 2618 TSGELVR 3118 RSDHLTR 3618 1.37
    1040 GGGGCTGGG 2119 RSDHLSR 2619 QSSDLQR 3119 RSDHLSK 3619 0.05
    1041 TCATAGTAG 2120 RSDNLTT 2620 RSDNLRT 3120 QSHDLTK 3620 2.06
    1043 CAGGGAGAG 2121 RSDNLAR 2621 QSGHLTR 3121 RSDNLRE 3621 0.16
    1044 CAGGGAGAG 2122 RSDNLAR 2622 QRAHLER 3122 RSDNLRE 3622 1.07
    1045 GGGGCAGGA 2123 QSGHLAR 2623 QSGSLTR 3123 RSDHLSR 3623 0.15
    1046 GGGGCAGGA 2124 QSGHLAR 2624 QSGDLRR 3124 RSDHLSR 3624 0.09
    1047 GGGGCAGGA 2125 QRAHLER 2625 QSGSLTR 3125 RSDHLSR 3625 24.7
    1048 CAGGCTGTA 2126 QSGALTR 2626 QSSDLQR 3126 RSDNLRE 3626 1.387
    1049 CAGGCTGTA 2127 QRASLAR 2627 QSSDLQR 3127 RSDNLRE 3627 55.6
    1050 CAGGCTGTA 2128 QSSSLVR 2628 QSSDLQR 3128 RSDNLRE 3628 0.125
    1051 GAGGCTGAG 2129 RSDNLTR 2629 QSSDLQR 3129 RSDNLVR 3629 0.02
    1052 TAGGACGGG 2130 RSDHLAR 2630 EKANLTR 3130 RSDNLTT 3630 0.28
    1053 TAGGACGGG 2131 RSDHLAR 2631 DRSNLTR 3131 RSDNLTT 3631 0.025
    1054 GCTGCAGGG 2132 RSDHLAR 2632 QSGSLTR 3132 QSSDLQR 3632 0.033
    1055 GCTGCAGGG 2133 RSDHLAR 2633 QSGSLTR 3133 TSGDLTR 3633 18.73
    1056 GCTGCAGGG 2134 RSDHLAR 2634 QSGSLTR 3134 QSSDLQR 3634 0.045
    1057 GCTGCAGGG 2135 RSDHLAR 2635 QSGDLTR 3135 TSGDLTR 3635 0.483
    1058 GGGGCCGCG 2136 RSDELTR 2636 DRSSLTR 3136 RSDHLSR 3636 6.277
    1059 GGGGCCGCG 2137 RSDELTR 2637 DRSDLTR 3137 RSDHLSR 3637 0.152
    1060 GCGGAGGCC 2138 ERGTLAR 2638 RSDNLAR 3138 RSDERKR 3638 0.69
    1061 GTTGCGGGG 2139 RSDHLAR 2639 RSDELQR 3139 QSSALTR 3639 0.165
    1062 GTTGCGGGG 2140 RSDHLAR 2640 RSDELQR 3140 TSGSLTR 3640 0.068
    1063 GTTGCGGGG 2141 RSDHLAR 2641 RSDELQR 3141 MSHALSR 3641 0.96
    1064 GCGGCAGTG 2142 RSDALTR 2642 QSGSLTR 3142 RSDERKR 3642 0.453
    1065 TGGGGCGGG 2143 RSDHLAR 2643 DRSHLAR 3143 RSDHLTT 3643 1.37
    1066 GAGGGCGGT 2144 QSSHLTR 2644 DRSHLAR 3144 RSDNLVR 3644 0.15
    1067 GAGGGCGGT 2145 TSGHLVR 2645 DRSHLAR 3145 RSDNLVR 3645 1.37
    1068 GCAGGGGGC 2146 DRSHLTR 2646 RSDHLTR 3146 QSGDLTR 3646 2.05
    1069 GCAGGCGGT 2147 DRSHLTR 2647 RSDHLTR 3147 QSGSLTR 3647 0.1
    1070 GGGGCAGGC 2148 DRSHLTR 2648 QSGSLTR 3148 RSDHLSR 3648 0.456
    1071 GGGGCAGGC 2149 DRSHLTR 2649 QSGDLTR 3149 RSDHLSR 3649 0.2
    1072 GGATTGGCT 2150 QSSDLTR 2650 RSDALTT 3150 QRAHLAR 3650 0.46
    1073 GGATTGGCT 2151 QSSDLTR 2651 RSDALTK 3151 QRAHLAR 3651 1.37
    1075 GTGTTGGCG 2152 RSDELTR 2652 RSDALTK 3152 RSDALTR 3652 0.915
    1076 GCGGCAGCG 2153 RSDELTR 2653 QSGSLTR 3153 RSDERKR 3653 4.1
    1077 GCGGCAGCG 2154 RSDELTR 2654 QSGDLRR 3154 RSDERKR 3654 6.2
    1078 GGGGGGGCC 2155 ERGTLAR 2655 RSDHLSR 3155 RSDHLSR 3655 0.2
    1079 GGGGGGGCC 2156 ERGDLTR 2656 RSDHLSR 3156 RSDHLSR 3656 4.1
    1080 CTGGAGGCG 2157 RSDELTR 2657 RSDNLAR 3157 RSDALRE 3657 1.37
    1081 GGGGAGGTG 2158 RSDALTR 2658 RSDNLTR 3158 RSDHLSR 3658 0.05
    1082 CTGGCGGCG 2159 RSDELTR 2659 RSDELTR 3159 RSDALRE 3659 0.152
    1083 CTGGTGGCA 2160 QSGDLTR 2660 RSDALSR 3160 RSDALRE 3660 0.152
    1084 GGTGAGGCG 2161 RSDELTR 2661 RSDNLAR 3161 MSHHLSR 3661 0.5
    1085 GGTGAGGCG 2162 RSDELTR 2662 RSDNLAR 3162 QSSHLAR 3662 0.46
    1086 GGGGCTGGG 2163 RSDHLSR 2663 QSSDLQR 3163 RSDHLTR 3663 0.1
    1087 CGGGCGGCC 2164 ERGDLTR 2664 RSDELQR 3164 RSDHLAE 3664 1.24
    1088 CGGGCGGCC 2165 ERGDLTR 2665 RSDELQR 3165 RSDHLRE 3665 0.905
    1089 GACGAGGCT 2166 QSSDLRR 2666 RSDNLAR 3166 DRSNLTR 3666 0.171
    1090 AAGGCGCTG 2167 RSDALRE 2667 RSDELQR 3167 RSDNLTQ 3667 30.3
    1091 GTAGAGGAC 2168 DRSNLTR 2668 RSDNLAR 3168 QRASLAR 3668 0.085
    1092 GCCTTGGCT 2169 QSSDLRR 2669 RGDALTS 3169 DRSDLTR 3669 2.735
    1093 GCGGAGTCG 2170 RSADLRT 2670 RSDNLAR 3170 RSDERKR 3670 0.046
    1094 GCGGTTGGT 2171 TSGHLVR 2671 QSSALTR 3171 RSDERKR 3671 12.34
    1095 GGGGGAGCC 2172 ERGDLTR 2672 QRAHLER 3172 RSDHLSR 3672 0.395
    1096 GGGGGAGCC 2173 DRSSLTR 2673 QRAHLER 3173 RSDHLSR 3673 0.019
    1097 GAGGCCGAA 2174 QSANLAR 2674 DCRDLAR 3174 RSDNLAR 3674 0.77
    1098 GCCGGGGAG 2175 RSDNLTR 2675 RSDHLTR 3175 DRSDLTR 3675 0.055
    1099 GCGGAGTCG 2176 TSGHLVR 2676 TSGSLTR 3176 RSDERKR 3676 0.45
    1100 GTGTTGGTA 2177 QSGALTR 2677 RGDALTS 3177 RSDALTR 3677 1.4
    1101 ATGGGAGTT 2178 TTSALTR 2678 QPAHLER 3178 RSDALRQ 3678 0.065
    1102 AAGGCAGAA 2179 QSANLAR 2679 QSGSLTR 3179 RSDNLTQ 3679 8.15
    1103 AAGGCAGAA 2180 QSANLAR 2680 QSGDLTR 3180 RSDNLTQ 3680 1.4
    1104 CGGGCAGCT 2181 QSSDLRR 2681 QSGSLTR 3181 RSDHLRE 3681 0.08
    1105 CTGGCAGCC 2182 ERGDLTR 2682 QSGDLTR 3182 RSDALRE 3682 2.45
    1106 CTGGCAGCC 2183 DRSSLTR 2683 QSGDLTR 3183 RSDALRE 3683 0.19
    1107 GCGGGAGTT 2184 QSSALAR 2684 QRAHLER 3184 RSDERKR 3684 0.06
    1108 CAGGCTGGA 2185 QSGHLAR 2685 TSGELVR 3185 RSDNLRE 3685 0.007
    1109 AGGGGAGCC 2186 ERGDLTR 2686 QRAHLER 3186 RSDHLTQ 3686 0.347
    1110 AGGGGAGCC 2187 DRSSLTR 2687 QRAHLER 3187 RSDHLTQ 3687 0.095
    1111 CTGGTAGGG 2188 RSDHLAR 2688 QSSSLVR 3188 RSDALRE 3688 0.095
    1112 CTGGTAGGG 2189 RSDHLAR 2689 QSATLAR 3189 RSDALRE 3689 0.125
    1113 CTGGGGGCA 2190 QSGDLTR 2690 RSDHLTR 3190 RSDALRE 3690 0.06
    1114 CAGGTTGAT 2191 QSSNLAR 2691 TSGSLTR 3191 RSDNLRE 3691 2.75
    1115 CAGGTTGAT 2192 QSSNLAR 2692 QSSALTR 3192 RSDNLRE 3692 0.7
    1116 CCGGAAGCG 2193 RSDELTR 2693 QSSNLVR 3193 RSDELRE 3693 12.3
    1117 GCAGCGCAG 2194 RSSNLRE 2694 RSDELTR 3194 QSGSLTR 3694 2.85
    1118 TAGGGAGTC 2195 DRSALTR 2695 QRAHLER 3195 RSDNLTT 3695 1.4
    1119 TGGGAGGGT 2196 TSGHLVR 2696 RSDNLAR 3196 RSDHLTT 3696 0.1
    1120 AGGGACGCG 2197 RSDELTR 2697 DRSNLTR 3197 RSDHLTQ 3697 2.735
    1121 CTGGTGGCC 2198 ERGDLTR 2698 RSDALTR 3198 RSDALRE 3698 2.76
    1122 CTGGTGGCC 2199 DRSSLTR 2699 RSDALTR 3199 RSDALRE 3699 0.101
    1123 TAGGAAGCA 2200 QSGSLTR 2700 QSGNLAR 3200 RSDNLTT 3700 0.065
    1124 GTGGATGGA 2201 QSGHLAR 2701 TSGNLVR 3201 RSDALTR 3701 0.101
    1126 TTGGCTATG 2202 RSDALTS 2702 TSGELVR 3202 RGDALTS 3702 0.46
    1127 CAGGGGGTT 2203 QSSALAR 2703 RSDHLTR 3203 RSDNLRE 3703 0.1
    1128 AAGGTCGCC 2204 ERGDLTR 2704 DPGALVR 3204 RSDNLTQ 3704 5.45
    1130 GGTGCAGAC 2205 DRSNLTR 2705 QSGDLTR 3205 MSHHLSR 3705 0.1
    1131 GTGGGAGCC 2206 ERGDLTR 2706 QRAHLER 3206 RSDALTR 3706 0.95
    1132 GGGGCTGGA 2207 QSGHLAR 2707 TSGELVR 3207 RSDHLSR 3707 0.055
    1133 GGGGCTGGA 2208 QRAHLER 2708 TSGELVR 3208 RSDHLSR 3708 0.5
    1134 TGGGGGTGG 2209 RSDHLTT 2709 RSDHLTR 3209 RSDHLTT 3709 0.067
    1135 GCGGCGGGG 2210 RSDHLAR 2710 RSDELQR 3210 RSDERKR 3710 0.025
    1136 CCGGGAGTG 2211 RSDALTR 2711 QRAHLER 3211 RSDTLRE 3711 0.225
    1137 CCGGGAGTG 2212 RSSALTR 2712 QRAHLER 3212 RSDTLRE 3712 0.085
    1138 CAGGGGGTA 2213 QSGALTR 2713 RSDHLTR 3213 RSDNLRE 3713 0.027
    1139 ACGGCCGAG 2214 RSDNLAR 2714 DRSDLTR 3214 RSDTLTQ 3714 0.535
    1140 AAGGGTGCG 2215 RSDELTR 2715 QSSHLAR 3215 RSDNLTQ 3715 0.3
    1141 ATGGACTTG 2216 RGDALTS 2716 DRSNLTR 3216 RSDALTQ 3716 1.7
    1148 TTGGAGGAG 2217 RSDNLTR 2717 RSDNLTR 3217 RGDALTS 3717 0.006
    1149 TTGGAGGAG 2218 RSDNLTR 2718 RSDNLTR 3218 RSDALTK 3718 0.004
    1150 GAAGAGGCA 2219 QSGSLTR 2719 RSDNLTR 3219 QSGNLTR 3719 0.004
    1151 GTAGTATGG 2220 RSDHLTT 2720 QRSALAR 3220 QRASLAR 3720 1.63
    1152 AAGGCTGGA 2221 QSGHLAR 2721 TSGELVR 3221 RSDNLTQ 3721 1.605
    1153 AAGGCTGGA 2222 QRAHLAR 2722 TSGELVR 3222 RSDNLTQ 3722 8.2
    1154 CTGGCGTAG 2223 RSDNLTT 2723 RSDELQR 3223 RSDALRE 3723 1.04
    1156 ATGGTTGAA 2224 QSANLAR 2724 QSSALTR 3224 RSDALRQ 3724 7.2
    1157 ATGGTTGAA 2225 QSANLAR 2725 TSGSLTR 3225 RSDALRQ 3725 0.885
    1158 AGGGGAGAA 2226 QSANLAR 2726 QSGHLTR 3226 RSDHLTQ 3726 0.1
    1159 AGGGGAGAA 2227 QSANLAR 2727 QRAHLER 3227 RSDHLTQ 3727 0.555
    1160 TGGGAAGGC 2228 DRSHLAR 2728 QSSNLVR 3228 RSDHLTT 3728 0.415
    1161 GAGGCCGGC 2229 DRSHLAR 2729 DRSDLTR 3229 RSDNLAR 3729 0.45
    1162 GTGTTGGTA 2230 QSGALTR 2730 RADALMV 3230 RSDALTR 3730 0.465
    1163 GTGTGAGCC 2231 ERGDLTR 2731 QSGHLTT 3231 RSDALTR 3731 1.45
    1164 GTGTGAGCC 2232 ERGDLTR 2732 QSVHLQS 3232 RSDALTR 3732 15.4
    1165 GCGAAGGTG 2233 RSDALTR 2733 RSDNLTQ 3233 RSDERKR 3733 1.4
    1166 GCGAAGGTG 2234 RSDALTR 2734 RSDNLTQ 3234 RSSDRKR 3734 0.195
    1167 GCGAAGGTG 2235 RSDALTR 2735 RSDNLTQ 3235 RSHDRKR 3735 0.95
    1168 AAGGCGCTG 2236 RSDALRE 2736 RSSDLTR 3236 RSDNLTQ 3736 2.8
    1169 GTAGAGGAC 2237 DRSNLTR 2737 RSDNLAR 3237 QSSSLVR 3737 0.053
    1170 GCCTTGGCT 2238 QSSDLRR 2738 RADALMV 3238 DRSDLTR 3738 2.75
    1171 GCGGAGTCG 2239 RSDDLRT 2739 RSDNLAR 3239 RSDERKR 3739 0.18
    1172 GCCGGGGAG 2240 RSDNLTR 2740 RSDHLTR 3240 ERGDLTR 3740 0.01
    1173 GCTGAAGGG 2241 RSDHLSR 2741 QSGNLAR 3241 QSSDLRR 3741 0.008
    1174 GCTGAAGGG 2242 RSDHLSR 2742 QSSNLVR 3242 QSSDLRR 3742 0.018
    1175 AAGGTCGCC 2243 DRSDLTR 2743 DPGALVR 3243 RSDNLTQ 3743 8.9
    1176 GTGGGAGCC 2244 DRSDLTR 2744 QPAHLER 3244 RSDALTR 3744 4.1
    1177 CCGGGCGCA 2245 QSGSLTR 2745 DRSHLAR 3245 RSDTLRE 3745 4.1
    1178 GAGGATGGC 2246 DRSHLAR 2746 TSGNLVR 3246 RSDNLAR 3746 0.085
    1179 GCAGCGCAG 2247 RSSNLRE 2747 RSSDLTR 3247 QSGSLTR 3747 2.735
    1180 AAGGAAAGA 2248 QSGHLNQ 2748 QSGNLAR 3248 RSDNLTQ 3748 4.825
    1181 TTGGCTATG 2249 RSDALRQ 2749 TSGELVR 3249 RGDALTS 3749 8.2
    1182 CAGGAAGGC 2250 DRSHLAR 2750 QSGNLAR 3250 RSDNLRE 3750 1.48
    1183 CAGGAAGGC 2251 DRSHLAR 2751 QSSNLVR 3251 RSDNLRE 3751 1.935
    1184 AAGGAAAGA 2252 KNWKLQA 2752 QSGNLAR 3252 RSDNLTQ 3752 2.785
    1185 AAGGAAAGA 2253 KNWKLQA 2753 QSHNLAR 3253 RSDNLTQ 3753 5.25
    1186 GCCGAGGTG 2254 RSDSLLR 2754 RSKNLQR 3254 ERGTLAR 3754 27.5
    1187 CTGGTGGGC 2255 DRSHLAR 2755 RSDALTR 3255 RSDALRE 3755 0.006
    1188 GTAGTATGG 2256 RSDHLTT 2756 QSSSLVR 3256 QRASLAR 3756 2.74
    1189 ATGGTTGAA 2257 QSANLAR 2757 TSGALTR 3257 RSDALRQ 3757 1.51
    1190 ATGGCAGTG 2258 RSDALTR 2758 QSGDLTR 3258 RSDSLNQ 3758 1.484
    1191 ATGGCAGTG 2259 RSDALTR 2759 QSGSLTR 3259 RSDSLNQ 3759 5.325
    1192 ATGGCAGTG 2260 RSDALTR 2760 QSGDLTR 3260 RSDALTQ 3760 2.364
    1193 ATGGCAGTG 2261 RSDALTR 2761 QSGSLTR 3261 RSDALTQ 3761 3.125
    1194 GAGAAGGTG 2262 RSDALTR 2762 RSDNRTA 3262 RSDNLTR 3762 2.19
    1195 GAGAAGGTG 2263 RSDALTR 2763 RSDNRTA 3263 RSSNLTR 3763 2.8
    1197 GAAGGTGCC 2264 ERGDLTR 2764 MSHHLSR 3264 QSGNLTR 3764 14.8
    1199 ATGGAGAAG 2265 RSDNRTA 2765 RSDNLTR 3265 RSDALTQ 3765 3.428
    1200 ATGGAGAAG 2266 RSDNRTA 2766 RSSNLTR 3266 RSDALTQ 3766 16.87
    1201 ATGGAGAAG 2267 RSDNRTA 2767 RSHNLTR 3267 RSDALTQ 3767 14.8
    1202 CTGGAGTAC 2268 DRSNLRT 2768 RSDNLTR 3268 RSDALRE 3768 2.834
    1203 GGAGTACTG 2269 RSDALRE 2769 QRSALAR 3269 QRAHLAR 3769 2.945
    1204 GGAGTACTG 2270 RSDALRE 2770 QSSSLVR 3270 QRAHLAR 3770 4.38
    1205 CGGGCAGCT 2271 QSSDLRR 2771 QSGDLTR 3271 RSDHLRE 3771 0.9
    1206 GCGGGAGTT 2272 TTSALTR 2772 QRAHLER 3272 RSDERKR 3772 0.034
    1207 CAGGCTGGA 2273 QRAHLER 2773 TSGELVR 3273 RSDNLRE 3773 0.45
    1209 CCGGAAGCG 2274 RSDELTR 2774 QSSNLVR 3274 RSDTLRE 3774 19.28
    1211 GCAGCGCAG 2275 RSDNLRE 2775 RSDELTR 3275 QSGSLTR 3775 6.5
    1212 CAGGGGGTT 2276 TTSALTR 2776 RSDHLTR 3276 RSDNLRE 3776 0.05
    1213 GAAGAAGAG 2277 RSDNLTR 2777 QSSNLVR 3277 QSGNLTR 3777 12.3
    1214 ATGGGAGTT 2278 TTSALTR 2778 QRAHLER 3278 RSDALTQ 3778 0.46
    1215 GTGGGGGCT 2279 QSSDLRR 2779 RSDHLTR 3279 RSDALTR 3779 0.003
    1217 GAAGAGGCA 2280 QSGSLTR 2780 RSDNLTR 3280 QSANLTR 3780 0.004
    1218 GCGGTGAGG 2281 RSDHLTQ 2781 RSQALTR 3281 RSDERKR 3781 0.46
    1219 AAGGAAAGG 2282 RSDHLTQ 2782 QSHNLAR 3282 RSDNLTQ 3782 0.68
    1220 AAGGAAAGG 2283 RSDHLTQ 2783 QSGNLAR 3283 RSDNLTQ 3783 0.175
    1221 AAGGAAAGG 2284 RSDHLTQ 2784 QSSNLVR 3284 RSDNLTQ 3784 1.4
    1222 CAGGAGGGC 2285 DRSHLAR 2785 RSDNLAR 3285 RSDNLRE 3785 0.155
    1223 ATGGACTTG 2286 RSDALTK 2786 DRSNLTR 3286 RSDALTQ 3786 7
    1224 ATGGACTTG 2287 RADALMV 2787 DRSNLTR 3287 RSDALTQ 3787 12
    1227 GAATAGGGG 2288 RSDHLSR 2788 RSDHLTK 3288 QSGNLAR 3788 25
    1228 ACGGCCGAG 2289 RSDNLAR 2789 DRSDLTR 3289 RSDDLTQ 3789 12
    1229 AAGGGTGCG 2290 RSDELTR 2790 MSHHLSR 3290 RSDNLTQ 3790 8.2
    1230 AAGGGAGAC 2291 DRSNLTR 2791 QSGHLTR 3291 RSDNLTQ 3791 0.383
    1231 AAGGGAGAC 2292 DRSNLTR 2792 QRAHLER 3292 RSDNLTQ 3792 0.213
    1232 TGGGACCTG 2293 RSDALRE 2793 DRSNLTR 3293 RSDHLTT 3793 0.113
    1233 TGGGACCTG 2294 RSDALRE 2794 DRSNLTR 3294 RSDHLTT 3794 0.635
    1234 GAGTAGGCA 2295 QSGSLTR 2795 RSDNLTK 3295 RSDNLAR 3795 0.101
    1236 GAGTAGGCA 2296 QSGSLTR 2796 RSDHLTT 3296 RSDNLAR 3796 0.065
    1237 GAAGGAGAG 2297 RSDNLAR 2797 QRAHLER 3297 QSGNLAR 3797 0.065
    1238 CTGGATGTT 2298 QSSALAR 2798 TSGNLVR 3298 RSDALRE 3798 0.313
    1239 CAGGACGTG 2299 RSDALTR 2799 DPGNLVR 3299 RSDNLKD 3799 0.144
    1240 GGGGAGGCA 2300 QSGSLTR 2800 RSDNLTR 3300 RSDHLSR 3800 0.056
    1241 GAGGTGTCA 2301 QSHDLTK 2801 RSDALAR 3301 RSDNLAR 3801 0.027
    1242 GGGGTTGAA 2302 QSANLAR 2802 TSGSLTR 3302 RSDHLSR 3802 0.02
    1243 GGGGTTGAA 2303 QSANLAR 2803 QSSALTR 3303 RSDHLSR 3803 0.101
    1244 GTCGCGGTG 2304 RSDALTR 2804 RSDELQR 3304 DRSALAR 3804 0.044
    1245 GTCGCGGTG 2305 RSDALTR 2805 RSDELQR 3305 DSGSLTR 3805 0.102
    1246 GTGGTTGCG 2306 RSDELTR 2806 TSGSLTR 3306 RSDALTR 3806 0.051
    1247 GTGGTTGCG 2307 RSDELTR 2807 TSGALTR 3307 RSDALTR 3807 0.117
    1248 GTCTAGGTA 2308 QSGALTR 2808 RSDNLTT 3308 DRSALAR 3808 5.14
    1249 CCGGGAGCG 2309 RSDELTR 2809 QSGHLTR 3309 RSDTLRE 3809 0.26
    1250 GAAGGAGAG 2310 RSDNLAR 2810 QSGHLTR 3310 QSGNLAR 3810 0.31
    1252 CCGGCTGGA 2311 QRAHLER 2811 QSSDLTR 3311 RSDTLRE 3811 0.153
    1253 CCGGGAGCG 2312 RSDELTR 2812 QRAHLER 3312 RSDTLRE 3812 0.228
    1255 ACGTAGTAG 2313 RSDNLTT 2813 RSDNLTK 3313 RSDTLKQ 3813 0.69
    1256 GGGGAGGAT 2314 QSSNLAR 2814 RSDNLQR 3314 RSDHLSR 3814 2
    1257 GGGGAGGAT 2315 TTSNLAR 2815 RSDNLQR 3315 RSDHLSR 3815 1
    1258 GGGGAGGAT 2316 QSSNLRR 2816 RSDNLQR 3316 RSDHLSR 3816 2
    1259 GAGTGTGTG 2317 RSDSLLR 2817 DRDHLTR 3317 RSDNLAR 3817 1.5
    1260 GAGTGTGTG 2318 RLDSLLR 2818 DRDHLTR 3318 RSDNLAR 3818 1.8
    1261 TGCGGGGCA 2319 QSGDLTR 2819 RSDHLTR 3319 RRDTLHR 3819 0.2
    1262 TGCGGGGCA 2320 QSGDLTR 2820 RSDHLTR 3320 RLDTLGR 3820 3
    1263 TGCGGGGCA 2321 QSGDLTR 2821 RSDHLTR 3321 DSGHLAS 3821 21
    1264 AAGTTGGTT 2322 TTSALTR 2822 RADALMV 3322 RSDNLTQ 3822 0.21
    1265 AAGTTGGTT 2323 TTSALTR 2823 RSDALTT 3323 RSDNLTQ 3823 0.077
    1266 CAGGGTGGC 2324 DRSHLTR 2824 QSSHLAR 3324 RSDNLRE 3824 6.1
    1267 TAGGCAGTC 2325 DRSALTR 2825 QSGSLTR 3325 RSDNLTT 3825 6
    1268 CTGTTGGCT 2326 QSSDLTR 2826 RAEDLMV 3326 RSDALRE 3826 1.52
    1269 CTGTTGGCT 2327 QSSDLTR 2827 RSDALTT 3327 RSDALRE 3827 12.3
    1270 TTGGATGGA 2328 QSGHLAR 2828 TSGNLVR 3328 RSDALTK 3828 0.4
    1271 GTGGCACTG 2329 RSDALRE 2829 QSGSLTR 3329 RSDALTR 3829 0.915
    1272 CAGGAGTCC 2330 DRSSLTT 2830 RSDNLAR 3330 RSDNLRE 3830 0.04
    1273 CAGGAGTCC 2331 ERGDLTT 2831 RSDNLAR 3331 RSDNLRE 3831 0.1
    1274 GCATGGGAA 2332 QSANLSR 2832 RSDHLTT 3332 QSGSLTR 3832 0.306
    1275 GCATGGGAA 2333 QRSNLVR 2833 RSDHLTT 3333 QSGSLTR 3833 0.326
    1276 TAGGAAGAG 2334 RSDNLAR 2834 QRSNLVR 3334 RSDNLTT 3834 0.685
    1277 GAAGAGGGG 2335 RSDHLAR 2835 RSDNLAR 3335 QSGNLTR 3835 0.421
    1278 GAGTAGGCA 2336 QSGSLTR 2836 RSDNLRT 3336 RSDNLAR 3836 0.019
    1279 GAGGTGTCA 2337 QSGDLRT 2837 RSDALAR 3337 RSDNLAR 3837 0.025
    1282 TCGGTCGCC 2338 ERGDLTR 2838 DPGALVR 3338 RSDELRT 3838 74.1
    1287 GTGGTAGGA 2339 QSGHLAR 2839 QSGALAR 3339 RSDALTR 3839 0.152
    1288 CAGGGTGGC 2340 DRSHLTR 2840 QSSHLAR 3340 RSDNLTE 3840 4.1
    1289 TAGGCAGTC 2341 DRSALTR 2841 QSGSLTR 3341 RSDNLTK 3841 1.37
    1290 GTGGTGATA 2342 QSGALTQ 2842 RSHALTR 3342 RSDALTR 3842 24.05
    1291 GTGGTGATA 2343 QQASLNA 2843 RSHALTR 3343 RSDALTR 3843 20.55
    1292 TTGGATGGA 2344 QSGHLAR 2844 TSGNLVR 3344 RSDALTT 3844 4.12
    1293 AAGGTAGGT 2345 TSGHLVR 2845 QSGALAR 3345 RSDNLTQ 3845 0.457
    1294 AAGGTAGGT 2346 MSHHLSR 2846 QSGALAR 3346 RSDNLTQ 3846 2.75
    1295 CAGGAGTCC 2347 DRSSLTT 2847 RSDNLAR 3347 RSDNLTE 3847 0.116
    1296 CAGGAGTCC 2348 ERGDLTT 2848 RSDNLAR 3348 RSDNLTE 3848 37
    1297 TAGGAAGAG 2349 RSDNLAR 2849 QRSNLVR 3349 RSDNLTK 3849 0.05
    1298 CAGGACGTG 2350 RSDLATR 2850 DPGNLVR 3350 RSDNLTE 3850 0.05
    1300 GTCTAGGTA 2351 QSGALTR 2851 RSDNLTK 3351 DRSALAR 3851 0.46
    1302 CCGGCTGGA 2352 QSGHLTR 2852 QSSDLTR 3352 RSDTLRE 3852 0.05
    1303 TAGGAGTTT 2353 QRSALAS 2853 RSDNLAR 3353 RSDNLTT 3853 0.088
    1306 CTGGCCTTG 2354 RSDALTT 2854 DCRDLAR 3354 RSDALRE 3854 2.285
    1308 TGGGCAGCC 2355 ERGTLAR 2855 QSGSLTR 3355 RSDHLTT 3855 0.305
    1309 TAGGAGTTT 2356 QSSALAS 2856 RSDNLAR 3356 RSDNLTT 3856 0.184
    1310 TAGGAGTTT 2357 TTSALAS 2857 RSDNLAR 3357 RSDNLTT 3857 0.075
    1311 TGGGCAGCC 2358 ERGDLAR 2858 QSGSLTR 3358 RSDHLTT 3858 0.91
    1312 GGGGCGTGA 2359 QSGHLTK 2859 RSDELQR 3359 RSDHLSR 3859 0.23
    1313 GGGGCGTGA 2360 QSGHLTT 2860 RSDELQR 3360 RSDHLSR 3860 0.09
    1314 GTACAGTAG 2361 RSDNLTT 2861 RSDNLRE 3361 QSSSLVR 3861 3.09
    1315 GTACAGTAG 2362 RSDNLTT 2862 RSDNLTE 3362 QSSSLVR 3862 9.27
    1318 ATGGTGTGT 2363 TSSHLAS 2863 RSDALAR 3363 RSDALAQ 3863 0.048
    1319 ATGGTGTGT 2364 MSHHLTT 2864 RSDALAR 3364 RSDALAQ 3864 0.228
    1320 TTGGGAGAG 2365 RSDNLAR 2865 QRAHLER 3365 RSDALTT 3865 0.044
    1321 TTGGGAGAG 2366 RSDNLAR 2866 QRAHLER 3366 RADALMV 3866 0.127
    1322 GTGGGAATA 2367 QSGALTQ 2867 QSGHLTR 3367 RSDALTR 3867 0.799
    1323 GTGGGAATA 2368 QLTGLNQ 2868 QSGHLTR 3368 RSDALTR 3868 0.744
    1324 GTGGGAATA 2369 QQASLNA 2869 QSHHLTR 3369 RSDALTR 3869 18.52
    1325 TTGGTTGGT 2370 TSGHLVR 2870 TSGSLTR 3370 RSDALTK 3870 0.306
    1326 TTGGTTGGT 2371 TSGHLVR 2871 QSSALTR 3371 RSDALTK 3871 4.385
    1327 TTGGTTGGT 2372 TSGHLVR 2872 TSGSLTR 3372 RSDALTT 3872 0.566
    1328 TTGGTTGGT 2373 TSGHLVR 2873 QSSALTR 3373 RSDALTT 3873 7.95
    1329 CTGGCCTGG 2374 RSDHLTT 2874 DRSDLTR 3374 RSDALRE 3874 0.68
    1330 GAGGTGTGA 2375 QSGHLTT 2875 RSDALTR 3375 RSDNLAR 3875 0.175
    1331 CTGGCCTGG 2376 RSDHLTT 2876 DCRDLAR 3376 RSDALRE 3876 0.388
    1334 CCGGCGCTG 2377 RSDALRE 2877 RSSDLTR 3377 RSDDLRE 3877 0.31
    1335 GACGCTGGC 2378 DRSHLTR 2878 QSSDLTR 3378 DSSNLTR 3878 1.4
    1336 CGGGCTGGA 2379 QSGHLAR 2879 QSSDLTR 3379 RSDHLAE 3879 1.4
    1337 CGGGCTGGA 2380 QSSHLAR 2880 QSSDLTR 3380 RSDHLAE 3880 0.235
    1338 GGGATGGCG 2381 RSDELTR 2881 RSDALTQ 3381 RSDHLSR 3881 1.04
    1339 GGGATGGCG 2382 RSDELTR 2882 RSDSLTQ 3382 RSDHLSR 3882 0.569
    1340 GGGATGGCG 2383 RSDELTR 2883 RSDALTQ 3383 RSHHLSR 3883 0.751
    1341 GGGATGGCG 2384 RSDELTR 2884 RSDSLTQ 3384 RSHHLSR 3884 4.1
    1342 CAGGCGCAG 2385 RSDNLRE 2885 RSSDLTR 3385 RSDNLTE 3885 0.68
    1343 CAGGCGCAG 2386 RSDNLTT 2886 RTSTLTR 3386 RSDNLTE 3886 37.04
    1344 CCGGGCGAC 2387 DRSNLTR 2887 DRSHLAR 3387 RSDTLRE 3887 2.28
    1346 GATGTGTGA 2388 QSGHLTT 2888 RSDALAR 3388 TSANLSR 3888 0.153
    1347 CAGTGAATG 2389 RSDALTS 2889 QSHHLTT 3389 RSDNLTE 3889 8.23
    1348 GGGTCACTG 2390 RSDALTA 2890 QAATLTT 3390 RSDHLSR 3890 2.58
    1350 CAGTGAATG 2391 RSDALTQ 2891 QSGHLTT 3391 RSDNLTE 3891 74.1
    1351 GGGTCACTG 2392 RSDALRE 2892 QSHDLTK 3392 RSDHLSR 3892 0.234
    1352 GTGTGGGTC 2393 DRSALAR 2893 RSDHLTT 3393 RSDALTR 3893 0.023
    1353 CTGGCGAGA 2394 QSGHLNQ 2894 RSDELQR 3394 RSDALRE 3894 56.53
    1354 CTGGCGAGA 2395 KNWKLQA 2895 RSDELQR 3395 RSDALRE 3895 20.85
    1355 GCTTTGGCA 2396 QSGSLTR 2896 RSDALTT 3396 QSSDLTR 3896 0.172
    1356 GCTTTGGCA 2397 QSGSLTR 2897 RADALMV 3397 QSSDLTR 3897 0.034
    1357 GACTTGGTA 2398 QSSSLVR 2898 RSDALTT 3398 DRSNLTR 3898 0.032
    1358 GACTTGGTA 2399 QSSSLVR 2899 RADALMV 3399 DRSNLTR 3899 0.05
    1360 CAGTTGTGA 2400 QSGHLTT 2900 RADALMV 3400 RSDNLTE 3900 41.7
    1361 AAGGAAAAA 2401 QKTNLDT 2901 QSGNLQR 3401 RSDNLTQ 3901 0.835
    1362 AAGGAAAAA 2402 QSGNLNQ 2902 QSGNLQR 3402 RSDNLTQ 3902 0.332
    1363 AAGGAAAAA 2403 QKTNLDT 2903 QRSNLVR 3403 RSDNLTQ 3903 74.1
    1364 ATGGGTGAA 2404 QSANLSR 2904 QSSHLAR 3404 RSDALAQ 3904 1.22
    1365 ATGGGTGAA 2405 QRSNLVR 2905 QSSLLAR 3405 RSDALAQ 3905 0.152
    1366 ATGGGTGAA 2406 QSANLSR 2906 TSGHLVR 3406 RSDALAQ 3906 22.63
    1367 ATGGGTGAA 2407 QRSNLVR 2907 TSGHLVR 3407 RSDALAQ 3907 1.028
    1368 CTGGGAGAT 2408 QSSNLAR 2908 QRAHLER 3408 RSDALRE 3908 0.051
    1369 CTGGGAGAT 2409 QSSNLAR 2909 QSGHLTR 3409 RSDALRE 3909 0.227
    1373 GTGGTGGGC 2410 DRSHLTR 2910 RSDALSR 3410 RSDALTR 3910 0.025
    1374 CCGGCGGTG 2411 RSDALTR 2911 RSDELQR 3411 RSDELRE 3911 0.003
    1375 CCGGCGGTG 2412 RSDALTR 2912 RSDDLQR 3412 RSDELRE 3912 0.008
    1376 CCGGCGGTG 2413 RSDALTR 2913 RSDERKR 3413 RSDELRE 3913 0.858
    1377 CCGGCGGTG 2414 RSDALTR 2914 RSDELQR 3414 RSDDLRE 3914 0.012
    1378 CCGGCGGTG 2415 RSDALTR 2915 RSDDLQR 3415 RSDDLRE 3915 0.012
    1379 CCGGCGGTG 2416 RSDALTR 2916 RSDERKR 3416 RSDDLRE 3916 0.25
    1380 GCCGACGGT 2417 QSSHLTR 2917 DRSNLTR 3417 ERGDLTR 3917 0.076
    1381 GCCGACGGT 2418 QSSHLTR 2918 DPGNLVR 3418 ERGDLTR 3918 0.23
    1382 GCCGACGGT 2419 QSSHLTR 2919 DRSNLTR 3419 DCRDLAR 3919 3.1
    1383 GCCGACGGT 2420 QSSHLTR 2920 DPGNLVR 3420 DCRDLAR 3920 1.74
    1384 GGTGTGGGC 2421 DRSHLTR 2921 RSDALSR 3421 MSHHLSR 3921 0.013
    1385 TGGGCAAGA 2422 QSGHLNQ 2922 QSGSLTR 3422 RSDHLTT 3922 0.229
    1386 TGGGCAAGA 2423 ENWKLQA 2923 QSGSLTR 3423 RSDHLTT 3923 0.193
    1389 CTGGCCTGG 2424 RSDHLTT 2924 DCRDLAR 3424 RSDALRE 3924 0.175
    1393 TGGGAAGCT 2425 QSSDLRR 2925 QSGNLAR 3425 RSDHLTT 3925 0.1
    1394 TGGGAAGCT 2426 QSSDLRR 2926 QSGNLAR 3426 RSDHLTK 3926 0.04
    1395 GAAGAGGGA 2427 QSGHLQR 2927 RSDNLAR 3427 QSGNLAR 3927 0.025
    1396 GAAGAGGGA 2428 QRAHLAR 2928 RSDNLAR 3428 QSGNLAR 3928 0.107
    1397 GAAGAGGGA 2429 QSSHLAR 2929 RSDNLAR 3429 QSGNLAR 3929 0.14
    1398 TAATGGGGG 2430 RSDHLSR 2930 RSDHLTT 3430 QSGNLRT 3930 0.065
    1399 TGGGAGTGT 2431 TKQHLKT 2931 RSDNLAR 3431 RSDHLTT 3931 0.1
    1400 CCGGGTGAG 2432 RSDNLAR 2932 QSSHLAR 3432 RSDDLRE 3932 0.371
    1401 GAGTTGGCC 2433 ERGTLAR 2933 RADALMV 3433 RSDNLAR 3933 0.167
    1402 CTGGAGTTG 2434 RGDALTS 2934 RSDNLAR 3434 RSDALRE 3934 0.15
    1403 ATGGCAATG 2435 RSDALTQ 2935 QSGSLTR 3435 RSDALTQ 3935 0.07
    1404 GAGGCAGGG 2436 RSDHLSR 2936 QSGSLTR 3436 RSDNLAR 3936 0.022
    1405 GAGGCAGGG 2437 RSDHLSR 2937 QSGDLTR 3437 RSDNLAR 3937 0.045
    1406 GAAGCGGAG 2438 RSDNLAR 2938 RSDELTR 3438 QSGNLAR 3938 0.025
    1407 GCGGGCGCA 2439 QSGSLTR 2939 DRSHLAR 3439 RSDERKR 3939 0.585
    1408 CCGGCAGGG 2440 RSDHLSR 2940 QSGSLTR 3440 RSDELRE 3940 0.305
    1409 CCGGCAGGG 2441 RSDHLSR 2941 QSGSLTR 3441 RSDDLRE 3941 0.153
    1410 CCGGCGGCG 2442 RSDELTR 2942 RSDELQR 3442 RSDELRE 3942 0.814
    1411 TGAGGCGAG 2443 RSDNLAR 2943 DRSHLAR 3443 QSGHLTK 3943 0.282
    1412 CTGGCCGTG 2444 RSDSLLR 2944 ERGTLAR 3444 RSDALRE 3944 0.172
    1413 CTGGCCGCG 2445 RSDELTR 2945 DRSDLTR 3445 RSDALRE 3945 0.152
    1414 CTGGCCGCG 2446 RSDELTR 2946 ERGTLAR 3446 RSDALRE 3946 0.914
    1415 GCGGCCGAG 2447 RSDNLAR 2947 DRSDLTR 3447 RSDELQR 3947 0.102
    1416 GCGGCCGAG 2448 RSDNLAR 2948 ERGTLAR 3448 RSDELQR 3948 0.153
    1417 GAGTTGGCC 2449 ERGTLAR 2949 RGDALTS 3449 RSDNLAR 3949 1.397
    1418 CTGGAGTTG 2450 RADALMV 2950 RSDNLAR 3450 RSDALRE 3950 0.241
    1422 GGGTCGGCG 2451 RSDELTR 2951 RSDDLTT 3451 RSDHLSR 3951 0.064
    1423 GGGTCGGCG 2452 RSDELTR 2952 RSDDLTK 3452 RSDHLSR 3952 0.034
    1424 CAGGGCCCG 2453 RSDELRE 2953 DRSHLAR 3453 RSDNLRE 3953 1.37
    1427 CAGGGCCCG 2454 RSDDLRE 2954 DRSHLAR 3454 RSDNLTE 3954 0.271
    1428 TGAGGCGAG 2455 RSDNLAR 2955 DRSHLAR 3455 QSVHLQS 3955 0.102
    1429 TGAGGCGAG 2456 RSDNLAR 2956 DRSHLAR 3456 QSGHLTT 3956 0.074
    1430 TCGGCCGCC 2457 ERGTLAR 2957 DRSDLTR 3457 RSDDLTK 3957 0.352
    1431 TCGGCCGCC 2458 ERGTLAR 2958 DRSDLTR 3458 RSDDLAS 3958 6.17
    1432 TCGGCCGCC 2459 ERGTLAR 2959 ERGTLAR 3459 RSDDLTK 3959 1.778
    1434 CTGGCCGTG 2460 RSDSLLR 2960 DRSDLTR 3460 RSDALRE 3960 0.051
    1435 TAATGGGGG 2461 RSDHLSR 2961 RSDHLTT 3461 QSGNLTK 3961 0.057
    1436 TGGGAGTGT 2462 TSDHLAS 2962 RSDNLAR 3462 RSDHLTT 3962 0.026
    1439 GGAGTGTTA 2463 QRSALAS 2963 RSDALAR 3463 QSGHLQR 3963 0.075
    1440 GGAGTGTTA 2464 QSGALTK 2964 RSDALAR 3464 QSGHLQR 3964 0.035
    1441 ATAGCTGGG 2465 RSDHLSR 2965 QSSDLTR 3465 QSGALTQ 3965 0.262
    1442 TGCTGGGCC 2466 ERGTLAR 2966 RSDHLTT 3466 DRSHLTK 3966 0.36
    1443 TGGAAGGAA 2467 QSGNLAR 2967 RSDNLTQ 3467 RSHHLTT 3967 0.22
    1444 TGGAAGGAA 2468 QSGNLAR 2968 RSDNLTQ 3468 RSSHLTT 3968 0.09
    1445 TGGAAGGAA 2469 QSGNLAR 2969 RLDNLTA 3469 RSHHLTT 3969 0.182
    1446 TGGAAGGAA 2470 QSGNLAR 2970 RLDNLTA 3470 RSSHLTT 3970 0.42
    1454 GGAGAGGCT 2471 QSSDLRR 2971 RSDNLAR 3471 QSGHLQR 3971 0.01
    1455 CGGGATGAA 2472 QSANLSR 2972 TSGNLVR 3472 RSDHLRE 3972 0.043
    1456 GGAGAGGCT 2473 QSSDLRR 2973 RSDNLAR 3473 QRAHLAR 3973 0.016
    1457 GCAGAGGAA 2474 QSANLSR 2974 RSDNTAR 3474 QSGSLTR 3974 0.014
    1460 TTGGGGGAG 2475 RSDNLAR 2975 RSDHLTR 3475 RADALMV 3975 0.007
    1461 GACGAGGAG 2476 RSANLAR 2976 RSDNLAR 3476 DRSNLTR 3976 0.014
    1462 CGGGATGAA 2477 QSGNLAR 2977 TSGNLVR 3477 RSDHLRE 3977 0.05
    1463 GAGGCTGTT 2478 TTSALTR 2978 QSSDLTR 3478 RSDNLAR 3978 0.003
    1464 GACGAGGAG 2479 RSDNLAR 2979 RSDNLTR 3479 DRSNLTR 3979 0.002
    1465 CTGGGAGTT 2480 TTSALTR 2980 QSGHLQR 3480 RSDALRE 3980 0.018
    1466 CTGGGAGTT 2481 NRATLAR 2981 QSGHLQR 3481 RSDALRE 3981 0.017
    1468 GGTGATGTC 2482 DRSALTR 2982 TSGNLVR 3482 MSHHLSR 3982 0.08
    1469 GGTGATGTC 2483 DRSALTR 2983 TSGNLVR 3483 TSGHLVR 3983 0.28
    1470 GGTGATGTC 2484 DRSALTR 2984 TSGNLVR 3484 QRAHLER 3984 0.156
    1471 CTGGTTGGG 2485 RSDHLSR 2985 QSSALTR 3485 RSDALRE 3985 0.09
    1472 TTGAAGGTT 2486 TTSALTR 2986 RSDNLTQ 3486 RADALMV 3986 3.22
    1473 TTGAAGGTT 2487 TTSALTR 2987 RSDNLTQ 3487 RSDSLTT 3987 0.47
    1474 TTGAAGGTT 2488 QSSALAR 2988 RSDNLTQ 3488 RADALMV 3988 1.39
    1475 TTGAAGGTT 2489 QSSALAR 2989 RSDNLTQ 3489 RLHSLTT 3989 0.39
    1476 TTGAAGGTT 2490 QSSALAR 2990 RSDNLTQ 3490 RSDSLTT 3990 0.305
    1477 GCAGCCCGG 2491 RSDHLRE 2991 DRSDLTR 3491 QSGSLTR 3991 2.31
    1479 GAAAGTTCA 2492 QSHDLTK 2992 MSHHLTQ 3492 QSGNLAR 3992 37.04
    1480 GAAAGTTCA 2493 NKTDLGK 2993 TSGHLVQ 3493 QSGNLAR 3993 62.5
    1481 GAAAGTTCA 2494 NKTDLGK 2994 TSDHLAS 3494 RSDELRE 3994 37.04
    1482 CCGTGTGAC 2495 DRSNLTR 2995 TSDHLAS 3495 RSDELRE 3995 111.1
    1483 CCGTGTGAC 2496 DRSNLTR 2996 MSHHLTT 3496 RSDELRE 3996 20.8
    1484 GAAGTGGTA 2497 QSSSLVR 2997 RSDALSR 3497 QSGNLAR 3997 0.01
    1485 AAGTGAGCT 2498 QSSDLRR 2998 QSGHLTT 3498 RSDNLTQ 3998 1.537
    1486 GGGTTTGAC 2499 DRSNLTR 2999 TTSALAS 3499 RSDHLSR 3999 0.085
    1487 TTGAAGGTT 2500 TTSALTR 3000 RSDNLTQ 3500 RLHSLTT 4000 0.188
    1488 AAGTGGTAG 2501 QSSDLRR 3001 QSGHLTT 3501 RLDNRTQ 4001 5.64
    1490 CTGGTTGGG 2502 RSDHLSR 3002 TSGSLTR 3502 RSDALRE 4002 0.04
    1491 AAGGGTTCA 2503 NKTDLGK 3003 DSSKLSR 3503 RLDNRTA 4003 4.12
    1492 AAGTGGTAG 2504 RSDNLTT 3004 RSDHLTT 3504 RSDNLTQ 4004 1.37
    1493 AAGTGGTAG 2505 RSDNLTT 3005 RSDHLTT 3505 RLDNRTQ 4005 15.09
    1494 GGGTTTGAC 2506 DRSNLTR 3006 QRSALAS 3506 RSDHLSR 4006 0.255
    1496 TTGGGGGAG 2507 RSDNLAR 3007 RSDHLTR 3507 RSDALTT 4007 0.065
    1497 GAGGCTCTT 2508 QSSALAR 3008 QSSDLTR 3508 RSDNLAR 4008 0.007
    1498 GAGGTTGAT 2509 QSSNLAR 3009 QSSALTR 3509 RSDNLAR 4009 0.101
    1499 GAGGTTGAT 2510 QSSNLAR 3010 TSGALTR 3510 RSDNLAR 4010 0.02
    1500 GCAGAGGAA 2511 QSGNLAR 3011 RSDNLAR 3511 QSGSLTR 4011 0.003
    1522 GCAATGGGT 2512 TSGHLVR 3012 RSDALTQ 3512 QSGDLTR 4012 0.08
  • [0120]
    TABLE 6
    FINGER (N→C)
    TRIPLET (5′→3′) F1 F2 F3
    AGG RXDHXXQ
    ATG RXDAXXQ
    CGG RXDHXXE
    GAA QXGNXXR
    GAC DXSNXXR DXSNXXR
    GAG RXDNXXR RXSNXXR RXDNXXR
    RXDNXXR
    GAT QXSNXXR TXGNXXR
    TXSNXXR
    TXGNXXR
    GCA QXGSXXR QXGDXXR
    GCC EXGTXXR
    GCG RXDEXXR RXDEXXR RXDEXXR
    RXDTXXK
    GCT QXSDXXR TXGEXXR
    QXSDXXR
    GGA QXGHXXR QXAHXXR
    GGC DXSHXXR DXSHXXR
    GGG RXDHXXR RXDHXXR RXDHXXR
    RXDHXXK
    GGT TXGHXXR
    GTA QXGSXXR
    QXATXXR
    GTG RXDAXXR RXDAXXR RXDAXXR
    RXDSXXR
    TAG RXDNXXT
    TCG RXDDXXK
    TGT TXDHXXS

Claims (49)

What is claimed is:
1. A zinc finger protein that binds to a target site, said zinc finger protein comprising a first (F1), a second (F2), and a third (F3) zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, said target site comprising, in 3′ to 5′ direction, a first (S1), a second (S2), and a third (S3) target subsite, each target subsite having the nucleotide sequence GNN, wherein if S1 comprises GAA, F1 comprises the amino acid sequence QRSNLVR; if S2 comprises GAA, F2 comprises the amino acid sequence QSGNLAR; if S3 comprises GAA, F3 comprises the amino acid sequence QSGNLAR; if S1 comprises GAG, F1 comprises the amino acid sequence RSDNLAR; if S2 comprises GAG, F2 comprises the amino acid sequence RSDNLAR; if S3 comprises GAG, F3 comprises the amino acid sequence RSDNLTR; if S1 comprises GAC, F1 comprises the amino acid sequence DRSNLTR; if S2 comprises GAC, F2 comprises the amino acid sequence DRSNLTR; if S3 comprises GAC, F3 comprises the amino acid sequence DRSNLTR; if S1 comprises GAT, F1 comprises the amino acid sequence QSSNLAR; if S2 comprises GAT, F2 comprises the amino acid sequence TSGNLVR; if S3 comprises GAT, F3 comprises the amino acid sequence TSANLSR; if S1 comprises GGA, F1 comprises the amino acid sequence QSGHLAR; if S2 comprises GGA, F2 comprises the amino acid sequence QSGHLQR; if S3 comprises GGA, F3 comprises the amino acid sequence QSGHLQR; if S1 comprises GGG, F1 comprises the amino acid sequence RSDHLAR; if S2 comprises GGG, F2 comprises the amino acid sequence RSDHLSR; if S3 comprises GGG, F3 comprises the amino acid sequence RSDHLSR; if S1 comprises GGC, F1 comprises the amino acid sequence DRSHLRT; if S2 comprises GGC, F2 comprises the amino acid sequence DRSHLAR; if S1 comprises GGT, F1 comprises the amino acid sequence QSSHLTR; if S2 comprises GGT, F2 comprises the amino acid sequence TSGHLSR; if S3 comprises GGT, F3 comprises the amino acid sequence TSGHLVR; if S1 comprises GCA, F1 comprises the amino acid sequence QSGSLTR; if S2 comprises GCA, F2 comprises QSGDLTR; if S3 comprises GCA, F3 comprises QSGDLTR; if S1 comprises GCG, F1 comprises the amino acid sequence RSDDLTR; if S2 comprises GCG, F2 comprises the amino acid sequence RSDDLQR; if S3 comprises GCG, F3 comprises the amino acid sequence RSDDLTR; if S1 comprises GCC, F1 comprises the amino acid sequence ERGTLAR; if S2 comprises GCC, F2 comprises the amino acid sequence DRSDLTR; if S3 comprises GCC, F3 comprises the amino acid sequence DRSDLTR; if S1 comprises GCT, F1 comprises the amino acid sequence QSSDLTR; if S2 comprises GCT, F2 comprises the amino acid sequence QSSDLTR; if S3 comprises GCT, F3 comprises the amino acid sequence QSSDLQR; if S1 comprises GTA, F1 comprises the amino acid sequence QSGALTR; if S2 comprises GTA, F2 comprises the amino acid sequence QSGALAR; if S1 comprises GTG, F1 comprises the amino acid sequence RSDALTR; if S2 comprises GTG, F2 comprises the amino acid sequence RSDALSR; if S3 comprises GTG, F3 comprises the amino acid sequence RSDALTR; if S1 comprises GTC, F1 comprises the amino acid sequence DRSALAR; if S2 comprises GTC, F2 comprises the amino acid sequence DRSALAR; and if S3 comprises GTC, F3 comprises the amino acid sequence DRSALAR.
2. The zinc finger protein of claim 1, wherein S1 comprises GAA and F1 comprises the amino acid sequence QRSNLVR.
3. The zinc finger protein of claim 1, wherein S2 comprises GAA and F2 comprises the amino acid sequence QSGNLAR.
4. The zinc finger protein of claim 1, wherein S3 comprises GAA and F3 comprises the amino acid sequence QSGNLAR.
5. The zinc finger protein of claim 1, wherein S1 comprises GAG and F1 comprises the amino acid sequence RSDNLAR.
6. The zinc finger protein of claim 1, wherein S2 comprises GAG and F2 comprises the amino acid sequence RSDNLAR.
7. The zinc finger protein of claim 1, wherein S3 comprises GAG and F3 comprises the amino acid sequence RSDNLTR.
8. The zinc finger protein of claim 1, wherein S1 comprises GAC and F1 comprises the amino acid sequence DRSNLTR.
9. The zinc finger protein of claim 1, wherein S2 comprises GAC and F2 comprises the amino acid sequence DRSNLTR.
10. The zinc finger protein of claim 1, wherein S3 comprises GAC and F3 comprises the amino acid sequence DRSNLTR.
11. The zinc finger protein of claim 1, wherein S1 comprises GAT and F1 comprises the amino acid sequence QSSNLAR.
12. The zinc finger protein of claim 1, wherein S2 comprises GAT and F2 comprises the amino acid sequence TSGNLVR.
13. The zinc finger protein of claim 1, wherein S3 comprises GAT and F3 comprises the amino acid sequence TSANLSR.
14. The zinc finger protein of claim 1, wherein S1 comprises GGA and F1 comprises the amino acid sequence QSGHLAR.
15. The zinc finger protein of claim 1, wherein S2 comprises GGA and F2 comprises the amino acid sequence QSGHLQR.
16. The zinc finger protein of claim 1, wherein S3 comprises GGA and F3 comprises the amino acid sequence QSGHLQR.
17. The zinc finger protein of claim 1, wherein S1 comprises GGG and F1 comprises the amino acid sequence RSDHLAR.
18. The zinc finger protein of claim 1, wherein S2 comprises GGG and F2 comprises the amino acid sequence RSDHLSR.
19. The zinc finger protein of claim 1, wherein S3 comprises GGG and F3 comprises the amino acid sequence RSDHLSR.
20. The zinc finger protein of claim 1, wherein S1 comprises GGC and F1 comprises the amino acid sequence DRSHLTR.
21. The zinc finger protein of claim 1, wherein S2 comprises GGC and F2 comprises the amino acid sequence DRSHLAR.
22. The zinc finger protein of claim 1, wherein S11 comprises GGT and F1 comprises the amino acid sequence QSSHLTR.
23. The zinc finger protein of claim 1, wherein S2 comprises GGT and F2 comprises the amino acid sequence TSGHLSR.
24. The zinc finger protein of claim 1, wherein S3 comprises GGT and F3 comprises the amino acid sequence TSGHLVR.
25. The zinc finger protein of claim 1, wherein S1 comprises GCA and F1 comprises the amino acid sequence QSGSLTR.
26. The zinc finger protein of claim 1, wherein S2 comprises GCA and F2 comprises the amino acid sequence QSGDLTR.
27. The zinc finger protein of claim 1, wherein S3 comprises GCA and F3 comprises the amino acid sequence QSGDLTR.
28. The zinc finger protein of claim 1, wherein S1 comprises GCG and F1 comprises the amino acid sequence RSDDLTR.
29. The zinc finger protein of claim 1, wherein S2 comprises GCG and F2 comprises the amino acid sequence RSDDLQR.
30. The zinc finger protein of claim 1, wherein S3 comprises GCG and F3 comprises the amino acid sequence RSDDLTR.
31. The zinc finger protein of claim 1, wherein S1 comprises GCC and F1 comprises the amino acid sequence ERGTLAR.
32. The zinc finger protein of claim 1, wherein S2 comprises GCC and F2 comprises the amino acid sequence DRSDLTR.
33. The zinc finger protein of claim 1, wherein S3 comprises GCC and F3 comprises the amino acid sequence DRSDLTR.
34. The zinc finger protein of claim 1, wherein S1 comprises GCT and F1 comprises the amino acid sequence QSSDLTR.
35. The zinc finger protein of claim 1, wherein S2 comprises GCT and F2 comprises the amino acid sequence QSSDLTR.
36. The zinc finger protein of claim 1, wherein S3 comprises GCT and F3 comprises the amino acid sequence QSSDLQR.
37. The zinc finger protein of claim 1, wherein S1 comprises GTA and F1 comprises the amino acid sequence QSGALTR.
38. The zinc finger protein of claim 1, wherein S2 comprises GTA and F2 comprises the amino acid sequence QSGALAR.
39. The zinc finger protein of claim 1, wherein S1 comprises GTG and F1 comprises the amino acid sequence RSDALTR.
40. The zinc finger protein of claim 1, wherein S2 comprises GTG and F2 comprises the amino acid sequence RSDALSR.
41. The zinc finger protein of claim 1, wherein S3 comprises GTG and F3 comprises the amino acid sequence RSDALTR.
42. The zinc finger protein of claim 1, wherein S1 comprises GTC and F1 comprises the amino acid sequence DRSALAR.
43. The zinc finger protein of claim 1, wherein S2 comprises GTC and F2 comprises the amino acid sequence DRSALAR.
44. The zinc finger protein of claim 1, wherein S3 comprises GTC and F3 comprises the amino acid sequence DRSALAR.
45. A polypeptide comprising a zinc finger protein according to claim 1.
46. A polypeptide according to claim 45, further comprising at least one functional domain.
47. A polynucleotide encoding a zinc finger protein according to claim 1.
48. A polynucleotide encoding a polypeptide according to claim 45.
49. A polynucleotide encoding a polypeptide according to claim 46.
US09/989,994 1999-03-24 2001-11-20 Position dependent recognition of GNN nucleotide triplets by zinc fingers Abandoned US20030104526A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/989,994 US20030104526A1 (en) 1999-03-24 2001-11-20 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/202,009 US7585849B2 (en) 1999-03-24 2005-08-11 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/225,686 US20060019349A1 (en) 1999-03-24 2005-09-12 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/893,341 US8383766B2 (en) 1999-03-24 2007-08-15 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US13/743,204 US8524874B2 (en) 1999-03-24 2013-01-16 Position dependent recognition of GNN nucleotide triplets by zinc fingers

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12623899P 1999-03-24 1999-03-24
US12623999P 1999-03-24 1999-03-24
US14659599P 1999-07-30 1999-07-30
US14661599P 1999-07-30 1999-07-30
US09/535,008 US6465629B1 (en) 1999-03-23 2000-03-23 BRG1 is a tumor suppressor that is mutated in prostate and other cancer types
US09/716,637 US6794136B1 (en) 2000-11-20 2000-11-20 Iterative optimization in the design of binding proteins
US09/989,994 US20030104526A1 (en) 1999-03-24 2001-11-20 Position dependent recognition of GNN nucleotide triplets by zinc fingers

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09/535,008 Continuation-In-Part US6465629B1 (en) 1999-03-23 2000-03-23 BRG1 is a tumor suppressor that is mutated in prostate and other cancer types
US53508800A Continuation-In-Part 1999-03-24 2000-03-23
US09/716,637 Continuation-In-Part US6794136B1 (en) 1999-03-24 2000-11-20 Iterative optimization in the design of binding proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/202,009 Continuation US7585849B2 (en) 1999-03-24 2005-08-11 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/225,686 Continuation US20060019349A1 (en) 1999-03-24 2005-09-12 Position dependent recognition of GNN nucleotide triplets by zinc fingers

Publications (1)

Publication Number Publication Date
US20030104526A1 true US20030104526A1 (en) 2003-06-05

Family

ID=35657704

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/989,994 Abandoned US20030104526A1 (en) 1999-03-24 2001-11-20 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/202,009 Expired - Fee Related US7585849B2 (en) 1999-03-24 2005-08-11 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/225,686 Abandoned US20060019349A1 (en) 1999-03-24 2005-09-12 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/893,341 Expired - Lifetime US8383766B2 (en) 1999-03-24 2007-08-15 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US13/743,204 Expired - Fee Related US8524874B2 (en) 1999-03-24 2013-01-16 Position dependent recognition of GNN nucleotide triplets by zinc fingers

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/202,009 Expired - Fee Related US7585849B2 (en) 1999-03-24 2005-08-11 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/225,686 Abandoned US20060019349A1 (en) 1999-03-24 2005-09-12 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US11/893,341 Expired - Lifetime US8383766B2 (en) 1999-03-24 2007-08-15 Position dependent recognition of GNN nucleotide triplets by zinc fingers
US13/743,204 Expired - Fee Related US8524874B2 (en) 1999-03-24 2013-01-16 Position dependent recognition of GNN nucleotide triplets by zinc fingers

Country Status (1)

Country Link
US (5) US20030104526A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20080182332A1 (en) * 2006-12-14 2008-07-31 Cai Qihua C Optimized non-canonical zinc finger proteins
JP2009538141A (en) * 2006-05-25 2009-11-05 サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for gene inactivation
WO2015073683A3 (en) * 2013-11-13 2015-07-09 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
KR101802393B1 (en) * 2008-06-10 2017-11-28 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for generation of bax- and bak-deficient cell lines
CN113066528A (en) * 2021-04-12 2021-07-02 山西大学 Protein classification method based on active semi-supervised graph neural network

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
EP1994155B2 (en) 2006-02-13 2022-05-04 Daiichi Sankyo Company, Limited Polynucleotide and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2013112595A2 (en) * 2012-01-23 2013-08-01 Sangamo Biosciences, Inc. Methods and compositions for gene editing of a pathogen
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
ES2758477T3 (en) 2013-02-20 2020-05-05 Regeneron Pharma Genetic modification of rats
MX369747B (en) 2013-04-16 2019-11-20 Regeneron Pharma Targeted modification of rat genome.
SI3080279T1 (en) 2013-12-11 2019-01-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
RU2725520C2 (en) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification
HUE049776T2 (en) 2014-06-06 2020-10-28 Regeneron Pharma Methods and compositions for modifying a targeted locus
LT3354732T (en) 2014-06-23 2020-04-10 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
KR102468108B1 (en) 2014-06-26 2022-11-18 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for targeted genetic modifications and methods of use
CA2963315A1 (en) 2014-10-15 2016-04-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
AU2015364427B2 (en) 2014-12-19 2021-05-27 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
CN108474007A (en) 2015-08-07 2018-08-31 联邦科学技术研究组织 The method for generating the animal comprising germline modification
EP3337908A4 (en) 2015-08-18 2019-01-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3150626A1 (en) * 2015-10-01 2017-04-05 University of Vienna Means and methods for accelerated breeding by inducing targeted stimulation of meiotic recombination
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
AU2016361455A1 (en) 2015-11-24 2018-06-21 Commonwealth Scientific And Industrial Research Organisation Production of viruses in cell culture
MX2018006386A (en) 2015-11-24 2018-11-09 Commonwealth Scient And Industrial Reseach Organisation Production of viruses in avian eggs.
CA3009194A1 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
AU2017207281B2 (en) 2016-01-11 2022-03-10 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
EP3474849A4 (en) 2016-06-27 2020-07-29 The Broad Institute, Inc. Compositions and methods for detecting and treating diabetes
US11674158B2 (en) 2016-07-15 2023-06-13 Salk Institute For Biological Studies Methods and compositions for genome editing in non-dividing cells
BR112019001783A2 (en) 2016-07-29 2019-05-07 Regeneron Pharmaceuticals, Inc. nonhuman mammal, and methods for producing the nonhuman mammal and screening a compound.
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
AU2018210364B2 (en) 2017-01-23 2022-03-17 Regeneron Pharmaceuticals, Inc. HSD17B13 variants and uses thereof
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210115407A1 (en) 2017-04-12 2021-04-22 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
EP3612232A1 (en) 2017-04-21 2020-02-26 The Broad Institute, Inc. Targeted delivery to beta cells
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
CA3064601A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
AU2018325363A1 (en) 2017-08-29 2020-04-09 Global Crop Innovations Pty. Ltd. Improved BLue Aleurone and other segregation systems
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
AU2018368786A1 (en) 2017-11-17 2020-06-18 Iovance Biotherapeutics, Inc. TIL expansion from fine needle aspirates and small biopsies
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US20210037798A1 (en) 2018-03-20 2021-02-11 Tsinghua University Alzheimers disease animal model and use thereof
KR20200141470A (en) 2018-04-06 2020-12-18 칠드런'즈 메디컬 센터 코포레이션 Composition and method for adjusting somatic cell reprogramming and imprinting
ES2922902T3 (en) 2018-04-24 2022-09-21 Kws Saat Se & Co Kgaa Plants with improved digestibility and marker haplotypes
KR20210005138A (en) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy
US20210147831A1 (en) 2018-04-27 2021-05-20 The Broad Institute, Inc. Sequencing-based proteomics
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN113164623A (en) 2018-09-18 2021-07-23 维恩维纽克公司 ARC-based capsids and uses thereof
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
JP2022505139A (en) 2018-10-15 2022-01-14 フォンダッツィオーネ・テレソン Genome editing methods and constructs
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
BR112021008266A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Methods for expanding tumor-infiltrating lymphocytes in a therapeutic population of tumor-infiltrating lymphocytes and for treating a subject with cancer, and, therapeutic population of tumor-infiltrating lymphocytes
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
US20220090018A1 (en) 2018-11-05 2022-03-24 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and used of the same in immunotherapy
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
CN116064550A (en) 2018-12-20 2023-05-05 瑞泽恩制药公司 Nuclease-mediated repeat amplification
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
CA3131305A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220152115A1 (en) 2019-03-13 2022-05-19 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
US20220143148A1 (en) 2019-03-14 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020191069A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
KR20210148154A (en) 2019-04-03 2021-12-07 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for insertion of antibody coding sequences into safe harbor loci
WO2020206139A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
CN113795588A (en) 2019-04-04 2021-12-14 瑞泽恩制药公司 Methods for scar-free introduction of targeted modifications in targeting vectors
US20220243287A1 (en) 2019-05-13 2022-08-04 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220249701A1 (en) 2019-05-14 2022-08-11 The Broad Institute, Inc. Compositions and methods for targeting multinucleated cells
AR118995A1 (en) 2019-05-25 2021-11-17 Kws Saat Se & Co Kgaa HAPLOID INDUCTION ENHANCER
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
KR20220017939A (en) 2019-06-07 2022-02-14 리제너론 파마슈티칼스 인코포레이티드 Non-Human Animals Comprising a Humanized Albumin Locus
WO2020252340A1 (en) 2019-06-14 2020-12-17 Regeneron Pharmaceuticals, Inc. Models of tauopathy
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN114846022A (en) 2019-10-17 2022-08-02 科沃施种子欧洲股份两合公司 Enhancing disease resistance in crops by downregulation of repressor genes
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
KR20220097414A (en) 2019-11-08 2022-07-07 리제너론 파마슈티칼스 인코포레이티드 CRISPR and AAV Strategies for X-Linked Combustion Retinal Delaminization Therapy
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CN114787362A (en) 2019-12-13 2022-07-22 中外制药株式会社 System for detecting extracellular purine receptor ligand and non-human animal introduced with the system
JP2023515671A (en) 2020-03-04 2023-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods and compositions for sensitizing tumor cells to immunotherapy
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
UY39237A (en) 2020-05-29 2021-12-31 Kws Saat Se & Co Kgaa INDUCTION OF HAPLOIDS IN PLANTS
JP2023530234A (en) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods for treating neoplasms
CN112016438B (en) * 2020-08-26 2021-08-10 北京嘀嘀无限科技发展有限公司 Method and system for identifying certificate based on graph neural network
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (en) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス,インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4308691A1 (en) 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
WO2022225981A2 (en) 2021-04-19 2022-10-27 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023006933A1 (en) 2021-07-30 2023-02-02 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US20230226116A1 (en) 2021-10-20 2023-07-20 University Of Rochester Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se
US20230133695A1 (en) 2021-10-20 2023-05-04 University Of Rochester Methods and compositions for rejuvenating cns glial populations by suppresion of transcription factors
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023150553A1 (en) 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
WO2023150557A1 (en) 2022-02-01 2023-08-10 University Of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023213831A1 (en) 2022-05-02 2023-11-09 Fondazione Telethon Ets Homology independent targeted integration for gene editing
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
EP4278891A1 (en) 2022-05-20 2023-11-22 KWS SAAT SE & Co. KGaA Clubroot resistance and markers in brassica
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024042199A1 (en) 2022-08-26 2024-02-29 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990607A (en) * 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5096814A (en) * 1984-03-23 1992-03-17 Kernforschungsanlage Juelich Gmbh Macroporous and microporous inorganic carrier for immobilization of cells
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5302519A (en) * 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
US5324818A (en) * 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5350840A (en) * 1989-11-13 1994-09-27 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5356802A (en) * 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5376530A (en) * 1987-12-16 1994-12-27 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) * 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5498530A (en) * 1991-10-16 1996-03-12 Affymax Technologies, N.V. Peptide library and screening method
US5578483A (en) * 1988-12-23 1996-11-26 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
US5597693A (en) * 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5639592A (en) * 1990-09-21 1997-06-17 The Salk Institute For Biological Studies Functional antagonism between proto-oncoprotein c-Jun and hormone receptors
US5674738A (en) * 1986-08-22 1997-10-07 Roche Molecular Systems, Inc. DNA encoding thermostable nucleic acid polymerase enzyme from thermus species Z05
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5830721A (en) * 1994-02-17 1998-11-03 Affymax Technologies N.V. DNA mutagenesis by random fragmentation and reassembly
US5869618A (en) * 1990-05-25 1999-02-09 Lippman; Marc E. Antibodies to ligand growth factors
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5871902A (en) * 1994-12-09 1999-02-16 The Gene Pool, Inc. Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids
US5916794A (en) * 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6001885A (en) * 1996-09-02 1999-12-14 Centre International De Recherches Dermatologiques Retinoid inhibition of expression of VEGF
US6007988A (en) * 1994-08-20 1999-12-28 Medical Research Council Binding proteins for recognition of DNA
US6160091A (en) * 1997-04-30 2000-12-12 Prolifix Limited Myc-binding zinc finger proteins, their preparation and their use
US20030021776A1 (en) * 2000-12-07 2003-01-30 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US549830A (en) * 1895-11-12 Subaqueous mining-machine
US548794A (en) * 1895-10-29 Solomon
US567438A (en) * 1896-09-08 alexander
US5356840A (en) * 1989-08-21 1994-10-18 Olympus Optical Co., Ltd. Distributed index of refraction type optical element and method of making the same
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
JP2784134B2 (en) * 1993-09-07 1998-08-06 三菱電機株式会社 Active filter device
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0770129B1 (en) 1994-01-18 2005-11-23 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
AU3331595A (en) 1994-08-18 1996-03-14 Ariad Pharmaceuticals, Inc. Composite dna-binding proteins and materials and methods relating thereto
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
DE4435919C1 (en) 1994-10-07 1995-12-07 Deutsches Krebsforsch DNA encoding zinc finger protein
WO1996020951A1 (en) 1994-12-29 1996-07-11 Massachusetts Institute Of Technology Chimeric dna-binding proteins
WO1996032475A2 (en) 1995-04-12 1996-10-17 University Of Washington Methods for preparing dna-binding proteins
AU725716C (en) 1996-01-23 2003-02-20 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP2002508971A (en) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド Regulation of biological events using multimeric chimeric proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
CA2319112C (en) 1998-02-13 2003-10-28 Genetrace Systems, Inc. Use of ribozymes for functionating genes
EP1062227A2 (en) 1998-02-20 2000-12-27 Genome Dynamics Inc. Method for designing dna-binding proteins of the zinc-finger class
EP1060261B1 (en) 1998-03-02 2010-05-05 Massachusetts Institute of Technology Poly zinc finger proteins with improved linkers
US6977154B1 (en) * 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) * 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
KR20020086508A (en) * 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 Cells for drug discovery
ATE353361T1 (en) * 2000-04-28 2007-02-15 Sangamo Biosciences Inc TARGETED MODIFICATION OF THE CHROMATE STRUCTURE
US6533689B1 (en) * 2000-11-02 2003-03-18 The Gates Corporation Belt installation tool

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096814A (en) * 1984-03-23 1992-03-17 Kernforschungsanlage Juelich Gmbh Macroporous and microporous inorganic carrier for immobilization of cells
US5674738A (en) * 1986-08-22 1997-10-07 Roche Molecular Systems, Inc. DNA encoding thermostable nucleic acid polymerase enzyme from thermus species Z05
US5376530A (en) * 1987-12-16 1994-12-27 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5403484A (en) * 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5578483A (en) * 1988-12-23 1996-11-26 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4990607A (en) * 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
US5597693A (en) * 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5350840A (en) * 1989-11-13 1994-09-27 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5869618A (en) * 1990-05-25 1999-02-09 Lippman; Marc E. Antibodies to ligand growth factors
US5639592A (en) * 1990-09-21 1997-06-17 The Salk Institute For Biological Studies Functional antagonism between proto-oncoprotein c-Jun and hormone receptors
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5324818A (en) * 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5302519A (en) * 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
US5498530A (en) * 1991-10-16 1996-03-12 Affymax Technologies, N.V. Peptide library and screening method
US5916794A (en) * 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5356802A (en) * 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) * 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
US5830721A (en) * 1994-02-17 1998-11-03 Affymax Technologies N.V. DNA mutagenesis by random fragmentation and reassembly
US6013453A (en) * 1994-08-20 2000-01-11 Medical Research Council Binding proteins for recognition of DNA
US6007988A (en) * 1994-08-20 1999-12-28 Medical Research Council Binding proteins for recognition of DNA
US5871902A (en) * 1994-12-09 1999-02-16 The Gene Pool, Inc. Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6001885A (en) * 1996-09-02 1999-12-14 Centre International De Recherches Dermatologiques Retinoid inhibition of expression of VEGF
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
US6160091A (en) * 1997-04-30 2000-12-12 Prolifix Limited Myc-binding zinc finger proteins, their preparation and their use
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US20030021776A1 (en) * 2000-12-07 2003-01-30 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
JP2009538141A (en) * 2006-05-25 2009-11-05 サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for gene inactivation
US9187758B2 (en) * 2006-12-14 2015-11-17 Sangamo Biosciences, Inc. Optimized non-canonical zinc finger proteins
TWI470079B (en) * 2006-12-14 2015-01-21 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
US20080182332A1 (en) * 2006-12-14 2008-07-31 Cai Qihua C Optimized non-canonical zinc finger proteins
US10662434B2 (en) 2006-12-14 2020-05-26 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
KR101802393B1 (en) * 2008-06-10 2017-11-28 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for generation of bax- and bak-deficient cell lines
KR101794638B1 (en) * 2008-06-10 2017-12-04 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for generation of bax- and bak-deficient cell lines
WO2015073683A3 (en) * 2013-11-13 2015-07-09 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
EP3492593A1 (en) * 2013-11-13 2019-06-05 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US11021696B2 (en) 2013-11-13 2021-06-01 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
EP3960856A1 (en) * 2013-11-13 2022-03-02 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
CN113066528A (en) * 2021-04-12 2021-07-02 山西大学 Protein classification method based on active semi-supervised graph neural network

Also Published As

Publication number Publication date
US20060024726A1 (en) 2006-02-02
US8383766B2 (en) 2013-02-26
US20060019349A1 (en) 2006-01-26
US7585849B2 (en) 2009-09-08
US20130123484A1 (en) 2013-05-16
US20080242847A1 (en) 2008-10-02
US8524874B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
US8524874B2 (en) Position dependent recognition of GNN nucleotide triplets by zinc fingers
EP1364020B1 (en) Position dependent recognition of gnn nucleotide triplets by zinc fingers
US7030215B2 (en) Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU2002239295A1 (en) Position dependent recognition of GNN nucleotide triplets by zinc fingers
CA2322700C (en) Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to binds to preselected sites
Kubo et al. Cys2/His2 zinc-finger protein family of petunia: evolution and general mechanism of target-sequence recognition
Yoshida et al. The 5′-AT-rich half-site of Maf recognition element: a functional target for bZIP transcription factor Maf
Lee et al. Characterization of Drosophila OVO protein DNA binding specificity using random DNA oligomer selection suggests zinc finger degeneration
US7943731B1 (en) Dimerizing peptides
Beltran et al. Role of DNA sequence in the binding specificity of synthetic basic‐helix‐loop‐helix domains
Iler et al. Rapid Identification of Homeodomain Binding Sites in theWnt-5aGene Using an Immunoprecipitation Strategy
Lee et al. Cloning and characterization of the rat Hsf2 promoter: a critical role of proximal E-box element and USF protein in Hsf2 regulation in different compartments of the brain
Saad STRUCTURAL DETERMINANTS OF NF-Y INTERACTION WITH PARTNER TRANSCRIPTION FACTORS ON DNA

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANGAMO BIOSCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIU, QIANG;REEL/FRAME:012461/0895

Effective date: 20020118

AS Assignment

Owner name: SANGAMO BIOSCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REBAR, EDWARD;JAMIESON, ANDREW C.;REEL/FRAME:014290/0114

Effective date: 20040116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION